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P R E F A C E
The 1993 National Agricultural Biotechnology Council meeting wit-nessed the “growing up” of NABC as the leadership passed from Ralph 
W. F. Hardy, President, Boyce Thompson Institute and cofounder of NABC in 
1988, to Bill R. Baumgardt, Director, Agricultural Research Programs, Purdue 
University and NABC Chair for 1993-94.
Ralph Hardy, NABC Chair from 1988 to 1993, has left his mark on this or-
ganization as it has grown under his enlightened and thoughtful leadership 
from four agricultural research and educational institutions (Boyce Thomp-
son Institute, Cornell University, Iowa State University and University of Cali-
fornia, Davis) to eighteen U.S. and Canadian institutions. His vision of a neu-
tral “playing field” where anyone and everyone could come to speak, to listen 
and to learn is now realized annually. NABC 5, A Public Conversation About 
Risk, is representative of how much can be learned, better understood, produc-
tively discussed when people with different views come together in a neutral fo-
rum to openly and freely speak about their specific concerns and to work with 
one another to establish common ground, understand areas of disagreement 
and, where possible, bring forth mutually agreed upon recommendations.
Since the first laboratory experiment in agricultural biotechnology, there 
have been questions, discussions and disagreements about “the risks.” The 
fifth annual NABC meeting focused on bringing together and facilitating con-
versations on risk and agricultural biotechnology among the many stakehold-
ers. Participants entered into dialogues, formal and informal, about technical 
assessments and personal perspectives of risk, on public perceptions and val-
ues of both risks and benefits, and about issues of communication and who to 
trust. It became obvious to participants that the technical is so intertwined 
with social issues and values that responses to new agricultural biotechnolo-
gies should not be discussed and cannot be understood separate from one an-
other.
This volume provides the reader with many perspectives about how risk is 
and/or should be assessed. The lively discussions in the workshops and the 
conversations in the hallways among NABC 5 participants with diverse view-
points resulted in surprising consensus in the conclusions reached and recom-
mendations presented at the end of the meeting. Hopefully, this report will 
provide an incentive for the reader to enter into conversations with those who 
have different perspectives on risk and agricultural biotechnology. Open dia-
logue will only improve understanding of various viewpoints and should pro-
vide a foundation for addressing concerns about agricultural biotechnology.
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Life involves choices. Many of the choices we make require an assessment of the potential benefits and risks associated with our choices. This is 
particularly true regarding biotechnology. The major objective of the fifth 
annual meeting of the National Agricultural Biotechnology Council (NABC) 
was to exchange understanding of the risks associated with agricultural bio-
technology and how these risks are perceived and assessed by various seg-
ments of society. NABC 5, A Public Conversation About Risk, achieved this 
objective using the NABC format of an open forum for participants to speak, 
to listen and to learn. Differing views on risks of agricultural biotechnology 
were expressed and discussed by over 130 agricultural biotechnology stake-
holders including consumers; farmers; environmentalists; industry scientists 
and administrators; journalists; ethicists; government agency professionals; 
and academic researchers; educators; and administrators.
The meeting topic and the dates for NABC 5 were rather timely, coincid-
ing with the release of Steven Spielberg’s blockbuster science-fiction movie 
Jurassic Park which raised questions about the potential dangers of imagined 
genetic engineering gone awry. Also, the Food and Drug Administration 
(FDA) issued, in May 1992, a request for comments on labeling of food prod-
ucts that are biotechnologically based. In addition, the risks of another
agricultural technology, pesticides, were being questioned in a National Acad-
emy of Sciences report on pesticides in the diets of infants and children since 
data are not available.
The NABC open forum on the risks of agricultural biotechnology was 
structured around a roundtable discussion, seven invited plenary speakers, 
and four concurrent workshops. Each workshop had two co-chairpersons 
who also served as roundtable discussants. The backgrounds of the plenary 
speakers and workshop co-chairs were as diverse as those of the participants.
Roundtable:  A  Public  Conversat ion  about  R isk
Marshall A. Martin, NABC 5 organizing committee co-chair, moderated a 
thought-provoking, and often lively and spirited, opening to the NABC 5 
meeting. The ideas conveyed in the roundtable set the stage for the remain-
der of the meeting. (Part IV, page 115, contains a complete transcript of the 
roundtable discussion.) Different scientific and personal views were ex-
pressed about the risks and benefits associated with various technologies, 
such as alternative modes of travel, consuming dairy products from cows 
treated with bovine somatotropin (bST) and eating genetically engineered 
tomatoes. These specific products of biotechnology were selected to draw 
out a number of issues—such as the role facts, values and emotions play 
when assessing risk—that were addressed later by the invited speakers and in 
the workshops. The discussion about the Flavr Savr™ tomato, Bt tomato and 
bST milk, illustrated how individuals can have different tastes and prefer-
ences for food, can differ frequently in their environmental concerns, can 
desire varying levels of information about food products, can have food al-
lergies that might require labeling of transgenic foods, and can display sub-
stantial diversity in their knowledge and understanding of agricultural bio-
technology. Hence, both technical and other risks and benefits must be con-
sidered, though neither is easy to quantify.
P L E N A R Y  S E S S I O N S
During the first full day of the meeting, participants heard presentations 
from five invited speakers.
Risk  Assessment and Communication
Roger A. Balk, an ethicist at the Royal Victoria Hospital in Montreal, spoke 
on the topic of “Public Values and Risk Assessment.” Dr. Balk caught the 
audience’s attention by recalling the story of Henny Penny who concluded, 
from being hit on the head by an acorn, that the sky was falling—jumping to 
conclusions that there is a risk without the relevant facts can lead to differ-
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ent, but real risks. Drawing examples from the field of medicine, Dr. Balk 
described a three-tiered system which would allow advanced technology to 
be supported while protecting those who would be its beneficiaries. Key ele-
ments of this system included: 1. the principle of informed consent; 2. the 
requirement that all applications for support of new technology be subjected 
to scientific and statistical cost/benefit analysis; and 3. the development of a 
process through which principles maybe combined with data to guide regu-
lation of the products of new technology. Dr. Balk applied this system to 
some current, controversial agricultural biotechnologies—bST and Flavr 
Savr™ tomato.
The next speaker, Sharon Dunwoody, addressed the subject of “Telling 
Public Stories About Risk.” Drawing from her own experiences in dealing 
with the discovery that her basement may contain asbestos, Dr. Dunwoody, a 
professor of journalism and mass communications, discussed how people 
choose information channels when faced with a risky situation. These chan-
nels are used to learn about risk as well as to decide how to respond to that 
risk. She concluded that, given an array of information channels, individuals 
choose different channels to help them make decisions about different di-
mensions of a risk. The cost of a channel is also a choice factor. While mass 
media may be an inexpensive, easily accessible, and important source of in-
formation about a risk, persons seeking guidance on appropriate responses 
to a recognized risk prefer the channel of personal counselors who can take 
their individual situation into account.
Risk  Assessment and Public Perception
During the second plenary session, Roy L. Fuchs spoke on “Risk Assessment: 
A Technical Perspective.” Dr. Fuchs, a Monsanto scientist, presented the per-
spective of the regulated agricultural biotechnology industry. He began with 
an overview of the regulatory authority of the various federal agencies and 
then summarized the approach taken by Monsanto to ensure the safety of 
one of its biotechnology products: genetically modified potatoes expressing 
resistance to the Colorado potato beetle. According to Dr. Fuchs, Monsanto’s 
guiding principles were: 1. to establish that the modified potatoes were “sub-
stantially equivalent” to the unmodified and widely consumed Russet 
Burbank potato; and 2. to confirm the environmental, human, and animal 
safety of the protein products encoded by the two genes introduced via ge-
netic engineering. During the course of his talk, Dr. Fuchs provided numer-
ous examples of the kinds of technical data gathered to evaluate the safety of 
a genetically modified food.
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In his presentation titled “Public Perceptions of the Benefits and Risks of 
Biotechnology,” Dr. Thomas Hoban, a sociologist at North Carolina State 
University, described results from an extensive national telephone survey 
and subsequent focus groups. In reviewing conclusions from the survey, Dr. 
Hoban emphasized that the public is generally optimistic about the potential 
benefit from and safety of biotechnology in agriculture and desires more in-
formation about agricultural biotechnology. However, when specific appli-
cations were discussed, considerable variability in perception was uncovered 
regarding: 1. the public’s confidence in sources of information and regula-
tions; and 2. a number of concerns over certain types of products. Survey re-
sults indicate that people are more likely to accept plant than animal applica-
tions of biotechnology. Views about the morality of biotechnology are very 
important. Also, respondents want to play a greater role in decisions about 
biotechnology—he suggested that surveys provide a cost-effective and sys-
tematic mechanism for public participation.
Following the Thursday evening dinner, Jerry Bishop, deputy news edi-
tor for science with the Wall Street Journal, addressed the topic of “Commu-
nicating with the Public about Risk.” Mr. Bishop recalled the continual 
stream of risk-associated issues which appears in the news each day. He 
noted that scientists often criticize journalists for irresponsibility in giving 
credence to issues, spokespersons, and data which have not been reviewed 
and evaluated through the critical eye of the scholarly peer-review process. 
He pointed out that it is often because an issue is controversial that it is of in-
terest to the public and newsworthy. Mr. Bishop reminded the audience that 
newspapers and other print media must select articles with an eye attuned 
sharply to what the public wants to read, not what the public should read, if 
they want to continue publishing.
Risk  Assessment and Public Perspective
In the opening plenary session the next morning, Dr. David MacKenzie 
spoke on “Regulatory Risk Assessment: A View from the Potomac.” A U.S. 
Department of Agriculture (USDA) administrator, Dr. MacKenzie provided 
an overview of current biotechnology regulation and reviewed the underly-
ing process of risk analysis. In his discussion of risk analysis, Dr. MacKenzie 
defined such terms as hazard, risk, risk analysis, risk assessment, risk man-
agement, risk characterization and risk communication. He emphasized 
that the science (risk assessment) and the policy/decision-making (risk man-
agement) must be kept separate. Dr. MacKenzie also discussed issues regard-
ing the Federal Coordinated Framework for Regulation of Biotechnology.
He explained how it has been difficult to fit into the Coordinated Framework
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the regulation of agricultural research and product development because this 
was a previously unregulated area (as opposed to pharmaceuticals). He indi-
cated that, while regulatory gaps exist, the agencies have done a good job of 
incorporating agricultural regulation and have worked well together. Al-
though the Coordinated Framework focuses biotechnology regulation on the 
product rather than the process, the issue of how to identify a hazard before 
the fact has not been resolved. Thus the process by which a specific product 
is made may need to be considered as the safety of the product is reviewed.
Dr. MacKenzie discussed the future challenges for biotechnology regulation. 
Educating the public about the scientific facts of biotechnology and reaching 
consensus by reconciling conflicting worldviews about biotechnology 
through ongoing dialogue are especially important.
The final plenary speaker was Mr. Will Erwin, an Indiana farmer, who 
spoke on “Risk Assessment: A Farmer’s Perspective.” In a warm and thought-
ful presentation, Mr. Erwin described the farmers’ perspective on new tech-
nology in general, characterizing farmers as informed risk-takers. He went 
on to discuss how farmers’ concerns are often dichotomous. On the one 
hand, farmers exhibit personal concerns over the safety of agricultural prac-
tices and products for the environment and the public. On the other hand, 
farmers also have business concerns over regulatory requirements, profit-
ability, the effect of technology on the structure of the industry, and public 
demand for products. Mr. Erwin emphasized the complexity of the techno-
logical issues involved and the need for more information presented clearly 
to a nontechnical audience. He pointed to the prevailing sentiment of public 
distrust of what they do not understand and of technology in general, and 
the pervasive public lack of confidence in government oversight. In his con-
cluding remarks, Mr. Erwin cautioned that people may look to sources other 
than science for guidance in resolving troublesome technological issues 
when their culture is saturated with information and hyped with fear.
WORKSHOPS
In addition to attending the roundtable discussion and plenary sessions, 
NABC 5 participants each took part in one of four workshops: 1. Technical 
Risk Assessment and Regulations; 2. Public Assessments of Benefits and 
Risks; 3. Public Values: Benefits and Harms; and 4. Public Communication 
About Risk. The goal of the workshops, as at all NABC meetings, was to en-
courage frank discussion and to seek consensus, where possible, on the ma-
jor issues in order to devise specific and useful recommendations for issue 
resolution and policy formation. While many of the stakeholders and inter-
est groups represented at NABC 5 had attended previous NABC meetings,
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this was the first NABC meeting for the majority of attendees. There were an 
unusually large number of farmers and representatives of the print and elec-
tronic news media at the Purdue University meeting. For many of these 
people, this was also their first workshop experience.
Participants in each workshop spent six hours identifying and discuss-
ing key issues and developing recommendations of appropriate responses. 
Their recommendations were then presented for discussion by the entire 
group of participants during the final afternoon. A few highlights from the 
workshops are outlined below. For complete reports with a full list of rec-
ommendations, see Part II beginning on page 19.
Technical Risk Assessment and Regulations
Part of the public debate about agricultural biotechnology has focused on the 
measurement and regulation of risk. Discussion in this workshop co-chaired 
by Rebecca Goldburg (Biologist, Environmental Defense Fund) and William 
Greenlee (Pharmacology and Toxicology, Purdue University), focused on as-
pects of risk characterization and risk management. Major issues identified 
by workshop participants included: 1. hazard identification of biotechnology 
products and processes; 2. establishment of scientific standards for measuring 
risks associated with biotechnology; and 3. better balancing of benefits and 
risks. Specific recommendations included:
More input is needed from the scientific community (e.g., commission study 
by the National Academy of Sciences) to develop hazard identification 
methodology for agricultural biotechnology products;
Legislative gaps in regulatory authority should be filled (e.g., fish, shellfish);
Land-grant universities need to address issues such as sustainable agricul-
ture, family farms, pesticide use, for which biotechnology now serves as a 
lightning rod or even a surrogate focus;
Models should be developed to assess the toxicity and allergenicity/antige-
nicity of expressed products as part of developing risk assessment guidelines.
Public Assessments of Benefits and Risks
Public perceptions may make or break the introduction of agricultural bio-
technology products. People’s actions will decide which applications ulti-
mately survive and which directions future research will take. Public percep-
tion research has shown diverse concerns about the risks associated with agri-
cultural biotechnology. Participants in this workshop co-chaired by Ted
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McKinney (Community Affairs and Contributions, DowElanco) and Ann 
Sorensen (Center for Agriculture and the Environment, American Farmland 
Trust), discussed public reactions to agricultural biotechnology, societal ties 
between the people and their leaders, and the public policy formation process. 
Two major themes emerged from this workshop: 1. a possible paradigm shift 
in society’s view of the role of humanity, science and technology in our world; 
and 2. the potential for biotechnology to significantly change our lives and 
our environment. The group’s perception was that these themes are conflict-
ing and suggest that the debate over acceptance of biotechnology will be influ-
enced by more than scientific facts alone. Participants agreed on the need for 
better understanding of public values and attitudes toward biotechnology and 
its products. Specific recommendations from the workshop participants in-
clude the following:
Develop and implement methods of identifying and monitoring public un-
derstanding of and awareness about issues and potential changes being 
brought about through biotechnology;
Place additional emphasis within education and the educational process de-
fining, assessing and understanding risk and decision-making under uncer-
tainty;
Expand the capacity and commitment of the scientific community to more 
effectively communicate with the public;
Broaden involvement of stakeholders in identification of priority needs to be 
addressed by biotechnology.
Public Value: Benefits and Harms
Agricultural biotechnology has generated an ethical debate on actual and per-
ceived benefits and harms. In some cases, scientists cannot measure risks be-
cause potential hazards have not been clearly delineated. Issues have arisen 
over the use of particular biotechnology processes (such as genetic engineer-
ing), the adoption of individual biotechnology products (such as genetically 
engineered tomatoes), and over decisions concerning regulation, research, in-
tellectual property rights and other aspects of biotechnology. Each person 
views these issues through a unique framework of values composed of ethical, 
religious, economic, scientific and other beliefs. In the workshop on Public 
Values: Benefits and Harms co-chaired by Rosetta Newsome (Scientific Affairs 
Information, Food Technologists) and Lilly-Marlene Russow (Philosophy, 
Purdue University), participants discussed why a diversity of views occurs,
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how these diverse views are formed and expressed, why or how they might be 
changed or harmonized, and who should make these decisions. The major 
issues identified by participants in this workshop included: 1. who should 
make decisions regarding biotechnology and its products; 2. what criteria are 
used to assign value to new biotechnology; 3. how safety is a factor affecting 
biotechnology; and 4. where communication about biotechnology needs to be 
improved. Following are some of the recommendations that were made to 
foster broader participation among stakeholders and to develop institutional 
mechanisms to enhance such an exchange of information and viewpoints:
Encourage and foster broad participation through a system responsive to 
stakeholders’ input;
Be sensitive to religious concerns and provide information in food labeling 
accordingly;
Develop information which is clear and understandable, so as to be acces-
sible to people with a variety of educational backgrounds;
Assess the social/economic impacts of specific biotechnology applications at 
the earliest state possible;
Single out and support land-grant universities and extension offices as 
particularly appropriate forums for discussion and dissemination of infor-
mation;
Support better education at all levels, beginning with kindergarten.
Public Communication about Risk
The electronic and print media play a critical role in reporting information 
and ideas to the public. Editorials, newspaper and magazine articles, books, 
movies, and news and informational television programming all shape public 
understanding of and attitudes toward agricultural biotechnology. Effective 
risk communication requires that persons in the media have an understand-
ing of the technology, the ability to use modern communication systems, and 
an awareness of people’s concerns and interests. Participants in this workshop 
co-chaired by Karen Bolluyt (Agricultural Information Services, Iowa State 
University) and David Judson (Gannett News Service) explored ways to con-
duct an effective dialogue on agricultural biotechnology to help society and 
consumers make informed long-term evaluations of the risks and benefits of 
biotechnology. Major issues identified included: 1. circular communication
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with effective consumer feedback must be developed and maintained; 2. im-
provements are needed to enhance the clarity and accuracy of the content of 
the message communicated to the public about biotechnology; and 3. greater 
effort is necessary to augment the credibility of biotechnology communica-
tors. Specific recommendations include the following:
Focus on specific products or technologies, discussing risks or benefits for 
specific groups;
Base information on sound science, identifying the source’s qualifications 
and affiliations;
Provide product information and access to process information;
Use language and concepts that the audience understands;
Share new and existing information from focus groups and surveys as 
widely as possible;
Employ mass media and targeted media to reach audiences, elicit re-
sponses from them, and build coalitions.
TYING IT TOGETHER
At the close of the conference, Dr. Theodore L. Hullar, Chancellor of the 
University of California, Davis and member of the NABC Council presented 
wrap-up comments for the group to consider as they returned to their daily 
professional routines. He noted how the meeting had captured society’s 
frustration with the public policy issues surrounding biotechnology and had 
illuminated the centrality of social concerns regarding risk. Dr. Hullar com-
mented on the uniqueness of the era in which discussions of biotechnology 
are held. He also explained the uniqueness of the issues raised by biotechnol-
ogy. This uniqueness is derived from: 1. the scope and pervasiveness of the 
technology; 2. from the fact that biotechnology reaches closer to the central-
ity of life itself than do other technologies; and 3. agricultural biotechnol-
ogy’s enormous power because of its application to multiple potential tar-
gets, its dissemination into the environment, and its extension beyond the 
range of individual control.
In conclusion, Dr. Hullar affirmed his belief that the NABC format 
was working and that participants in this meeting would leave thinking dif-
ferently as a direct result of the NABC experience. He challenged the par-
ticipants to search for new risk evaluation paradigms and to engage in joint
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efforts, involving both social and biological scientists, to deal directly with 
the socioeconomic issues which biotechnology raises. Furthermore, he 
recommended that USDA proceed with a critical evaluation of socioeconomic 
issues associated with such topics as agricultural biotechnology and sustain-
able agriculture by fully funding basic and applied research on these topics 
through the National Research Initiative. He also supported the desirability 
of joint public-private partnership in the evaluation of the social implications 
of proposed new biotechnology products. Dr. Hullar concluded by emphasiz-
ing the need for these discussions to move from the realm of theory to the per- 
sonal/practical level.
The fifth annual NABC open forum concluded with the new Chair of 
the NABC Council, Bill R. Baumgardt, Director of Purdue University’s Agri-
cultural Research Programs, charging the participants to take home with 
them the information from both the plenary sessions and workshops and 
from the many conversations in the corridors and over meals, and to imple-
ment the recommendations whenever and wherever possible. Reminding 
those present that individuals matter, he encouraged that broad, meaningful 
dialogue on agricultural biotechnology continue and wished all participants 
productive conversations about risk.
Agricultural Biotechnology: A Public Conversation About Risk
Putting It In Context
Theodore L. Hullar 
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Biotechnology' is, without doubt, one of the most precocious of discov-eries, quickly moving into the center of biological sciences. It is provid-
ing for new products which promise to add much to commerce and industry, 
including specific biomedical therapies and dramatically improved agricul-
tural practices and products. At the same time, biotechnology spawns strong, 
even fierce, controversy about manipulation of genome and environment 
alike. The annual meeting of the National Agricultural Biotechnology Coun-
cil (NABC) addressed issues which confront our understanding of biotech-
nology, especially for agriculture. The purpose of this paper is to offer per-
spective on major features of this contentious terrain and to suggest some 
specific actions which might be usefully taken to clarify understanding and 
resolve issues.
T H E  C E N T R A L I T Y  O F  O U R  S O C I A L  E N V I R O N M E N T
Biotechnology engages the social environment, it would seem as fully as it en-
gages the study of the investigator. The principle issue today with biotechnol-
ogy is with the social environment within which it must necessarily function.
1 Biotechnology, as used in this paper, is used generically to describe all manipula-
tions at the molecular or cellular level that affect genetic material in a specific 
manner. Agricultural biotechnology, as used in this paper, refers to biotech-
nology on organisms and practices of importance to agriculture. It also refers, 
in the appropriate context, to biotechnology applied to food products and 
processes and also to environmental biotechnology.
We struggle to rationalize public concern about manipulating a single gene 
with the easy public acceptance of manipulating the whole plant or animal 
genome, such as it is, that has long been done in the traditional plant and 
animal breeding. We wonder how can it be that the possibilities of major 
manipulation by traditional breeding—where many genes are manipulated 
in unknown ways—are more socially acceptable than specific changes in a 
single gene or small set of related genes? Is it that we believe that an “unde-
sirable” combination of genes in the traditional breeding will result in a le-
thal cross, and thus preclude socially “bad” crosses, whereas a nonlethal in-
sertion of a single gene from a phylogenetically distant-related organism 
will give a nonlethal, but necessarily “bad” cross? Or is it something more?
Whatever it may be, the social issues of biotechnology were very early 
with us, starting with the Asilomar Conference in which scientists voluntar-
ily agreed to monitor and control dissemination of their biological research, 
requiring their products and processes to pass voluntary government review, 
first with the Recombinant DNA Advisory Committee of the National Insti-
tutes of Health, and then for a counterpart committee for agricultural bio-
technology managed by the U.S. Department of Agriculture (USDA). By all 
accounts, these methods are working very well. But, notwithstanding the 
obvious success, there is still broad social concern. And this concern leads to 
understandable frustration and steady struggle for understanding. It is likely 
true that these social concerns will continue to be with us until a body of ex-
perience and knowledge builds substantially further.
But I believe there is much more to these concerns.
B R O A D E R  D I M E N S I O N S  O F  T H E  C O N T E X T  F O R  A G R I C U L T U R A L  
B I O T E C H N O L O G Y
Biotechnology does not function in isolation. It is now an intimate part of 
our international technological fabric. It is part of our technological con-
text, and it is thus afflicted by the same concerns besetting other technolo-
gies. Agricultural biotechnology, especially, has the potential to be pervasive 
through no effort once released into the environment. And the effects can be 
irreversible. It has the very real potential to create new life forms, possibly to 
obliterate old forms, and to spread its effects with- 
Biotechnology         out control. In all of these ominous qualities it is 
does not function similar to nuclear energy. More positively, it also
in isolation. has powers akin to those of the information revolu-
tion, the other molecular revolution in which we 
are engaged: powers to permit rapid, molecular-level changes: to give excep-
tionally high specificity and rapidity of effect; to tailor crops and agricultural 
practices in ways heretofore only dreamed about; to provide for major pro-
ductivity increases, increasing the quality of produce in ways believed not
14 Agricultural Biotechnology: A Public Conversation About Risk
possible. Because agricultural (and environmental) biotechnology is inter-
national, with the potential of affecting all manner of peoples and prac-
tices, it also becomes part of our cultural fabric. So biotechnology inextrica-
bly weaves itself through our technology and culture and like the information 
revolution, is seen as doing so unchecked by the normal forces guiding tech-
nological progress.
Agricultural biotechnology can, and likely soon will, focus on all the crops 
of the world; on most, if not all, of the cultural practices; 
and in virtually myriad environments. In all of this, 
it is much more complex and pervasive, and thus likely 
more vexatious, than biomedical biotechnology which fo-
cuses only on humankind, a single species with but little 
variation among its parts. This is a large part of our con-
founding context.
But there is more. Biotechnology gets to life itself.
Its technological focus is control of genetic codes, of restructuring the ge-
nome, of making new forms of life, of tailoring life as we would have it be. 
Never before has there been this technological power, nor the number of ex-
pert practitioners working it.
It is no surprise, then, given the power of biotechnology over that which 
is most sacred—individual identity and character—that our skeptics are so 
troubled. They should be. Ours (scientists) is a trust that is, itself, sacred.
And this trust, itself, is wrapped in puzzlement. Discovery always is. 
What is being studied anyway? What value does it have? Who will control 
the results? And discovery in biotechnology, and the more difficult field 
of agricultural biotechnology, is even more vexatious because of the excep-
tional speed and specificity with which results can come. And control of the 
results is vested with the scientists themselves, or they are vested with the in-
dustrial laboratories that have, presumably, at least some self-interest in 
mind. So the cloak of silence of discovery roils the social context yet further. 
And this is exacerbated by the lack of personal control, perceived and real, 
over the results of biotechnology such as evidenced by concerns for the pos-
sible spread of genetic characteristics to unwanted organisms or to environ-
ments which are desired free of such interventions.
Biotechnology is also afflicted by the lack of trust in traditional leaders, 
such as scientists, government officials, major industries and university pro-
fessors. We are perceived as out of touch, concerned with issues other than 
those of concern to society, unwilling or even unable to understand. Not 
much of that may be true, but it is widely believed, nonetheless.
Our agricultural biotechnology clearly has a complicated, intertwined, 
vexed context within which must be developed and used. And its human di-
mensions are especially important.
Biotechnology 
is also afflicted 
by the lack of 
trust in tradi-
tional leaders...
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S E A R C H I N G  F O R  P A R A D I G M S
Given the challenges, we must, foremost, be humbled by our knowledge and 
tools, and we must be awed by the responsibilities that are ours. And then we 
must necessarily consider carefully what to do to make progress, to create 
understanding, to make wise decisions, to be responsible stewards of that 
with which we have been entrusted. What are we to do?
First, we must never forget that individuals make a difference. Each has 
concerns and a life history that matter. We need to get information through 
the appropriate information channels to each of those who need and wish to 
know, and we must do so in ways each person can individually understand. 
Trust be engendered through straight talk, humility, and concern for truth 
and understanding.
Second, we need to understand what the relevant social structures are 
for agricultural biotechnology. Are they that of biomedical biotechnology?
A patient-doctor relationship? An individual, willful undertaking? Or are 
they something different? I believe it much different because of the dram-
atic differences between biomedical biotechnology and agricultural biotech-
nology already referred to, such as pervasiveness in the environment, mul-
tiple and difficult-to-understand effects on many organisms, and evolution- 
arily permanent, at least in potential. This brings us directly to the impor-
tance of ecosystems and their functioning and stability, understandings we 
unfortunately know too little about, but which are so crucial to agricultural 
biotechnology.
Third, we need to do better at joining social science, values and ethics 
to our biological, physical and technological societies. Biotechnology proves 
to us that the separations between values and technology are nonexistent, or 
at least artificial. We had best fuse our concerns. The 
competitive grants program in the U.S. Department 
of Agriculture provides a new, significant avenue for 
making these connections.
Fourth, we must recognize that biotechnology is 
often a surrogate for other issues such as unchecked 
productivity increases, manipulation of the natural 
environment, changes in the structure of agriculture, 
continuation of technology-based agriculture as con-
trasted to some persons definition of sustainable agri-
culture, vertical integration and industrial hegemony in a heretofore highly 
decentralized and individualistic enterprise, unnatural means of producing 
food, and the like. What makes this so difficult is that each of these issues has 
plenty enough grist for the discussion and resolution mill without admixing 
them with biotechnology.
Fifth, to aid our understanding and decision-making we need to continue 
to work out the logical similarities and differences between analogies. Two
Biotechnology 
proves to us that 
the separations be-
tween values and 
technology are 
nonexistent, or at 
least artificial.
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...biotechnology is 
often a surrogate 
for other issues.
such analogies are: 1. traditional plant and animal breeding (which could be 
called organismal biotechnology) as compared with biotechnology as now 
practiced (which could be called molecular and cellu-
lar biotechnology); and 2. biomedical biotechnology 
as compared to agricultural biotechnology.
Sixth, progress in product development should 
be continued, with tough-minded but scientifically 
and procedurally fair reviews of products such as for 
approving genetically engineered fruits like the tomato and for changes in 
cultural practices as for herbicide-resistant plants and genetically engi-
neered biological control agents.
Seventh, the NABC itself should continue to focus on being a crucible 
for testing similarities and differences of views, for finding common threads, 
for increasing understanding thereby.
Eighth, the USDA has some special opportunities and responsibilities 
which should be addressed forthwith: 1. The surrogate issues, outlined 
above, should be energetically and comprehensively dealt with, to the extent 
that is not already being done; 2. The relationships between agriculture and 
environment should be a special, ongoing emphasis. The two need not be in 
conflict. Indeed, they are not in inherent conflict. They are only made so by 
partisan adherents. Nowhere can this be more easily and productively ad-
dressed than in biotechnology for agricultural practice, concomitant with 
environmental improvement. A focused, integrated set of studies to this 
end—mutually undertaken by USDA, the Department of the Interior and the 
Environmental Protection Agency—should be established as soon as fea-
sible, but not later than October 1, 1994; 3. The social science, ethics, and 
values issues embodied within agricultural biotechnology, as well as within 
the total agricultural enterprise, should be addressed through both basic and 
applied research convoked through the Department’s competitive grants pro-
gram; 4. evaluation protocols appropriate for agricultural and food (and 
environmental)biotechnologies should be developed distinct from those used 
for biomedical biotechnology, as has been oft-noted at this conference. This 
study could effectively be done by the National Research Council through its 
Board on Agriculture in collaboration with the Council’s Food and Nutrition 
Board and its Commission on Life Sciences.
Lastly, these issues can, and must, be considered at the intellectual, even 
abstruse level, which university faculty enjoy. But, the issues are real and they 
are ultimately felt by all humankind the world over. Our challenge, then, 
must be to deal with theory and rational analysis, as is our wont, but we must 
also be sure we deal, ultimately, with the issues in the fundamentally human 
and individual terms that are, after all, the real focus of our attention.
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W O R K S H O P  R E P O R T
Technical Risk Assessment and Regulations
Co-chairs: Rebecca Goldburg, Biologist, Environmental Defense Fund 
William F. Greenlee, Pharmacology and Toxicology,
Purdue University
Products of agricultural biotechnology, such as field tests of genetically engineered crops or foods derived from genetically engineered crops, 
may pose risks to ecosystems or human health. However, the traditional risk 
assessment paradigm, developed to assess the carcinogenicity of chemicals, is 
not easily applied to products of agricultural biotechnology. Thus it is nec-
essary to develop new risk assessment approaches in order to assess the risks 
of many agricultural biotechnology products.
After making scientific assessments of the nature and magnitude of any 
risks, regulators and other decisionmakers must elect a course of action. This 
risk management process often involves weighing risks and benefits of a par-
ticular product. The process can be difficult for agricultural products (e.g., 
pesticides, whether genetically engineered or not), since many of the indi-
viduals who bear direct risks from these products may not be the primary 
beneficiaries of the products.
Workshop participants set out to identify issues and make recommenda-
tions concerning risk characterization and risk management in agricultural 
biotechnology. Participants were first split into three groups to identify im-
portant issues. From the large number of issues identified by all three groups, 
participants selected, by vote, three issues for further discussion. The selected 
issues were essentially consecutive steps in the risk characterization and man-
agement process:
Identify hazards of process/product 
Measure risks and establish scientific standards 
Balance risk and benefits
Workshop participants then divided back into three groups, one for each is-
sue, to develop recommendations. These three groups reported their recom-
mendations to the workshop as a whole, and all participants were given an op-
portunity to discuss the recommendations before they were made final. The 
third group noted that risk is a part of life, and many participants felt that 
consideration of biotechnology products should somehow involve benefits as 
well as risks. Balancing risks and benefits for agricultural biotechnology
products can be extremely difficult, however, especially when risks and ben-
efits are not, for the most part, borne by the same individuals or groups. No 
specific recommendations were agreed upon for balancing risks and benefits.
R E C O M M E N D A T I O N S
Identify Hazards of Process/Product
The National Academy of Sciences should study and develop strategies for hazard 
identification in agricultural biotechnology.
Regulators have extensive experience identifying the hazards of syn-
thetic chemicals, but this experience is not always directly applicable to 
agricultural biotechnology products.
More input is needed from the scientific community to develop hazard identi­
fication methodology for agricultural biotechnology products.
Legislative gaps should be filled (e.g.,fish, shellfish).
Regulatory agencies, in some instances, lack the authority to adequately 
address risks of agricultural biotechnology products. Fish and shellfish 
present a clear example of such a gap. No agency has a clear Congres-
sional mandate to regulate either the risks of releases of genetically engi-
neered fish and shellfish or to regulate the safety of fish and shellfish 
(genetically engineered or not) for human consumption.
Land-grant universities need to address issues such as sustainable agriculture, 
family farms, and pesticide use, for which biotechnology now serves as a 
lightening rod or even a surrogate focus.
Some agricultural biotechnology products are the focus of considerable 
criticism or opposition from individuals who believe that these products 
may exacerbate existing trends in agriculture. Many issues about the 
structure of agriculture, (e.g., the loss of family farms), merit public de-
bate. Unfortunately, few obvious forums are now available for public 
discussion of these issues. As a result, in some cases biotechnology 
products are serving as the primary vehicle for debate.
Government officials need to develop integrated approaches to regulation 
that incorporate knowledge of product and process.
As has been noted by many others, risk assessment of biotechnology 
products should be based on the characteristics of the products and not 
the fact that biotechnology was used to develop the product. Neverthe-
less, knowledge of the process used to develop a product can sometimes 
help form the questions asked in risk assessment or aid in decisions con-
cerning which products to assess (e.g., in assessing the safety of a drug, 
regulators often consider the process used in its manufacture because the 
process can affect the presence of impurities in the product). Regulation
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of biotechnology products should be based on science and the law, and 
not on ideological avoidance of all references to biotechnology.
Measure Risks and Establish Scientific Standards
Tools (appropriate test systems) should be developed to evaluate the potential 
hazards of three classes of organisms: animals, plants and microorganisms.
Scientific guidelines need to be developed to ensure that any ecological 
or human and animal health risks of agricultural biotechnology prod-
ucts are adequately addressed. The following are examples of areas that 
may merit the development of such “tools:”
Animals
-containment/ecological effect of releases 
-human safety of expressed products 
-unforeseen metabolic effects
Plants
-containment/ecological effect of releases: 
altered disease/insect susceptibility, 
weediness, and 
outcrossing.
-human safety of expressed products 
-unforeseen metabolic effects
Microorganisms
-containment/ecological effect of releases: 
colonization,
pathogenicity/toxicity to nontarget organisms, and 
frequency and impact of gene transfer to other microbial species, 
-unforeseen metabolic effects
Models should be developed to assess the toxicity and allergenicity/antigenic-
ity of expressed products as part of developing risk assessment guidelines.
It also should be noted that it is impracticable to measure any and all po-
tential unforeseen effects. One can only look for specified unforeseen ef-
fects of particular concern.
Technical Risk Assessment 2 3
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WORKSHOP REPORT
Public Assessments of Benefits and Risks
Cochairs: Ted A. McKinney, Community Affairs & Contributions, DowElanco 
A. Ann Sorenson, Center for Agriculture and the Environment,
American Farmland Trust 
with Patrick A. Stewart, American Farmland Trust
The purpose of this workshop was to establish an understanding of the underlying reasons for public concerns about agricultural biotechnology. 
This was accomplished by dividing the 28 participants into three smaller 
groups to discuss issues and possible solutions followed by an open group 
discussion in order to reach consensus. Over the course of two days, the often 
spirited discussion revolved around public perceptions and ways in which to 
respond to the public’s need for credible information.
MAJOR THEMES
Discussions centered around two interrelated themes that came into sharp fo-
cus later on in the workshop. Both dealt with public perceptions of biotech-
nology. The first was a possible paradigm shift in the way the public thinks 
about the benefits and risks of biotechnology. The perception of the group 
was that there is no longer an unquestioning acceptance of the social para-
digm in which humans are seen as dominating the planet and its resources.
It is being replaced by an environmental paradigm, in which the public per-
ceives limits to growth. Biotechnology’s place in this new paradigm has not 
yet been determined, but its perceived role may affect its acceptance.
The second underlying theme that emerged from the workshop was that 
of the potential of biotechnology to bring about change. With the introduc-
tion and development of biotechnology, society has been given a powerful 
tool to change its environment in unforeseen ways. This leads to questions 
about how society should shape itself and who should make decisions as to 
the form and extent of change. This has understandably raised public con-
cerns. However, the workshop participants saw that decisions pertaining to 
biotechnology must be made because the technology cannot be suppressed, 
only channeled into desired uses. The participants further saw that if the 
public did not become involved in the decision-making process early on, the 
marketplace would make decisions in its absence.
These two themes are seemingly in conflict. On the one hand, many 
people are fearful of new technologies and express an increasing desire for
nonintervention in the ecology of the planet. On the other hand, biotechnol-
ogy offers the possibility of more controlled and targeted interventions into 
the environment, minimizing negative side-effects. Ironically, even as science 
has developed a technology that can change the environment, the public’s 
perception and acceptance of biotechnology has turned away from the prom-
ise of benefits, and focused on risks associated with technological change. 
Technical analysis of benefits and risks is no longer sufficient to assure accep-
tance of biotechnology. Increasingly, an appraisal of the public’s perception 
of those risks and benefits by stakeholders must be considered as well.
STAKEHOLDERS
The participants felt it was important to define who the stakeholders in pub-
lic assessment of risks and benefits associated with agricultural biotechnol-
ogy are. The stakeholders fall into five broad groupings:
Government: Local, state and federal level policymakers in the legisla-
tive, executive/administrative and judicial branches. 
Universities/Research Organizations: Groups providing the scientific 
knowledge and information on which policy decisions are often 
based.
Special Interest Groups/Organizations: Groups with an interest in pre-
serving or changing the social and economic status quo. These in-
clude environmental groups, farm groups, industry/trade organiza-
tions, health groups, unions, religious groups and others. 
Corporations/Organizations Funding Research: Organizations creating 
products and technologies to serve their constituents/consumers. 
Consumers/The Public: Individuals directly affected by the production 
and consumption of biotechnology.
ISSUES
Workshop participants identified three major issue areas in public percep-
tion of agricultural biotechnology: personal issues, societal issues and pro-
cess issues. Intervention to influence public policy can take place at any of 
these levels.
Personal Issues
Personal issues deal with how an individual views the impact of biotechnol-
ogy on themselves. Personal issues identified by workshop participants in-
cluded: food safety/health, economic impact, environmental/animal health, 
and the spiritual/moral-ethical dimensions of genetic engineering.
Food Safety/Health: Questions about the safety of food manipulated 
through genetic engineering and its impact on human health are of particu-
lar concern for the agricultural biotechnology industry.
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Economic Impact: Individual concerns over the economic impact of ag-
ricultural biotechnology center around possible positive and negative impacts 
on jobs and the introduction of new products into the market.
Environmental/Animal Health: Individuals are becoming increasingly 
aware of negative impacts to both the environment and animals. The percep-
tion of agricultural biotechnology’s role in ameliorating or aggravating current 
conditions will influence the acceptance and use of agricultural biotechnology.
Spiritual/Moral-Ethical Dimensions: Some individuals seem to have a 
“gut reaction” to biotechnology, not necessarily connected with religious be-
liefs, that no amount of scientific knowledge or data will change.
Societal Issues
Societal issues deal with ties between society and its leaders, and the strength 
of those ties. Again, in no particular order, the participants identified the fol-
lowing issues:
Trust: Public involvement in policymaking has increased in the past two 
decades. Citizens are increasingly suspicious that policymakers, who they see 
as manipulated by private interests, may be trying to manipulate them. This 
leaves them wondering who to trust with decision-making and who to turn to 
for credible information. Debate over the scientific accuracy of information 
also has contributed to a basic distrust of authority.
Motives: The public also has developed a distrust of some individuals 
and groups on the basis of their motives. They perceive an imbalance between 
those who bear the risk and those who benefit in society. The brunt of this 
distrust has been directed at industry because of its necessary focus on profit-
making.
Socioeconomic Concerns: There was concern over the possible impacts 
of biotechnology on the socioeconomic structure of groups and communities. 
The possibility of concentration of ownership of food production through 
control of biotechnology is disconcerting to some. The potential impact of 
agricultural biotechnology on small and medium-size farms, and its possible 
contribution to the loss of a traditional way of life, is of special concern.
Process Issues
The third tier of concern was that of process issues, or how policies are made 
and who makes them.
Public Policy: Questions over public policy on biotechnology focused on 
who determines policy, who should determine the policy, and how policy 
should be implemented. There was an expressed need to find a process of 
technology control with which the public is comfortable and involved.
Public Understanding of Agricultural Biotechnology: The issue of 
public knowledge was seen as going beyond that of agricultural biotech-
nology to science and technology as a whole. Participants felt that lack of
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public knowledge was understated by most people and that some people 
simply are not concerned or likely to ever be concerned about the impacts of 
biotechnology on their lives. In spite of this, there was a desire to distribute 
accurate information ranging from the technical aspects, the socioeconomic 
impacts and the moral/ethical concerns of biotechnology.
Public Attitude About Biotechnology: There was a two-pronged ques-
tion about the public’s attitude concerning agricultural biotechnology and 
how to assess it. The public currently receives information from competing 
channels: special interest groups, media, government, industry and university 
sources. Because these messages often conflict, public attitudes about bio-
technology are shaped by what appears to be the most trustworthy source. It 
is at this point that information moves from being a scientific issue to being a 
political issue.
Process and Value of Measuring Public Response to Risk: The value of 
measuring public perception of risk was questioned for two reasons. First, 
gaps between the public’s statements of what it would do and what it actually 
does always exist. Second, even if such information were known, changing 
public attitudes is difficult.
What Does the Public Think vs. What is Known: There was a belief that 
the majority of public decisions are made on the basis of emotion and limited 
information. This is of great concern to researchers and industry who must 
deal with a public that cares little about science and must attempt to bridge 
the gap between science and the public’s understanding of it.
SUMMARY STATEMENT
After much discussion, workshop participants agreed on the following sum-
mary statement on public assessment of risks and benefits of bio technology:
We recognize that technical assessment is not the only factor in public 
acceptance of technology. We recognize the need for better understanding 
of personal and societal values. We also recognize the need to under-
stand the factors influencing public attitudes about biotechnology and 
biotechnology-derived products on the part of stakeholders.
RECOMMENDATIONS
On the basis of the preliminary discussions, the combined group developed 
recommendations for dealing with personal, societal and process issues. 
These objectives address the concerns outlined in the group’s summary 
statement:
Develop and implement methods of identifying and monitoring public under-
standing of and awareness about issues and potential changes being brought 
about through biotechnology.
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Greater support is needed for social science research through multiple 
methods such as surveys, informal information gathering, expanded dia-
logues between stakeholders, public forums and content analysis.
Place additional emphasis within education and the educational process on 
defining, assessing, and understanding risk and decision-making under uncer-
tainty.
Expand the capacity and commitment of the scientific community to more ef-
fectively communicate with the public.
Expand to an ongoing dialogue about the implications of the knowledge 
being generated.
Place additional emphasis on science education in kindergarten through 
twelfth grade.
Expand public dialogue and discussion about the forces of change being gener-
ated by biotechnological developments beyond traditional channels (the Fed-
eral Register, Public Comment, university extension services, etc.) in order to 
reach the public at the grassroots level.
Broaden involvement of stakeholders in identification of priority needs to be 
addressed by biotechnology.
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WORKSHOP REPORT
Public Values: Benefits and HarmsC
Cochairs: Rosetta Newsome, Scientific Affairs and Information,
Institute for Food Technologists 
Lilly-Marlene Russow, Philosophy, Purdue University
The workshop began with clarification of the topic of the workshop, and howit might be separated from the other topics. It was noted that the 
concepts of benefit and harm—particularly the latter—were considerably 
broader than the more specific idea of risk. “Risk” tends to invite a focus 
on health and safety issues, while benefits and harms extend beyond these 
specific concerns. Nonetheless, it was clear that the topic is very broad, that 
nearly every question about biotechnology is a question about public values, 
and hence that any attempt to predetermine the focus of the workshop would 
restrict the discussion too much. Two themes were repeatedly emphasized:
1. public values grow out of attempts to acknowledge and balance the values 
of diverse individuals; and 2. the whole issue of public values must consider 
the process by which values are shaped, expressed and recognized.
IDENTIFYING ISSUES
The participants were asked first to identify, and then to prioritize, topics of 
greatest concern. The results were as follows. Issues are listed in the order 
they were assigned as the result of vote, with comments voiced by participants 
and examples of topics within specific issues included under each general 
heading1. Topics are reproduced exactly as formulated by the workshop, since 
in many cases there was substantial debate about the wording. The results of 
the voting upon which the ranking was based are included. The first issue, 
identified below, ranked considerably higher than the others2.
1 The summaries under the heading “Elaboration/Analysis of Major Issues” reflect 
only the initial discussion. The workshop discussed the top-ranked issues in more 
depth on the second day; the discussions are summarized under the heading 
“Other Issues.”
2 Each participant was asked to list all seven topics in order of importance. Each list 
was then weighed, with the issue listed first receiving a “1”, the second a “2”, and 
so on to the last, which received a “7.” Since there were sixteen participants who 
voted, there was a possible range of 16-112 points, with the lower numbers rep-
resenting the issues judged more important.
Who should have the right or power to make decisions that have broad 
social implications? (29 points). Participants decided to consider the ques-
tion of who ought to have a voice, rather than simply to ask how decisions 
are currently made. Participants pointed out that public institutions are 
poorly funded and need to be empowered, and that a sharp, reductionistic 
divide between science and technology and other sources of value (e.g., reli-
gion or spirituality) exists. More generally, this topic encompasses the ques-
tions of who sets research agendas, who shapes and controls the regulatory 
process, how the food-production system is determined and controlled, and 
who decides what products are available.
What criteria are used to assign value to new biotechnology? (53 points). 
The discussion began with a look at how the public views biotechnology and 
other “new” technologies in contrast with familiar products and processes. 
Some view new scientific discoveries as “progress,” and “new” as equivalent 
to “better” or “improved.” However, at least since Hiroshima, others express 
increasing numbers of questions, and perhaps skepticism, about the wisdom 
and value of some so-called “advances.”
How safe is safe enough? (59 points). This discussion began with the 
observation that people today have different expectations about safety than 
they did earlier; they are more likely to raise questions about the safety of ev-
erything from food to playgrounds than they were fifty years ago. Although 
safety is only one factor in public value, it is important enough, and complex 
enough, to warrant careful consideration. Participants noted that there were 
conflicting ideas about what is included in judgments about safety. Percep-
tions of safety were tied to control in that something one can choose to avoid 
(e.g., bungee jumping) is less likely to raise serious safety concerns than 
things that are more difficult to avoid (e.g., drinking water). It was also 
pointed out that there are discrepancies between what people say they want 
and what they are willing to pay for, but that economic and class value systems 
were important factors to keep in mind. The importance of avoiding an elitist 
structure was emphasized: safety should not be a luxury limited to those who 
can afford to pay for it. On the other hand, concern about safety rarely over-
rides basic needs—one participant mentioned that people starving in Sudan, 
or even getting canned food from a soup kitchen, are less likely to worry 
about insect damage or contamination than affluent Americans.
What communication is needed among all citizens affected by biotech-
nology? (65 points). Preliminary versions of this topic were phrased in terms 
of information, but people soon changed to a discussion of communication 
in order to emphasize the need for true dialogue and the importance of 
avoiding an arrogant “us vs. them” attitude. Specific questions noted under 
this general heading were: 1. what sort of information consumers need and 
want; 2. the concept of “informed consent” and what that standard requires;
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and 3. what sort of information regulators and legislators need in order to 
reach decisions.
How does biotechnology affect distribution of assets, incomes and 
power? (73 points). In general, public values will vary according to who wins 
and who loses through biotechnological advances. If large corporations are 
perceived as profiting while small family farms are perceived as harmed (as 
the bST/bGH controversy is sometimes portrayed), biotechnology is more 
likely to be viewed as harm. A more specific subheading under this issue had 
to do with the impact of biotechnology on the structure of the food produc-
tion and distribution system.
What is the environmental impact of biotechnology? (85 points). There 
was little initial discussion of this issue, but subsequent comments indicated 
that it included, among other things, affect on the type and quantity of 
pesticide used, water quality and biodiversity. On the issue of biodiver-
sity, one participant pointed out that more thought must be given to the 
choice of plant species used, e.g., to develop substances such as plastic 
substitutes. Choosing alfalfa rather than corn as a ‘host’ for example, the 
participant said, would be beneficial in that it would help stem the ten-
dency towards monocultures and their attendant problems.
How should concerns for animals be taken into account? (93 points). 
There was considerable debate about the wording of this point. Some people 
wanted to describe the issue in terms of a contrast between concern for ani-
mal welfare and animal rights (“Should animal welfare be expanded to in-
clude animal rights?”). Others felt that terms like “animal rights” were 
prejudicial and unclear, and that a broader and more neutral description of 
the issue would be preferable. By majority vote, the form given above was 
chosen by the group.
E laborat ion /Analysis  of  Major  Issues
The workshop was then asked to break into two subgroups to explore the two 
issues identified as the most important topics. Each group was given one 
topic, and asked to identify: 1. barriers which hindered the group from 
addressing the issue effectively and appropriately, and; 2. recommenda-
tions about how to deal with the issue and the associated barriers. The 
barriers and recommendations developed by each subgroup were then 
presented to the entire workshop for discussion.
Who Should Have the  Right or Power to Make Decisions That Have  
Broad Social Implications?
The subgroup which discussed this highest-ranking issue began by iden-
tifying the various sorts of “players” in the process of evaluating biotech-
nology. The following were identified: 1. regulators (including legislators
Public Values 33
and regulatory agencies such as USDA, FDA, etc.); 2. developers (industry, 
scientists, granting agencies, academia); and 3. consumers (including both 
consumers in the literal sense of people who buy a product and also people 
seeking other benefits, such as environmental groups). The news media were 
also cited as players which can wield significant influence.
Next, the group identified the following barriers:
—Exactly what people want to know is not always known.
—Not everyone wants to get involved; some people want someone else to 
make the decisions. Consumers typically are overwhelmed; scientists 
typically want to be left alone to focus on their own work.
—Current procedures for gathering views and disseminating information 
are too formal to be widely effective (e.g., most people do not read the 
Federal Register).
—A common base of shared knowledge cannot be presupposed.
—In determining value, the scientific processes which are learned, the in-
vestigative tools which are developed and the advances in basic science, 
not just the concrete products of biotechnology need to be considered.
—The complexities of diverse cultures and value systems need to be un-
derstood and respected. This will affect, among other things, choices 
about whether, when and how, to compete with other countries in the 
international marketplace.
—Although the current political forum in which policy is shaped is sup-
posed to be democratic, questions are raised concerning how demo-
cratic it is in practice.
Recommendations
Finally, the group offered two recommendations:
Increase the opportunity for “friendly” participation in the formal process. A 
system is needed which encourages and fosters broad participation, and which 
really listens and responds to input from all stakeholders.
Congressional hearings, by contrast, are often unfriendly, and people 
who testify often leave with the feeling that their input made no difference.
Real discussion (as opposed to mere dissemination of information) needs to be 
promoted among broad and diverse audiences.
NABC meetings represent a valuable first step, but do not represent the 
diversity of positions and values that must ultimately be included.
What Criteria are Used to Assign Value to New Biotechnology?
The second subgroup identified barriers and made recommendations re-
garding this second major issue. Barriers fell into two major categories. 
Several examples are identified in each category.
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The first category of barriers or complexities in defining value or public 
good concerned the heterogeneity of people affected by biotechnology and public 
values. Religious, ethnic, economic, age and educational differences were all 
thought to effect how people judge the benefits and harms of biotechnology. 
Specific biotechnological developments will rarely be perceived similarly by 
all segments of the population. Moreover, people differ with respect to their 
willingness and/or ability to accept risks.
The second category of barriers related to information, and the difficulty 
of getting information into a public forum early enough. Full and free ex-
change of information is often hindered by concerns for intellectual property 
rights, the proprietary interests of an industry and competitiveness between 
industries, the desire of scientists to keep findings to themselves until their 
work has been published, and regulatory restrictions on discussion of prod-
ucts under regulatory review. It was suggested that there is a possible “win-
dow of opportunity” for earlier exchange of information after a patent has 
been granted, yet prior to marketing. This suggestion was countered by the 
observation that the restrictions of the patent process limit this potential 
“window.” Participants recognized that within the current system, a signifi-
cant investment, both public and private, is made before public value is fully 
established.
Recommendations
The group then offered several specific recommendations to help overcome 
the problems inherent in dealing with the heterogenicity of the public.
While the general theme reflected an encouragement of broad public in-
volvement and consideration, these items were considered more as examples 
than as a complete list. The following suggestions were identified:
Be sensitive to religious concerns and provide information in food labeling ac-
cordingly.
Develop information which is clear and understandable, so as to be accessible 
to people with a variety of educational backgrounds.
Assess the social/economic impacts of specific biotechnology applications at 
the earliest stage possible.
Specifically, applications should not adversely impact individuals in the 
low income sector, e.g., applications that would raise significantly the 
cost of foods should be avoided.
Establish a societal “minimum acceptable risk level,” recognizing that some 
products or processes might be too risky to be acceptable at all; and identify 
risk levels of acceptable applications to enable individuals to make personal 
decisions about risk acceptability.
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To deal with information barriers, the group suggested:
Land-grant universities and extension offices be singled out as particularly 
appropriate forums for discussion and dissemination of information.
However, effective functioning in these roles requires increased funding, 
more attention to and respect for extension activities as part of the origi-
nal mission of land-grant institutions, and more autonomy from industry 
support.
More attention be given to the “window of opportunity” (see above).
Information should be exchanged and made available as widely as pos-
sible during this period, and consideration should be given to modifying 
the processes and regulations to allow for better exchange of informa-
tion as soon as possible. Thus, open forums (designed to encourage per-
sonal communication and dialogue, not promotion) during the early 
stages of development before beginning marketing, need to be fostered. 
This would require, among other things, clarification of restrictions on 
discussion of patent applications under review and products under 
regulatory review.
Finally, participants offered a variety of additional criteria likely to arise in 
various applications of biotechnology. This list is not to be interpreted as 
recommended standards or criteria to be formally incorporated into the ap-
proval process, but rather, items which warrant consideration as early as pos-
sible in the developmental process. The difficulty of accurately projecting 
impact of various applications was recognized, though. The first point men-
tioned in this regard was the need to pay attention to both long-term and 
short-term impact, people evaluate a product on the basis of what its impact 
maybe in twenty years as well as what it maybe now.
Other criteria mentioned were: impact on the food supply—nutritional 
value, food quantity, quality, variety and cost, and impact on the structure of 
agriculture. With regard to agricultural structure, concerns were: Will the 
application accelerate vertical integration and the role of farmers in the 
decision-making process and will it impact the sustainability of the process?
Is government support required? Impact of the new development on current 
products and on food production were also offered.
Environmental concerns generated another set of possible criteria. Wa-
ter quality, sustainabililty and biodiversity were a few of the concerns that 
were highlighted. International effects also were mentioned, including com-
petitiveness and impact on Third World or developing nations. Finally, eco-
nomic and social considerations were brought up again, with particular em-
phasis on concern for equitable distribution of financial gains.
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O T H E R  I S S U E S
The detailed discussion of the two most important issues did not leave much 
time to pursue the other topics that had been identified during the first ses-
sion. Nonetheless, some of the lower-ranking topics (e.g., the environment) 
had been taken up in the course of discussing one or both of the first two is-
sues, and some discussion of the third and fourth issues (safety and commu-
nication) was possible. The variety of participant comments on the third 
and fourth issues are detailed below.
How Safe is Safe Enough?
Several barriers were noted. The first was short-term versus long-term 
safety considerations. A related point emphasized generational consider-
ations, and the fact that people are often willing to take risks for themselves, 
but not for their children. (Alar was cited as an example of this point). Sec-
ond, the public is increasingly unwilling to trust science and industry, and to 
view assurances from these sectors with suspicion. Next, the tension that of-
ten arises between public safety and individual freedom and choice was men-
tioned. Laws requiring motorcycle helmets, and New Jersey’s short-lived at-
tempt to prevent restaurants from serving soft-boiled or sunny-side up eggs 
were cited as examples. Finally, the apparent failure of our educational sys-
tem to provide people with an adequate understanding of scientific methods 
and the limits of science, for example, was cited.
Recommendations
These problems gave rise several recommendations:
The need for better education at all levels, beginning with kindergarten.
The need to avoid absolutes when talking about safety.
Nothing is simply or absolutely safe, and this requires open communica-
tion about levels of safety.
It is necessary to take a much broader perspective when considering safety. 
One should attempt to evaluate the whole process, source as well as out-
come. In considering Salmonella contamination for example, all stages 
of the poultry and egg production process are to be evaluated, not just 
egg preparation and consumption practices.
What Communication Is Needed Among All Citizens Affected by  Biotechnology?
This last issue addressed the need to improve communication. The main 
point conveyed here was the need to communicate on an effective, personal 
level, which requires, among other things, listening to public concerns as
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well as providing information in an appropriate way. Educational levels and 
vocabulary were two factors that should be kept in mind. Realism is always 
necessary; practitioners must listen to real situations expressed by the pub-
lic. It also was recognized that many individuals exhibit a narrow vision or 
focus on their own specific agenda, and that communication may be ham-
pered by people’s unwillingness to get involved, or doubt about whether they 
should really care about these issues.
Recommendations
To address these problems, the group recommended:
Better support for land-grant institutions and extension offices.
Better education programs at the K-12 levels.
More strenuous efforts to support scientific societies (e.g., Institute of Food 
Technologists) with information for broad dissemination.
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WORKSHOP REPORT
   Public Communication About Risk
Co-chairs: Karen Bolluyt, Agricultural Information Services,
Iowa State University 
David Judson, Gannett News Service
MISSION
To provide society the information it needs to evaluate the potential risks and 
benefits of agricultural biotechnology.
BACKGROUND
Certain basic principles can guide all involved in public communication 
about risk as it relates to biotechnology.
Opinions about risk vary from one perceived risk to another. Peter Sand-
man, professor of environmental communication at Rutgers University, has 
described “outrage factors” that drive personal assessments of risk. Commu-
nication about any perceived risk should include an analysis of the risk in 
light of factors that influence personal perceptions of risk. According to 
Sandman, these include: 1. individual control in assuming risk (voluntary vs. 
involuntary exposure); 2. fairness or the extent to which a risk is distributed 
equally; 3. morality or the extent to which technology or behavior not only 
poses a risk but is perceived to be evil; 4. dread, e.g., the belief that the poten-
tial damage may be catastrophic or may cause a fatal, lingering illness; 5. fa-
miliarity, as illustrated in the difference between fear that peanut butter may 
contain carcinogens or the fear that irradiation may change foods in undesir-
able ways; and 6. trust as earned or lost in all areas of organizational behavior.
Some elements of modern technology help cause increased perceptions 
of risk. These include: 1. the improved ability to detect toxic substances (one 
part per quintillion); 2. new technology that is not understood except by 
people with exceptional skills or highly specialized education; 3. knowledge of 
catastrophes or instances in which technology believed to be beneficial proved 
to be harmful (e.g., thalidomide); 4. experts disagreeing during litigation, 
hearings or other widely publicized public discussions; 5. growing production 
and distribution systems that increase the potential for technologies and 
products to affect millions of people each day, thus increasing the chances for 
catastrophe; and 6. growth in knowledge and the accompanying growth in 
awareness of gaps in knowledge (How valid are methods of risk assessment?).
Categorizing some perceptions of risk as “irrational fears” interferes with 
risk communication and is a counterproductive substitution for thoughtful
exploration of issues/answers. “Many risk experts insist that ‘the data’ alone, 
not the ‘irrational’ public, should determine policy. When a risk manager 
continues to ignore [outrage] factors—and continues to be surprised by the 
public’s response of outrage—it is worth asking just whose behavior is irra-
tional.” (Sandman, 1987)
The long-term view for risk communication is that society and/or con-
sumers determine the success or failure of new technology and new products. 
This long-term outlook should drive communications plans and activities.
In the United States a majority of people express some belief that bio-
technology in agriculture can benefit them and express some support for the 
development of biotechnology. The public strongly expresses a need/desire 
for information about biotechnology and for the opportunity to be involved 
in decisions about the use of biotechnology in the development and use of 
products.
Communication is not the easy task of message distribution once the 
difficult decisions about financing, research, development, marketing, etc. 
are made. It is a crucial, complex, continuous, circular interchange that 
should be a central part of all planning and budgeting. In general, communi-
cation plans and efforts have been inadequate.
R E C O M M E N D A T I O N S
The workshop participants prepared recommendations on three topics: 
communication content, credible communication, and circular communica-
tion. Some recommendations were made for more than one topic, but each 
is reported only once here.
Communication Content
Communication should contain more than facts. Opinions and values should 
enter the communication mix at every juncture, and that is taken into account 
later in this report. The following recommendations regarding factual infor-
mation were made:
Communicate in specifics as much as possible.
Focus on specific products or technologies, risks or benefits.
Focus on what a product/technology will mean to specific audiences.
Use simple language (old, short words).
Prepare to be brief and concise about key ideas and information, and be pre-
pared to provide detail (probably written).
For all sources of information, identify the source’s qualifications and af-
filiations.
Base information on sound science.
40 Agricultural Biotechnology: A Public Conversation About Risk
Credible Communication
Beginning with the assumption that credibility must be earned and con-
ferred, that it can not be claimed or bought, the following recommendations 
were made:
Provide full disclosure of information about benefits, risks, and the assump-
tions on which the information is based.
Be clear and forthright in describing biases or financial interests that an audi-
ence should understand to evaluate information and opinions from various 
sources.
Provide product information and 1. provide, or 2. make it easy to obtain pro-
cess information.
Do not simply state conclusions; provide background information about 
how conclusions were reached and distinguish between opinion and fact.
Use language and concepts that the audience understands.
Clarity is credible. People are more likely to be suspicious of what they 
do not understand.
Choose spokespeople carefully, considering each audience and using the 
audience’s criteria for trustworthiness.
Build bridges with key groups by identifying people who can serve as liaisons. 
All members of most groups will not become experts in biotechnology, 
so they identify a trusted group member or liaison who is knowledgeable 
and they rely on him or her for guidance.
Circular Communication
If one accepts the proposition that the consumer will be one of the primary 
determining factors in the process of acceptance, then there are two critical 
communication questions to be addressed: 1. How do we provide the infor-
mation consumers need? and 2. How do we develop and maintain effective 
feedback from consumers? This process is complex, but it has a circular na-
ture that provides points of reference for plans and actions. These points of 
reference are: 1. provide information for the forum of pubic debate; 2. listen 
to the feedback in the ensuing dialogue; and 3. go back to point one. The fol-
lowing recommendations for establishing circular communication are made:
Listen more than you talk.
All participants should make special efforts to listen attentively, with the 
goal of understanding the facts and beliefs behind various points of 
view. A corollary to this is that multiple sides of an issue should be pre-
sented during meetings/discussions.
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Adopt the wheel model for risk com-
munication. (right)
The hub is society/the con-
sumer. The spokes are con-
duits for information flowing 
to and from the public, and the 
rim is the arena of interaction 
containing multiple sources of 
information and opinion. Any 
poorly functioning part of the 
wheel will have a negative im-
pact on the whole.
Identify the stakeholders at the rim 
of the wheel, and key individuals and 
groups among the general public at the hub.
Deciding whether an individual or group belongs at the rim or in the hub 
will be a useful part of communication planning.
Identify the communication channels.
Define the role, the costs and the importance of each channel, and de-
velop communication plans accordingly. Among the channels that might 
be used to exchange information are the following: K-12 education, 
land-grant institutions—particularly their extension services, interper-
sonal communication, mass media, targeted media, coalitions, focus 
groups and surveys, consumer behavior, organizational boards, and for-
mal or informal opinion leaders.
The following were selected recommendations for channels of communication:
Increase funding for such programs as “Ag in the Classroom.”
Science teachers’ associations should be invited to cooperate in planning 
educational programs.
Provide scholarships for teachers and students that could bring them to uni-
versity and industry labs as interns or workshop participants.
Take advantage of all opportunities to build coalitions. Bringing together 
groups that disagree often works.
Areas of disagreement are based partly in misunderstandings and lack of 
information. Common ground and common goals often can be identi-
fied. Such coalitions can become credible communications channels be-
cause they do not represent a single point of view.
Share new and existing information from focus groups and surveys as widely as 
possible.
This is one efficient way to identify problems and issues early and to 
build general understanding of biotechnology and of public opinion and 
behavior.
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Use the land-grant model for coordinating communication.
Cooperative Extension might be empowered to build and coordinate co-
operative agricultural biotechnology communication programs.
Identify and use opportunities for interpersonal communication.
Several decades ago, research on the adoption of innovations pointed to 
the importance of interpersonal communications for decision-making. 
Recent research on risk communication indicates that human behavior 
has not changed in this regard. This inefficient channel for communica-
tion may be the only effective channel/best channel in many instances. 
Organizations should make interpersonal communication (i.e., listening 
and talking) a strategic part of communication plans.
Use mass media and targeted media to reach audiences and to elicit responses 
from them.
Media relations strategies have changed considerably with the growth of 
special interest publications. There never has been any such creature as 
“the general public,” but media targeted at specific groups have increased 
in importance while many “mass media,” (e.g., daily newspapers) have 
decreased. The role of mass media and more targeted media as sources 
of facts and as mechanisms for calling attention to issues also has re-
mained relatively stable since the time of the adoption-diffusion studies 
of the 1940s.
Use the body of communications research on the role of these communications 
channels to plan risk communications.
Advise organizations and institutions to incorporate diverse points of view into 
their leadership.
This should begin with The National Agricultural Biotechnology 
Council.
Recognize the importance of informal and formal leaders.
For many issues, formal and informal leaders are sought out for their 
opinions. Sometimes they are in decision-making positions, but not al-
ways. They are, however, channels for information. Special efforts 
should be made to understand how they obtain information and to keep 
them informed.
Communication about biotechnology is a complex process that requires equal 
attention to facts about the science and understanding of human behavior. It 
requires planning, resources and respect for the consumer. It can be frus-
trating. Poorly executed, it can create ill will and a great drain on resources 
directed at damage control. It should receive careful as the attention from 
the beginning of any efforts in biotechnology.
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Regulatory Risk Assessment: 
A View from the Potomac*
David R. MacKenzie 
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CSRS-USDA
One needs to understand the history of U.S. biotechnology regulations in order to comprehend the present regulatory structure. It all began with 
the recombinant DNA research in the early 1970s. At that time the hazards of 
the research were not known and the scientific community formulated its own 
program for biosafety oversight, managed through the National Institutes of 
Health (NIH), coordinated through the Recombinant DNA Advisory Com-
mittee (RAC), and operated through a distributed network of Institutional 
Biosafety Committees. The NIH-RAC evolved a series of guidelines for re-
combinant DNA research that has become the standard for contained labora-
tory experimentation.
After a decade of successfully using guidelines and institutional over-
sight, the technology followed its normal sequence of activities leading to 
small-scale testing to be conducted outside of laboratory containment. Quite 
independently, but coincidentally, the National Research Council (NRC) pub-
lished the “Redbook” (NAS, 1983) which set out a new paradigm for risk
'The views expressed are not necessarily those of the U.S. Department of Agriculture.
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analysis. It is important to understand the dimensions of the NRC risk para-
digm because it directly influenced subsequent policy decisions regarding 
the regulation of biotechnology.
PRINCIPLES OF RISK ANALYSIS
The risk paradigm provided in the “Redbook” described the process of risk 
analysis as being made up of:
Risk Assessment 
Risk Management 
Risk Communication
The sequential steps in risk assessment are: the identification of a hazard, fol-
lowed by an assessment of exposure, and then risk characterization. Exposure 
is made up of fate and effects, when the focus of the assessment is on the envi-
ronmental release of an organism. Conceptually taken together the identifi-
cation of a hazard times the exposure is the characterization of a risk, or:
Risk Characterization = Hazard x Exposure, 
when
Exposure = Fate x Effects
Risk assessment should be conducted with a sound scientific basis and use 
inferences as appropriate.
Risk management is the process of determining what to do about a char-
acterized risk. This includes risk prevention, as well as the identification, se-
lection and use of mitigating measures to reduce risk. Environmental risk 
management considerations often include social, economic and political 
judgements. The process of risk management should be institutionally sepa-
rated from risk assessment.
Risk communication is an interactive process that promotes the ex-
change of information and opinions about risk among individuals, groups 
and institutions. This process should include providing access for stake-
holders, or participation by and appreciation of public perceptions of risks.
THE FEDERAL COORDINATED FRAMEWORK
As the process of biotechnology research approached small-scale testing out-
side of contained laboratories, the Executive Branch of the Federal govern-
ment began extensive discussions on how to coordinate regulatory activities 
to assure adequate protection of public health and the environment vis-a-vis 
biotechnology (ca. 1984). One of the foundations of the Federal Coordi-
nated Framework for Regulation of Biotechnology (OSTP, 1986) is that the 
regulatory decision should be risk-based, and thus was set in motion the 
process of applying the “Redbook’s” principles for risk analysis.
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The first step in risk analysis is the identification of a hazard. It was 
clearly evident to the Federal Coordinated Framework policymakers that 
not all biotechnology represented a hazard. For instance, the application of 
somaclonal variation to crop improvement was definitely biotechnology, but 
it did not represent an unusual hazard. Additionally, some activities in re-
combinant DNA biotechnology were accepted as no, low or reasonable risk, 
and therefore these were not prime candidates for regulation.
What was identified was the fact that 
some products of biotechnology may repre-
sent an unusual hazard. Thus, these prod-
ucts should be the subject of risk assessment 
and regulation. It was therefore asserted that 
the products of biotechnology, not the pro-
cess, should be the focus of Federal biotech-
nology regulation.
This distinction eventually became misconstrued by a few zealots of the 
Federal Coordinated Framework for Regulation of Biotechnology. They 
took the principle one step further, in an inept attempt to obliterate the dis-
tinction between conventional methods and the new biotechnologies. A ter-
minology mind-game reminiscent of the popular book 1984 (Orwell, 1949), 
dominated Federal regulatory terminology during the Bush Administration. 
The use of common scientific terms like “genetically modified organisms,” 
“transgenic” and “genetically engineered,” was forbidden in regulatory lan-
guage. As policy was derived from the Federal Coordinated Framework, 
some creative terminology had to be invented by technical editors (e.g.,“de-
liberately modified hereditary traits”) to comply with these policies.
Another primary principle of the Federal Coordinated Framework was 
that there would be no new laws. This principle was derived from the as-
sumption that existing statutory authorities were sufficient for Federal regu-
latory agencies to regulate the products of biotechnology. In the beginning 
this made a lot of sense. The first applications of biotechnology were emerg-
ing as pharmaceuticals and drugs, and this industry had long been regulated. 
Thus, there was considerable resistance on the part of the drug industry to 
biotechnology regulation per se, inasmuch as the existing regulatory struc-
ture seemed clearly sufficient.
This was not however the case for much of the rest of the applications 
of biotechnology, especially in agriculture. Much of the agriculture research 
enterprise had never been regulated, and existing authorities to deal with 
clearly identified special threats (such as plant pests; pesticides; toxic sub-
stances; animal viruses, serums and toxins; meat and poultry inspections; 
and food additives) stretched this eclectic collection of authorities over the 
domain of agricultural biotechnology. This became a challenge that has
Risk assessment should 
be conducted with a 
sound scientific basis 
and use inferences as 
appropriate.
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pretty much been met successfully. This success was achieved through the 
promulgation of new regulations under existing legislative authorities, indi-
vidual efforts and a commendable level of interagency coordination to get 
the job done.
In spite of the extraordinary efforts to make the Federal Coordinated 
Framework fit the structure of agricultural biotechnology, some gaps and
overlaps still exist. For example, it is still not clear 
how transgenic fish will be regulated, either in the 
research stage or as commercial products. U.S. 
Federal authority for the regulation of aquatic 
species is yet to be resolved, and as a consequence 
there is no existing statutory authority for fish 
and shellfish biotechnology products. Similar 
situations exist for non-pest insects, amphibians, 
reptiles, plants that have been transformed with 
sequences not from plant pests, and non-pest and 
non-pesticidal microorganisms when the re-
search has no commercial intent (e.g., some types of university research with 
rhizobium). Moreover, the final promulgation of the Environmental Protec-
tion Agency (EPA) authorities under the Federal Insecticide, Fungicide, and 
Rodenticide Act (FIFRA) and the Toxic Substances Control Act (TSCA) has 
yet to take place.
Given the above considerations some have called it remarkable that the 
Federal Coordinated Framework has been so successful for agricultural bio-
technology regulation. A lot of the credit for this success goes to a few people 
in the Federal regulatory agencies that have given extraordinary effort to 
make it succeed.
If the regulation of 
biotechnology is to be 
risk-based, a clear and 
general agreement on 
what constitutes a 
hazard needs to be 
reached.
THE NEXT GENERATION
As the technology progresses through its normal sequence, many of the prod-
ucts of agricultural biotechnology are ready for larger-scale performance test-
ing, pre-commercial evaluations and eventual commercialization. As a con-
sequence there are considerations that go beyond small-plot testing during 
these subsequent stages of product development that will place further strain 
on the processes of the Federal Coordinated Framework. Certainly the expe-
riences and knowledge gained from small-scale testing can be used to better 
predict performance in larger-scale testing and commercial use, but not ev-
erything is directly translatable. The identification of the hazards of large- 
scale testing, the consideration of exposure, the numerics of large popula-
tions, and the probability values for fate will all take on new dimensions in 
large-scale tests. The question now being asked is: Is the Federal Coordinated 
Framework for Regulation of Biotechnology fully adequate to address today’s 
and tomorrow’s questions regarding the risks of biotechnology?
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As the question on the Federal Coordinated Framework’s adequacy is 
asked, is this the time to revisit the fundamental principles upon which it rests?
The regulatory issue of product versus process is not truly a settled issue, 
at least in the minds of many. The process of biotechnology and the trans-
forming of organisms with foreign DNA represents to many an identified haz-
ard requiring risk analysis. This perspective is no doubt related to the U.S. 
Food and Drug Administration’s (FDA) May 1992 request for more public 
comment on its policy regarding the labeling of foods derived from new 
plant varieties. The FDA wants to know:
—Should all foods derived from new plant varieties developed using 
“genetic engineering” techniques be required to be labeled as such?
—Should labeling the source of introduced DNA be required?
—Under what circumstances is ingredient labeling appropriate?
—How can required labeling for food allergies be accomplished?
—What are the practical difficulties and economic impacts of labeling 
“genetically engineered” foods?
Clearly the regulatory issue of hazard identification for biotechnology is not 
resolved. Different perspectives on what constitutes a hazard complicates the 
development of a consensus. Without completing the first step of risk as-
sessment, the application of scientific objectivity to the rest of the process 
will not be sufficient for those with opposing views.
WHAT IS NEEDED?
If the regulation of biotechnology is to be risk-based, a clear and general 
agreement on what constitutes a hazard needs to be reached. This involves 
reconciliation of the different views of the world where commercial interests 
advise the use of marketplace determinants; regulators prefer the use of a 
hierarchial, authoritative decision-making process; scientists assert the need 
for a rational process; and those concerned for the environment wish to apply 
a natural standard to the identification of a hazard.
Adding further complication is how different standards of objectivity are 
judged. Scientific objectivity is based on standardized techniques which per-
mit experimental reproducibility. Social inquiry studies are considered objec-
tive if devoid of personal bias. Legal proceedings are considered objective if 
the participants adhere to the principle of disinterestedness. A lawyer would 
hardly view a scientist as objective if the scientist has an interest in that brand 
of science. Conversely, a scientist would accuse the lawyer of being subjective 
if the judgements were not truly reproducible. Social scientists share similar 
concerns for jurisprudence and biological science as they do not see them as 
necessarily free of personal bias. Who then is to provide objective judgements 
for biotechnology regulation?
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Until we can resolve the issues of what constitutes a biotechnology haz-
ard and who will make the objective judgements, it is not very likely that a 
consensus will emerge on how to proceed.
CONSENSUS BUILDING
Figure 1, taken from Douglas and Wildavsky (1983) presents the four prob-
lems of consensus building in risk analysis. In each of the four cells there is 
represented a risk problem, and a proposed solution. The dimensions of the 
block are knowledge and consent. In the upper left cell knowledge is certain 
and consent is complete. If there is a technical problem, it is merely a matter 
of making a calculation to derive a solution.
In other circumstances knowledge is uncertain, although consent is 
complete (upper right cell). In these situations the problem is not enough
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information and the indicated solution is to conduct risk assessment re-
search to resolve the problem. This is the approach that the U.S. Department 
of Agriculture (USDA) has implemented through Section 1668 of the 1990 
Farm Bill. The USDA sets aside 1.0 percent of its biotechnology research 
outlays to conduct risk assessment research to fill knowledge gaps. This year 
the Department will award competitively $1.7 million for risk assessment re-
search projects to help facilitate science-based, regulatory decision-making.
In those cases where knowledge is certain, but consent is contested, the 
problem becomes one of disagreement and the solution is dialogue (lower left 
cell). The role of organizations such as the National Agricultural Biotechnol-
ogy Council (NABC) is very important in this type of circumstance. Through 
public dialogue, understanding can be built on existing, certain knowledge 
and perspectives of divergent views being more clearly understood.
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It is the fourth cell (lower right cell) that represents the most difficult 
situation. In this case knowledge is uncertain and consent is contested. 
Presently, there is not a good solution for this type of situation. Clearly dia-
logue would be desirable. And more research might help resolve the un-
known. But bringing together the information and divergent views for prob-
lem resolution represents one of the most tricky responsibilities facing sci-
ence, government, public and private institutions, and the concerned public.
WHAT IS BEING DONE?
Discussions are now underway as to the adequacy of the Federal Coordinat-
ing Framework for Regulation of Biotechnology. As research discoveries 
progress along the path to commercialization, closing the information gaps, 
eliminating unnecessary duplication, and deregulating technologies known 
to be safe seem to be important items for our national agenda. Some of these 
changes can be seen with the recent implementation of an Animal and Plant 
Health Inspection Service (APHIS) notification and petition process for 
plant biotechnology regulation under the Plant Pest Act authority.
Also, the USDA’s Marketing and Inspection 
Service is meeting with the FDA to coordinate new 
regulations for meat and poultry biotechnology 
and to close the gap for fish and shellfish. This 
latter gap may however require new legislation and 
this would represent a departure from a major 
principle embedded in the Federal Coordinated 
Framework. Other existing regulatory gaps may 
require similar gap-filling legislation.
There is clearly a need for more biosafety information exchange, both 
nationally and internationally. The Stockholm Environmental Institute re-
cently established a free advisory service for Third World countries wishing 
an evaluation of the safety of field tests with genetically modified organisms. 
U.N. agencies are now looking at their role in information support systems for 
biotechnology on a global basis. The Organization of Economic Cooperation 
and Development is continuing to provide international leadership on the 
principles of biotechnology regulation and safety, and the European Eco-
nomic Committee is working with the U.S. government to coordinate re-
search and regulatory activities.
A major issue in these efforts is the extent to which the U.S. scientific 
community can and should become involved in the international exchange 
of information. If biotechnology is expected to be a major advantage in U.S. 
competitiveness in global markets, how much information should the U.S. 
share, given the advantage of a technological lead? Opportunities to collabo-
rate in biotechnology risk assessment, biosafety data exchange, and regulatory
There is clearly a 
need for more 
biosafety informa-
tion exchange, both 
nationally and 
internationally.
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practices seem to be obvious areas for international collaboration for mutual 
benefit. But to be successful, greater organizational and financial support 
for such international collaboration is needed.
There is a clear need for national educational programs in biotechnol-
ogy that would organize factual information to be shared with the interested 
public, both youth and adult. The USDA’s National Biological Impact As-
sessment Program is sponsoring a pilot project with the University of 
California,Davis, targeting school-age children with teaching materials on the 
scientific principles of biotechnology. The Agricultural Research Institute 
is looking for partners to assist in the development of a biotechnology educa-
tional program focused on adults. These are but two examples of what has been 
started in biotechnology public education.
Finally, there is a need for more national biotechnology dialogue, as 
there is not so much the absence of factual knowledge, but clearly different 
views on values, standards and preferences. NABC should continue to play 
an important role by providing a forum for continued biotechnology dia-
logue that will hopefully diminish disagreements and build toward a consen-
sus on a national direction for agricultural biotechnology.
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Risk Assessment: A Technical Perspective
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Regulatory Jurisdiction: Genetically Engineered Plants  
After more than ten years of plant biotechnology research and extensive field 
evaluation at sites throughout the United States (Gasser and Fraley, 1989), 
the first of several improved crop products being developed are undergoing 
regulatory review prior to market introduction. Before these products were 
submitted for review, the various U.S. regulatory bodies had considerable in-
put and oversight into the research and development undertaken to verify 
the performance and safety of these products. Initial research in the labora-
tory was performed under the National Institutes of Health (NIH) Recombi-
nant DNA Guidelines (1976; 1982). Several years of field-testing were car-
ried out under the jurisdiction of the United States Department of Agricul-
ture (USDA), in conjunction with the U.S. Environmental Protection Agency 
(EPA) for pesticidal plants. Regulatory approvals may be required by all 
three regulatory agencies (USDA, EPA and FDA [ Food and Drug Administra-
tion] ) prior to marketing these products. Early in this regulatory process, 
the Office of Science and Technology Policy (OSTP) issued the “Coordinated 
Framework for Regulation of Biotechnology” (1986) which assigned appro-
priate regulatory oversight and responsibility for biotechnology to these fed-
eral agencies, (see discussion by MacKenzie, p. 47)
USDA regulates the movement and release of genetically engineered 
plants under the Plant Pest and Quarantine Act since many of these plants are 
generated using organisms or DNA sequences from organisms that are plant 
pests. The program is administered by the Animal and Plant Health Inspec-
tion Service (APHIS). APHIS will make a determination concerning the 
plant pest status of varieties derived via biotechnology prior to market intro-
duction. EPA regulates the safety of the plant pesticidal products (e.g., pro-
teins that provide insect or disease resistance) as active ingredients and the 
protein(s) used in the selection process for generating these plants (e.g., se-
lectable marker proteins) as inert ingredients. FDA oversees the food and 
feed safety of products derived from these plants.
During the past decade, as progress has been made in the production, 
testing and development of plant biotechnology products, regulations and 
safety assessment requirements have developed to assure the safety of these 
products. There has been significant progress in the past twelve months by 
each of the three regulatory agencies in providing guidance and requesting 
public feedback on how these products will be regulated. The USDA pub-
lished draft guidelines in June of 1992 (APHIS, 
1992a) for public comment. The final policy 
was published in March, 1993 (APHIS, 1993). 
EPA published their proposed policy on regu-
lating plant pesticides, under the Federal Insec-
ticide, Fungicide and Rodenticide Act (FIFRA), 
for public comment and sponsored a Science 
Advisory Panel discussion on December 18,
1992 to obtain public input on this proposed policy (EPA, 1992). Likewise, 
FDA published their proposed policy for regulating genetically engineered 
plants and plant products on May 29,1992 for public comment (FDA, 1992).
The first of the products produced by plant biotechnology, the Flavr 
Savr™ tomato by Calgene, Inc. (Sheedy et al., 1988), has been reviewed for 
plant pest status by the USDA (APHIS, 1992c) and is presently under review 
for food and feed safety by the FDA (Redenbaugh et al., 1992). A petition to 
the USDA has also been submitted for virus-resistant squash by the Upjohn 
Company (APHIS, 1992b). With over 500 field tests that have been per-
formed around the world to date (Huttner et al., 1992; Casper and 
Landsmann, 1992) many other products are being extensively evaluated for 
agronomic, environmental and consumer value. The food, feed and environ-
mental safety of each of these will be assessed prior to marketing. One of 
these, a potato improved to control a specific insect pest without the use of 
chemical pesticides, serves as a case study for how this safety assessment is 
being performed to assure product wholesomeness and safety, environmen-
tal soundness and to support public confidence in these products.
The food, feed and 
environmental safety of 
each of these will he 
assessed prior to 
marketing.
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COLORADO POTATO BEETLE RESISTANT POTATOES
Potato plants that control that crop’s most serious insect pest, the Colorado Po-
tato Beetle (CPB), are among the first products that Monsanto has developed 
and for which we are completing a safety assessment. We have worked for nearly 
10 years to develop and evaluate these potato plants, which resist CPB through 
the production of an insect control protein, found in nature, that selectively 
controls the beetle without affecting nontarget in-
sects, humans or animals. These plants were pro-
duced by inserting and expressing a gene from Ba-
cillus thuringiensis subsp. tenebrionis (B.t.t.) in the 
potato plant (Perlaket al., 1993) using Agrobacterium 
transformation (Newell et al., 1991). The CPB-re- 
sistant plants produce low levels of two new proteins, 
the B.t.t. protein for resistance to CPB and the 
neomycin phosphotransferase (NPTII) protein produced to enable the 
selection of cells expressing the B.t.t. protein in tissue culture. The B.t.t. pro-
tein produced in these potato plants is the same as one of the insecticidal pro-
teins contained in several microbial formulations that have been used safely and 
have been commercially available since 1988 (EPA, 1988).
CPB is the most damaging pest of the $2.3 billion U. S. potato crop (Casa- 
grande, 1987; National Potato Council, 1992) and economically important 
in the majority of the North American potato production regions. Loss of 
revenue in Michigan alone was estimated at more than $15 million in a state 
where potato production is valued at $70 million (Potato Growers of Michi-
gan, 1992; Olkowski et al., 1992). If untreated or poorly managed, the CPB 
can devastate potato production in some areas (Hare, 1980; Ferro et al.,
1983; Shields and Wyman, 1984). Current treatment of CPB primarily in-
volves the use of insecticides that are variably effective due to environmental 
factors and insect insensitivity, and significantly reduce field populations of 
beneficial insects which help control other potato pests. These pesticides are 
also expensive, with costs that can exceed $200 per acre per season (Ferro 
and Boiteau, 1992).
Field trials conducted in 1991 with CPB-resistant potatoes demonstrated 
effective control of feeding damage by all stages of the CPB. There were sig-
nificantly fewer immature larvae, adults and egg masses of CPB on the gene-
tically improved potatoes, compared to the control plants. Without insecti-
cide application, defoliation of the improved potato plants was less than, or 
equal to, control plants sprayed with insecticides on a regular schedule. In 
addition, agronomic evaluations consisting of plant vigor, growth habit char-
acteristics and general insect and disease susceptibility, have shown the CPB- 
resistant potatoes to be equivalent to the parental Russet Burbank potatoes. 
Field tests were expanded in 1992 with similar results.
CPB [Colorado Potato 
Beetle] is the most 
damaging pest of the 
$2.3 billion U.S. potato 
crop...
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These genetically improved potatoes offer several advantages to the 
grower, the consumer and the environment for controlling this devastating 
insect pest. The superior CPB control offered by the plants will enable grow-
ers to significantly reduce the amount of chemical insecticide now applied to 
their crop while maintaining comparable yields. Re-
ducing the amount of insecticide applied to potatoes 
will further aid the implementation of Integrated 
Pest Management (IPM) practices as beneficial in-
sect populations will be maintained, which can help 
reduce the other pests of potatoes not directly con-
trolled by the CPB-control protein. The B.t.t. pro-
tein also has been shown to be safe to nontarget spe-
cies, including humans (EPA, 1988) and thus pro-
vides an environmentally safe means to control 
CPB. In addition, CPB-resistant potatoes will ben-
efit both large and small growers as no additional 
labor, planning or machinery is required for adoption. Prior to market in-
troduction, the potato lines will continue to be evaluated for performance 
and to refine insect management programs. Efforts will focus on confirming 
CPB control across the potato growing regions and developing production 
systems that optimize the benefits of these improved potatoes.
As with other food crops improved through biotechnology, USDA, EPA 
and FDA exercise joint regulatory oversight for these genetically improved po-
tatoes. All field tests have been carried with the approval of the USDA. In Oc-
tober 1992, an Experimental Use Permit (EUP) was requested from the EPA. 
The EUP permit, approved in May, 1993, allows for more extensive field eval-
uation of CPB-resistant potato varieties to be performed on more than 10 
acres. Prior to commercialization, a USDA determination of the nonreg- 
ulated status and an EPA product registration will be obtained under the re-
spective policies described above. Likewise, appropriate consultations with 
and oversight by FDA will be conducted as described in the FDA policy.
SAFETY ASSESSMENT OF CPB-RESISTANT POTATOES
Monsanto’s policy for ensuring the safety of the CPB-resistant potatoes is 
consistent with the published policies of the three regulatory agencies and 
relies on two approaches. The first approach is to provide appropriate infor-
mation to establish that the CPB-resistant potatoes are “substantially equiva-
lent” to the Russet Burbank potatoes from which this variety was derived.
The term “substantial equivalence” refers to the concept that the genetically 
improved potatoes are comparable to the Russet Burbank potatoes in respect 
to composition, nutritional quality, yield, morphology and in other aspects 
that could impact the use, value, and the environmental, food and feed safety 
of this product. The only significant difference that has been observed be-
The first approach is to 
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tween the genetically improved potatoes and the Russet Burbank potatoes is 
that the CPB-resistant potatoes effectively control the insect pest by express-
ing two additional proteins (B.t.t. and NPTII). No other differences have 
been observed. The concept of “substantial equivalence” or “substantial 
similarity” has been used by FDA (1992) and other international organiza-
tions (Organization for Economic Co-operation and Development, 1992; 
International Food Biotechnology Council, 1990) in their recommended ap-
proaches for safety assessment. In essence, this is the way new plant varieties 
and plant products have traditionally been regulated. In addition to estab-
lishing the “substantial equivalence” of the CPB-resistant potatoes to the 
Russet Burbank potatoes, we will also provide data to confirm the environ-
mental, human and animal safety of the two newly expressed B.t.t. and 
NPTII proteins.
SUBSTANTIAL EQUIVALENCE OF CPB-RESISTANT POTATOES TO 
RUSSET BURBANK POTATOES
Information concerning the source(s) of the genes introduced, the methods used 
to produce the genetically improved potato plants, the molecular characteriza-
tion of DNA introduced into these plants, and characterization of the levels 
of the B.t.t. and NPTII proteins serves as a basis for characterizing the CPB- 
resistant plants. The important nutritional and natural products in potato are 
being determined for both the genetically improved and Russet Burbank pota-
toes to show that the composition of the potato tuber has not been altered dur-
ing the transformation and regeneration processes. Levels of the macronutri-
ents—protein, fat, carbohydrate, dietary fiber and ash—are being determined. 
The levels of the important vitamins—vitamin C, vitamin B6, thiamine, nia-
cin, folic acid and riboflavin—are being assessed. Levels of important miner-
als—calcium, copper, iron, iodine, magne-
sium, phosphorus, potassium, sodium and 
zinc—are being evaluated. The only class of 
important potato natural toxicants, the 
glycoalkaloids (solanine and chaconine), have 
been quantified and shown to be comparable 
in both the genetically improved and Russet 
Burbank potatoes. Raw potato tubers from both the CPB-resistant and Russet 
Burbank potatoes were fed, along with the regular rat diet, to rodents in a 28- 
day study to assess the palatability of these potatoes. No differences in consumption, 
growth rates, or observations during gross necropsy were observed during these 
studies. These data have confirmed that the CPB-resistant potatoes are com-
parable to the Russet Burbank potatoes in all aspects except for the ability to 
control the CPB pest due to the presence of minor amounts of B.t.t. and NPTII 
proteins.
...use of registered B.t.t. 
products offers no significant 
risks to human health or 
nontarget organisms.
Fuchs, Stone & Lavrik 59
SAFETY OF THE Bt PROTEIN
The Bt gene used to produce CPB-resistant potato plants, designated 
cry Ilia, (Hofte and Whiteley, 1989) was isolated from DNA from Bacillus 
thuringienses subsp. tenebrionis (McPherson et al., 1988). The Bt gene en-
codes an insecticidal protein produced by these bacteria during sporulation. 
The protein is selectively active against coleopteran larvae. Upon ingestion 
by susceptible species, feeding is inhibited with disruption of the gut epithe-
lium and eventual death of the insect pest (Slaney et al., 1992). The amino 
acid sequence encoded by the gene inserted into potato plants produces a 
protein that is identical to that produced by Bt found in nature 
(McPherson et al., 1988).
Based on the available scientific data, EPA and other regulatory agencies 
worldwide have determined that use of registered Bt products offers no 
significant risks to human health or nontarget organisms (Shields and 
Wyman, 1984; EPA, 1991). In published reviews and the EPA documents, 
studies are referenced where large doses (5000 mg per kg) of Bt prepara-
tions were administered as single or multiple doses to different laboratory 
animals with no adverse effects. Avian and aquatic organisms have also been 
fed Bt preparations with no adverse effects. The preparations which were 
administered contained varying amounts of crystalline proteins from Bt, 
either as a mixture with spores or encapsulated in killed Pseudomonas 
fluorescent cells (EPA, 1991). While target insects are susceptible to oral 
doses of Bt proteins (pg per gram of body weight), there was no evidence 
of any toxic effects observed in nontarget laboratory mammals, including 
fish or birds given the equivalent of up to 106 pg of protein per gram of body 
weight. No deleterious effects were observed on nontarget insects at doses 
over 300- to 700—fold that needed to control the target insects (Macintosh et 
al., 1990). In addition to the predicted lack of receptors for the Bt protein, 
the absence of adverse effects in nontarget animals is further facilitated by 
the poor solubility and rapid degradation of Bt proteins in the acid envi-
ronment of the digestive system.
To confirm the safety of the Bt protein expressed in CPB-resistant po-
tatoes, we have obtained gram quantities of purified Bt protein by express-
ing this protein in microbial systems (E. coli). Limited expression of this 
protein prohibited the isolation of large quantities of this protein from the 
potato tubers or potato plant directly. Minor amounts of this protein, puri-
fied from the potato tuber and from microbes, were shown to be chemically 
and functionally equivalent. A series of commonly used analytical assays 
were used for this equivalence assessment. An acute gavage study was con-
ducted in mice to confirm the safety of the Bt protein. A dose, following 
EPA guidelines, was used that was equivalent to over 2.5 million-fold safety 
factor based on the average consumption of potato and the level of the Bt
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protein present in the tuber. No adverse effects were observed in terms of 
food consumption, weight gain, mortality or gross necropsy observations. 
Purified protein was also used in an in vitro digestion experiment which 
demonstrated that the Bt protein has an extremely short half-life (less 
than 20 seconds) under simulated gastric conditions (The United States 
Pharmacopeia, 1990). These studies confirm the safety of the Bt protein 
to humans and animals.
The specificity of the Bt protein to CPB was confirmed by host-range 
studies using the purified Bt protein. Five nontarget, beneficial insects 
(including honey bees, lacewings, ladybird beetles and a parasitic wasp) were 
also shown to be unaffected by doses of the purified Bt protein that are 
greater than 100 times the amount required to affect the CPB-target insect. 
These studies confirm the specificity of the Bt protein and the safety of 
this protein to nontarget insects. We are also performing studies to confirm 
the rapid degradation of the Bt protein in the soil after potato tubers are 
harvested.
SAFETY OF THE NPTII PROTEIN
The NPTII protein, and hence the gene encoding this protein, was used as a 
selectable marker to enable the identification of potato cells that contained 
the B.t.t. gene. The description and safety assessment of the NPTII protein 
has been discussed in detail in the FDA submission for an advisory opinion 
by Calgene (1990) and by recent articles by Flavell et al. (1992) and Nap et al. 
(1992). In addition to this information, we have performed similar equiva-
lence acute gavage and digestive fate studies as described for the Bt protein 
above, with similar results. No adverse effects were observed in the acute 
gavage study with greater than a 5 million-fold safety compared to projected 
consumption, and the half-life of the NPTII protein in the simulated diges-
tive fate study was also less than 20 seconds, confirming the mammalian 
safety of this protein.
SUMMARY
A variety of plant biotechnology products have been developed and exten-
sively tested under field conditions. Appropriate regulatory oversight has 
evolved, and continues to evolve, through the various stages of the develop-
ment of this technology. All three regulatory agencies in the U.S. issued ei-
ther draft or final policies during 1992 that outline their policies on regulat-
ing genetically engineered plants. Two plant products are currently being 
reviewed under these policies and several more are expected to follow closely 
behind. One of these is the CPB-resistant potatoes that is described in this 
report. We have described the approaches that we are using to assess the 
food, feed and environmental safety of this product as an example. The
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philosophy is based on the concept of “substantial equivalence.” The new 
potato variety, derived using plant biotechnology, is established to be com-
parable to traditionally bred potatoes by comparing nutritional quality, level 
of important natural products, and agronomic and environmental perfor-
mance. In addition, a direct safety assessment of the newly expressed proteins 
(Bt and NPTII, for the CPB-resistant potato) confirmed the safety of these 
components. These safety assessments have confirmed the food, feed and 
environmental safety of the CPB-resistant potatoes. Similar assessments are 
being performed for other plant varieties derived using plant biotechnology 
to assess the safety of these products.
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Risk Assessment: A Farmer’s Perspective
Will Erwin 
Indiana Farmer 
(center)
It is important to understand that this is only one farmer’s perspective.I simply cannot speak for other farmers—who range from small, part-time 
farmers to large corporate farmers who have large professional staffs and 
many employees. I speak as an individual farmer reflecting the thoughts of a 
Midwest commercial family farmer who has had a number of responsibilities 
in state and federal government.
This presentation will discuss what farmers are like—really like—the 
comprehensive environment in which they operate, the macro changes in 
farmer decision-making, how farmers look at change in general, how farmers 
look at changes in biotechnology in particular, how farmers assess a new 
product and some of the issues we, as farmers, will be facing in the future.
It will highlight those points which tend to be overlooked about farmers 
and have particular relevance.
WHAT ARE FARMERS REALLY LIKE?
Farmers are well-educated people, averaging slightly more years of educa-
tion than non-farmers, often with university degrees and frequently with 
master degrees and PhDs. As a group they work for less per hour than non-
farmers, consume less and accumulate more than others. In short, they live 
poorer but die richer, but they doit because they want to for noneconomic
reasons.
Among those noneconomic reasons are personal independence, love of 
and attachment to the soil, love of animals and nature, and a deep sense of 
stewardship. Most farmers put a high premium on religion. Daily working 
with the life and death realities of nature and isolation to think without in-
terruption, increases religious commitment which the community discipline 
of rural people reinforces.
Farmers are increasingly anxious economically as they have felt the agri-
cultural depression. They are increasingly uncomfortable about seemingly 
endless environmental hazards, be they perceived or real. Radon, the ozone
layer and the unknowns of pesticides and biotech-
nology cause concern. Recent news stories of 
women with breast cancer having higher levels of 
DDT in their systems intensify concerns, both in 
the specific and in the future, about what their new 
information may indicate about all pesticides.
There is increasing fear of unreasonable regu-
lation and even of entrapment—where farmers 
may follow all the rules and be found negligent, or 
where they may make the extra effort to be environmentally responsible and 
be found liable.
Farmers tend to trust their neighbors, their clergy, their farm organiza-
tion, their university and extension people, as well as the business people 
they deal with. However, they are less comfortable with their government 
and the extremists who may influence government.
Increasingly, farmers are uncomfortable with agricultural leaders who 
take extreme anti-environmental positions, but they are also very concerned 
with unrealistic positions taken by some animal rightists and environmental 
spokespeople. Perhaps farmers’ most rapidly escalating hunger is for fact 
and truth, and they are less sure where to get it.
WHAT IS THE ENVIRONMENT IN WHICH FARMERS OPERATE?
The knowledge explosion has left farmers increasingly awed by the realization 
that what they do know is a constantly reducing percent of the knowledge 
available. They feel a need for more knowledge and yearn for sources they be-
lieve are sound.
Farmers are increasingly vulnerable. A county judge once told me he 
could put anyone in the county in jail. There are so many laws, everyone is 
technically violating something, no matter how conscientious he or she is.
This is compounded for the individual entrepreneurs who do not have profes-
sional staffs.
Farmers are misunderstood. The first real shock I had at the Environ-
mental Protection Agency (EPA) was the reality that many fine, conscien-
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tious government employees were writing regulations for farmers while they 
themselves did not understand agriculture. For example, early on I was told 
by a fine, conscientious public servant who was writing regulations for farm-
ers, that most of the farmland in the U.S. was owned by large corporations. 
(Farmers know that more than 90 percent of farmland is owned by families 
or individuals.) It is unreasonable for 98 percent of the population to be pre-
occupied with understanding the roughly 2 percent who farm. But the 2 per-
cent who farm are the custodians of much of the surface of the earth, and un-
less reality is understood, everyone will lose.
The increasing sophistication of agricultural production technology in 
which biotechnology looms large raises increased questions as to how and if 
individual farms can function effectively without vertical integration or new 
systems to insure that the new technology is operative on smaller and me-
dium-sized farms.
MACRO CHANGES IN DECISION-MAKING
Before discussing the changes in American farmers’ decision-making, I want to 
point out that one of our great resources is that 
American farmers can make decisions. In my work 
in Bulgaria, I find that one of the major impediments 
to progress is that where people have had the State 
make business decisions for them for fifty years, the 
people have great difficulty in making the decisions 
required for doing business.
Based on my almost half century of farming, I 
would suggest the following as major changes in 
decision-making during the 20th century:
The decision-making process is more complex 
due to increased information—some of which has to be inaccurate—increased 
and sometimes inconsistent regulations, and a decision-making climate of po-
tential, and sometimes real, media-hyped anxiety.
Dependence on crop consultants, marketing consultants, management 
consultants, environmental consultants, feed consultants, accountants, law-
yers and others to sort out the information avalanche has increased.
Farmers are less confident in decisions they make. Increased insur-
ance—liability, pollution, health, and workman’s compensation—reflect 
this. There is also some increase in the “I’ll do my best and let the chips fall 
where they may” attitude.
There is more anxiety in the whole process of farming. Last week a 
county agricultural extension agent told me of a recent meeting on biotech-
nology in his area; he said people are really afraid of it. It appears to me that 
this fear typifies most current decision-making because:
—Scientific data are too complex for non-trained people to understand it;
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—There is deep and vocal disagreement about the risk;
—Our culture hypes anxiety about the unknown;
—Farmers have been alarmed by past traumas such as DES, EDB and 
Alar;
—The rate in which science is disproving previous positions causes 
insecurity; and
—There is a substantial sense of regulatory harassment among farmers 
and anything new and complex bodes of more harassment.
HOW FARMERS LOOK AT CHANGE
Historically farmers have looked at change as exciting. This nation was 
settled by risk-takers who looked at the frontier as an opportunity to change 
their lives for the better while they made the wilderness more productive.
Currently, there is still the same excitement for change. Farm shows, 
demonstrations, field days and farm tours excite farmers as they see new 
things and concepts. But change is viewed with increased anxiety, feelings of 
vulnerability and sometimes even futility. Perhaps the shift is reflective of a 
general perception that rural discipline is shifting from a discipline based fun-
damentally on individual and community conscience to a discipline of gov-
ernment enforcement.
HOW FARMERS LOOK AT CHANGES IN BIOTECHNOLOGY
The initial response to how farmers look at changes in biotechnology is a 
combination of excitement and fear—excitement 
about the production potential; the hope of such 
things as genetic immunity reducing the losses from 
diseases and pests without the use of vaccines and 
pesticides, and fear that undesirable or even danger-
ous dimensions maybe introduced. Farmers re-
member that the introduction of rabbits to Austra-
lia was supposed to be highly beneficial, and many of us here in Indiana had a 
hassle with multiflora rose which was to be a beneficial fence. But biotechnol-
ogy carries a much higher fear level. Terms like “insecticidal protein” in corn 
create some anxiety as we are just now hearing more about the dangers of the 
pesticides used many years ago.
There is further fear that genetic alterations may introduce risk to those 
with rare but intense allergies. For example, someone with a peanut allergy 
might now react to cornflakes made from transgenic corn containing a peanut 
protein.
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There is further fear that something created by biotechnology might not 
be contained once released. DDT, EDB and Alar could be removed from the 
system, but a science fiction-type biological plague 
could escape and be “uncontrollable.” I do not think 
this doomsday fear is very strong among farmers, but 
the 100 percent safe Delaney Amendment-type think-
ing has some appeal to everyone. There is some feeling 
that the traditional“nothing risked, nothing gained” 
philosophy should be rendered obsolete by science.
Following the initial response we find economic 
opportunity and anxiety. The hope of farmers to produce a larger and better 
product at a lower cost is universal, but the unknowns create anxiety. Some of 
these are:
   The initial response to 
 how farmers look at 
     changes in biotechnol-
     ogy is a combination of 
    excitement and fear...
—Will it create huge surpluses and break markets?
—If the U.S. regulates biotechnology, will the rest of the world run with 
it and take our foreign, and even domestic, markets?
—Will the big corporations monopolize the new products?
—Will it force vertical integration of farms? and 
—Will it frighten consumers and destroy demand?
There is also what might be called the political-social fear. This is simply the 
discomfort of being caught in a whipsaw between differing societal and politi-
cal action groups where no one is quite sure whom to believe, and the pro-
ducer is in the middle faced with the reality that he has to decide while others 
debate.
HOW DO FARMERS ASSESS A NEW PRODUCT?
While farmers differ in systems and priorities in decision-making, most in-
clude the following questions:
—Is the new product safe? (Farmers have concerns about immediate 
toxicity, long-term health risk, immediate and long-term environ-
mental risk and how reliable the safety measures are for its use.)
—Will it increase profitability if I use it, and will I be left behind if I do not?
—Will this product affect demand for what I produce positively or negatively?
—Does it fit in the systems of my farm? and
—Is it moral?
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It is quite common to hear farmers say, “I don’t want to use that stuff because 
it is too ‘hot,’” or they do not want to use any chemicals they do not have to 
use because of residues and unknowns. In general, I think these same con-
cerns are even greater regarding biotechnology.
WHAT ARE SOME OF THE ISSUES WE WILL BE FACING IN THE FUTURE? 
How will we get leaders to take the risk of leading? When I was still at EPA,
I had a call from the president of a state farm group who said he was in big 
trouble because he had urged his farmers to be envi-
ronmentally responsible and turn in their used oil 
for recycling rather than use it on the farm in a way 
that it might damage the environment. He said that 
about half followed his lead and they were now being 
held liable because the recycling plant had gone un-
der and was a Superfund site, while the other half who had ignored him were 
home free. Policy officials at EPA were sympathetic, but the enforcement 
people were adamant, taking the attitude that “the law is the law.” What is of 
particular concern was the number of knowledgeable people who, upon hear-
ing of this problem, indicated that they were not surprised, and that it never 
pays to get out in front.
How do we develop a realistic attitude toward risk? Risk, risk assess-
ment, risk management and risk-to-benefit relationships have all consumed 
much of our thoughts. But logic does not grab human attention as much as 
fear does. The body politic wants simple brief explanations. Unfortunately, 
risk assessment at the citizens level is too often typified by the young mother 
who came to my wife during the Alar scare smoking a cigarette with her child 
in her arms and said, “Will apples hurt my baby?”
Progress and quality of life will be enhanced by our ability to focus on 
reality in relationship to risk and to communicate this reality to people in 
simple terms. Risk is a price of progress. It must be assessed and managed.
Unperceived risks can do great damage, but non-
risks perceived as risks retard progress. Whom the 
public will trust and how to communicate complex 
science to laypeople in simple terms are ongoing is-
sues of increased urgency.
How to communicate realism about risk is par-
ticularly difficult in our democracy. The free en-
terprise system encourages competition, therefore, our people are bom-
barded with a “fear-fix” syndrome. TV commercials create insecurity about 
everything from bad breath to being cheated, so that they can sell security. 
News commentators and headline writers, competing for viewers and read-
ers, each try to make their story the most exciting. Exaggerating risk is more
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exciting than cool analysis, and the limits of ethics are pressed. Politicians 
get elected by identifying risks they can fix, and they get little media coverage 
if they understate the risk. Some environmental extremists get prominence 
and contributions from extreme positions, and some agricultural extremists 
get prominence and contributions from extreme positions. Hard science and 
truth are often too complex, and, perhaps to the layman, too dull to attract 
much public interest until the issues are too polarized for easily reasoned so-
lutions. All of this increases fear, and most have a fix to sell that is not as con-
vincing as the fear. All of this makes the NABC meetings very important.
Finally, it is clear that farmers are uncomfortable about how much they 
need to know and with the recognition that they can never know enough.
And they, like all the others, are evaluating whom to trust. We have lived 
through what I hope is the extreme of the antihero era, but not without dam-
age to our most revered institutions. Unfortunately, some scar tissue re-
mains, but credibility acceptance levels will recover slowly.
I am a product of the land-grant system and have profound and con-
tinuing respect for it. There is, however, a real need for our educational and 
research institutions to not only continue to look at their daily tactical need 
to survive during difficult times, but to examine in depth their strategic posi-
tions and set their sights on the horizon.
Many farmers have, over the years, received much of their thought 
stimulation both from their churches and the state university system. Some 
historically appreciated the theology of the church, but were somewhat 
“turned off” by the fundamentalist preoccupation with the evils of smoking, 
drinking and sexual promiscuity, while they were more inspired by the open- 
minded scientific approach of the university people.
In May, on the plane to Bulgaria, I read in the air-
line magazine a pragmatic article on communicative 
diseases which stated that the best cure for AIDS is 
to control sexual promiscuity. I then saw on CNN that 
the Senate was considering requiring warning labels 
on all alcoholic beverages. When this is added to the 
overwhelming evidence on smoking, I realized that 
those fundamentalists had been the most accurate in 
their positions, even though their views were arrived 
at through a theological rather than scientific analysis.
When this is compounded by the concern farmers have 
when they read the current labels on pesticides and realize that the guid-
ance given them in the past (which was the best science had to offer at the 
time) put them at risk by today’s standards, there is real soul-searching.
In a cultural situation where individuals are increasingly overwhelmed 
by an explosion of information and made anxious in a culture that hypes fear,
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their increased anxiety and frustration may lead them to look to other than 
hard science for guidance.
This may seem unlikely, but when I was in India, I was amazed to see edu-
cated Indians defending the tradition of sending cows to old cows’ homes, 
their carcasses to remain uneaten in a society abounding with protein-defi-
cient children.
Frustrated and insecure people often reach out in unexpected ways. This 
is one more reason why this meeting which encourages an open dialogue on 
risk is so important.
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During the next decade, biotechnology is expected to have major impacts on food production and processing. Supporters predict significant eco-
nomic, social and environmental benefits. Opponents raise serious concerns 
about risks and ethics of biotechnology. Biotechnology has become an im-
portant and controversial public policy issue that is drawing the attention of 
the media and the public. Social science research can provide industry, gov-
ernment, universities and others with valuable insights into public percep-
tions of biotechnology and related public policies. This paper presents an 
overview of the role of social science research and examines selected results 
of a recently completed project.
Most experts recognize that public knowledge and perceptions of bio-
technology must be systematically evaluated. Stenholm and Waggoner (1992) 
explain how consumers will be the ultimate judge of emerging technologies. 
They will appraise the merits of a particular product and determine its suc-
cess or failure. The Office of Technology Assessment (1992) points out that 
while many new technologies will soon be commercially viable, they will not 
automatically be put to use. The public increasingly questions whether tech-
nological change is good or needed. People are voicing new concerns about 
food safety, the environment and the changing structure of agriculture. Lack 
of public acceptance could prevent some technologies from being used even 
if they are approved by regulatory agencies.
Public participation will 
promote more effective 
and acceptable biotech-
nology policies.
Social science research can help design effective educational programs 
and public policies. Political, industrial and educational leaders need more 
information about potential public reaction to biotechnology. Consumers 
will make the ultimate decisions about the acceptability of food products de-
veloped through biotechnology through their market behavior. However, it is
also useful to anticipate consumer reaction to the 
products of biotechnology before there has been 
a significant investment in research and develop-
ment. Cross (1992) argues that government, 
academia and private industry must not wait un-
til the questions are asked before information is 
provided to the public. It is necessary to identify 
different audiences and know how to reach them. 
Industry, government and universities must understand and respond to pub-
lic opinion. Social science research helps make that possible.
Social science research also serves to broaden the debate to include more 
diverse perspectives. Much of the controversy surrounding biotechnology is 
not simply a matter of scientific facts and expert opinion. Some of the key is-
sues revolve around the public’s confidence in and ability to influence public 
and private decisions about the future of biotechnology. The Office of Tech-
nology Assessment (1992) notes that biotechnology is not so different from 
previous agricultural technologies as to raise novel scientific issues concern-
ing the safety of foods. What is substantially different, however, is the climate 
in which this new class of technologies is being introduced. Society is increas-
ingly skeptical of how new technologies are developed and regulated.
Social science research can serve as a valid and reliable mechanism for 
public participation. Public participation will promote more effective and 
acceptable biotechnology policies. Stiles (1989) argues that without adequate 
participation in decisions about biotechnology, the public will react as it has 
to other technologies. He explains how a technology must fit into society to 
maximize benefits and minimize social and political disruption. Public par-
ticipation in society’s decisions cannot be avoided. It either occurs in a 
planned and orderly fashion or in a reactive and disruptive fashion.
Social science research can also provide guidance to improve the design 
and implementation of educational programs. Public attitudes and knowl-
edge must be researched, understood and considered before developing edu-
cational programs and communication efforts. Such research must illumi-
nate the diverse types of information that are important to the public. Even 
after the issues have been identified, communication will not be easy or effec-
tive without systematic evaluation. Foreman (1990) explains the problems 
with assuming that communication will resolve public concerns about bio-
technology. Differences over this issue may represent not a failure to commu-
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nicate, but a conflict in values. Conflict also occurs if the risks and benefits of 
biotechnology do not accrue to the same individuals or groups. Social science 
research can help identify and evaluate the effectiveness of conflict manage-
ment efforts.
Social science research helps better define the social and political context 
in which biotechnology is developing. The use of biotechnology in agricul-
ture and food production could elicit food safety and environmental con-
cerns similar to those expressed about ag-
ricultural chemicals. Other dimensions of 
biotechnology also draw public attention 
(e.g., socioeconomic impacts and ethical con-
cerns). Senator A1 Gore (1991) explains that 
what is needed to balance our technologi-
cal prowess is a renewed engagement in the 
debate over biotechnology policy—not just 
the ethics of genetic engineering, but the en-
tire relationship between biotechnology and 
our future. He concludes that it is important to not lose sight of the larger policy 
questions that will determine whether our ability to manipulate the basic pro-
cess of life will benefit the world community.
Social science research can enhance the debate by providing a systematic 
and credible mechanism for incorporating societal values and preferences 
into public and private decisions. Social science provides useful insights for 
the important policy debates and educational programs that are needed. 
However, social science often tries to reach a moving target. Public percep-
tions are complex and dynamic. It is important to recognize that many fac-
tors will ultimately affect consumer acceptance of foods developed through 
biotechnology. Public awareness and attitudes will change as more informa-
tion and actual food products become available. In that sense, any research 
project serves as a baseline for future work.
PROJECT METHODOLOGY
The purpose of the project was to determine what consumers think and want 
to know about the use of biotechnology in food production and processing. 
Results should prove useful in several ways. One outcome will be to provide 
guidelines for development and implementation of educational programs. 
Another outcome will be to enlighten the formulation and evaluation of pub-
lic policies by providing a valid means of citizen input. Third, the results will 
recommend appropriate and acceptable types of biotechnology research and 
product development activities.
This project involved several complementary research methodologies. 
All work was conducted in a collaborative manner using established social
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science methods. Full details on project methodology can be found in the 
technical reports which are available from the authors (Hoban and Kendall, 
1992; Kendall and Hoban, 1993). An extensive literature review assessed ex-
isting studies on public attitudes about biotechnology, as well as surveys on 
similar topics. From this review, conceptual models were developed that 
guided survey development.
Several organizational structures were developed to carry out this project 
in a consultative and interdisciplinary manner. At North Carolina State Uni-
versity and Colorado State University, interdisci-
plinary project teams were established. In addi-
tion, a national advisory committee consisting of 
university and government experts was estab-
lished. The campus teams and national commit-
tee assisted with development and review of the 
telephone survey and focus group instruments, as 
well as the technical reports.
Development of the telephone survey instru-
ment involved several related tasks. At the outset, 
a series of open-ended individual and small group 
interviews were conducted in Washington, DC with public and private sector 
leaders in the area of biotechnology. Results of the interviews were summa-
rized to inform development of the telephone survey. To further inform sur-
vey development and test the face validity of potential questions, personal in-
terviews were conducted with about 40 consumers in North Carolina and fo-
cus groups were conducted with 67 consumers in Colorado, Ohio, New York, 
Pennsylvania and Nebraska. Results of these interviews and focus groups led 
to further refinement of the telephone survey instrument. Additional tele-
phone pretests were then conducted to finalize question wording.
The sampling frame for the telephone survey was the entire population 
of households in the United States with telephones. The random sample of 
telephone numbers was purchased from Survey Sampling Incorporated (SSI). 
Their samples are systematically drawn using random digit dialing. Both 
listed and unlisted numbers are included in the sample. All telephone inter-
views were conducted by the Applied Research Group at North Carolina State 
University during February and March of 1992. A total of 1,228 interviews 
were completed. The final telephone interviews averaged about 26 minutes 
in length. At least ten attempts were made at various times to reach each tele-
phone number selected before a number was eliminated from the sample.
The response rate for the survey was just over 60 percent. The sample popula-
tion appears quite representative of the country as a whole on most major 
background characteristics. Full demographic profiles of respondents are in-
cluded in the project technical report (Hoban and Kendall, 1992).
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After the telephone survey, focus groups were conducted during Octo-
ber of 1992 to assess reactions to specific food products, obtain more de-
tailed opinions about biotechnology, and have consumers generate ideas 
about educational needs. Subjects were randomly selected from city tele-
phone directories in Denver and Raleigh. Eight focus group sessions were 
held: four in Colorado and four in North Carolina. A total of 46 people par-
ticipated in the eight groups. The focus-group lasted approximately two 
hours. Discussion focused on eight topics: general knowledge of biotech-
nology; reaction to specific products; information needs and sources; label-
ing issues; environmental issues; economic issues; moral and ethical issues; 
and the role of citizens. In general, focus groups results supported many of 
the phone survey results and added additional qualitative insights. Full de-
tails can be found in the Focus Group Technical Report which is available 
from the authors (Kendall and Floban, 1993).
SELECTED SURVEY RESULTS
This paper focuses on selected results of the telephone interviews. In keep-
ing with the NABC 5 theme, we mainly discuss findings related to public per-
ceptions of the benefits and risks of biotechnology. Some key relationships 
between a selected set of background characteristics and general reaction to 
biotechnology will be analyzed. Due to limits on length, we cannot present 
information on all the background variables. Full information, including 
the wording for all questions and detailed analysis results, are included in the 
Telephone Survey technical report (Hoban and Kendall, 1992).
General Attitudes about Biotechnology
Respondents were read several statements about the general benefits and risks 
of biotechnology and asked the extent to which 
they agreed or disagreed. Almost three quarters 
agreed that “Biotechnology will personally ben-
efit people like me in the next five years.” On a 
related statement, over two-thirds agreed that 
“Government should fund more biotechnology re-
search because of the potential benefits.” Concerns 
about risk are evident by the fact that nearly half 
of the respondents agreed that “Biotechnology 
should not be used because of potential risks to the environment.”
As we designed the survey, it became evident that most people did not 
know enough about biotechnology to provide a detailed assessment of po-
tential benefits or risks. One set of questions did measure respondents’ gen-
eral expectations concerning the potential impacts of biotechnology. Over-
all, respondents anticipated generally positive effects of biotechnology in
...most people did not 
know enough about 
    biotechnology to provide 
   a detailed assessment of 
     potential benefits or risks.
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most areas. Almost three quarters of the respondents saw the effects as posi-
tive for farmers’ economic conditions, as well as for food quality and nutri-
tion. Nearly two-thirds felt the effects of biotechnology would be positive 
for environmental quality. Between one-half and two-thirds of the respon-
dents saw positive effects of biotechnology on farmers’ use of chemicals 
and fish and wildlife. In all cases, between five and ten percent of all re-
spondents did not have an opinion about whether the effects would be posi-
tive or negative.
One pair of questions assessed whether respondents would have 
moral objections to the use of biotechnology in either animal or plant appli-
cations. The first question asked: “Do you believe 
the use of biotechnology to change plants is mor-
ally wrong or not?” In this case, almost one quarter 
of the respondents felt that it would be morally 
wrong. Respondents had stronger views concern-
ing the moral aspects of animal biotechnology. 
When asked “Do you believe the use of biotechnol-
ogy to change animals is morally wrong or not?” 
over half said that it was. This turns out to be one 
of the most important and unique issues associated 
with the use of biotechnology in agriculture and 
food production.
This [morality] turns 
out to he one of the 
most important and 
unique issues associ-
ated with the use of 
biotechnology in 
agriculture and food 
production.
Acceptance of Biotechnology
The interview attempted to address a fairly complex and controversial area 
involving consumer acceptance of food products that involved clearly 
transgenic characteristics. Such issues have received considerable attention 
from the media, consumer groups and industry. Examples were used that ei-
ther reflected actual applications or were representative of possible future 
uses. These questions were sequenced to move from the least dramatic to 
most dramatic examples. This set of questions was introduced with the fol-
lowing statement: “Genes from most types of organisms are interchange-
able.” Respondents were first asked “Would potatoes made more nutritious 
through biotechnology be acceptable or unacceptable to you if genes were 
added from another type of plant, such as corn?” Two-thirds of all respon-
dents said they would find such plant-to-plant gene transfer acceptable. 
Respondents were next asked “Would such potatoes be acceptable or unac-
ceptable to you if the new genes came from an animal?” In this case, only 
one quarter of all respondents indicated they would find such animal-to- 
plant gene transfer acceptable.
Two examples were used to determine reaction to animal-related gene 
transfers. First, respondents were asked: “Would chicken made less fatty
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through biotechnology be acceptable or unacceptable if genes were added to 
the chicken from another type of animal?” In this case, just under 40 percent 
of the respondents said they would find such a gene transfer acceptable. As a 
final, relatively dramatic (but technically feasible) application, respondents 
were asked: “Would such chicken be acceptable or unacceptable if the genes 
came from a human?” Only 10 percent of all respondents indicated that such 
human-animal gene transfer would be acceptable.
There seems to be 
considerable interest 
in biotechnology.
Public Policy and Citizen Participation
One set of questions examined the area of government credibility. Respondents 
were asked if they would have a lot, some, or no confidence in the U.S. Depart- 
mentof Agriculture (USDA), Food and Drug Admin-
istration (FDA), Environmental Protection Agency 
(EPA), and state agencies to effectively regulate bio-
technology. In all cases, about two-thirds of the re-
spondents reported “some” confidence. Of the remain-
ing respondents, the percent reporting“no confidence” 
exceeded the percent reporting“a lot” of confidence.
Differences among the levels of confidence in each of the agencies were quite small.
Two statements measured respondents’ opinions about the role of citi-
zens in biotechnology decisions. Over three quarters agreed that “Citizens 
have too little say in decisions about whether or not to use biotechnology.” 
On a related point, almost all respondents agreed that: “Government should 
pay more attention to what people like me think about biotechnology.” This 
likely reflects more general feelings that people have about government re-
sponsiveness and effectiveness.
Interest in Biotechnology
There seems to be considerable interest in biotechnology. This suggests that 
biotechnology will be a major public policy issue. One in five respondents 
said they had a lot of interest in learning more about biotechnology. Almost 
half reported some interest. One in five had only a little interest and the re-
maining 14 percent said they had no interest in learning more about biotech-
nology.
Those respondents who reported at least “a little” interest in learning 
more about biotechnology were then asked how important they felt it would 
be for them to receive each of six different types of information regarding 
biotechnology. This indicates the relative level of importance people attach 
to each of the major issue areas. Over two-thirds felt it would be “very im-
portant” for them to have information about the potential risks or negative 
effects of biotechnology. Most of the rest said such information would be 
somewhat important. Just under two-thirds said it would be very important
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to have information about new uses of biotechnology in human health care. 
About half indicated that it would be very important to have more informa-
tion about the potential benefits or positive effects of biotechnology. Under 
half felt information about new uses of biotechnology in food production 
would be very important. Almost as many felt that information about how 
government regulates biotechnology would be very important. The informa-
tion considered least important involved the basic science behind biotechnol-
ogy. However, even in this case over one-third said this information would be 
very important and over half said it would be somewhat important.
Overall Reaction to Biotechnology
It seemed important to obtain a general assessment of respondents’ bottom- 
line reaction to biotechnology. This was done by asking: “Overall, would you 
say you support or oppose the use of biotechnology in agriculture and food 
production?” Almost two-thirds of all respondents said they supported the 
use of biotechnology in agriculture and food production. Just over a quarter 
opposed its use. Almost 10 percent did not have an opinion on the question.
Some additional analysis reveals the types of respondents who were 
likely to support the use of biotechnology in agriculture and food produc-
tion. In terms of demographic and background characteristics, men were
more likely to support the use of biotechnology 
than were women. Respondents with higher edu-
cational and/or income levels also expressed 
greater support for biotechnology. People who 
considered religion to be more important in 
their daily lives tended to express greater oppo-
sition to the use of biotechnology. Interest in 
new scientific and technological developments 
was positively correlated with support for the 
use of biotechnology.
Other attitudes about and awareness of bio-
technology were also significantly related to support for the use of biotech-
nology in agriculture and food production. Those who had read or heard 
more about biotechnology, as well as respondents with a greater interest in 
learning about biotechnology, expressed greater support. Respondents who 
felt biotechnology was morally wrong were much more likely to oppose its 
use. High levels of confidence in government, as well as trust in information, 
had a significant positive relationship with support for biotechnology.
Interest in new 
scientific and 
technological 
developments was 
positively correlated 
with support for the 
use of biotechnology.
Reasons for Supporting Biotechnology
About two-thirds of all respondents answered positively when asked whether 
they supported or opposed the use of biotechnology in agriculture and food
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production. A wide range of answers were given in response to the follow-
up question: “Can you describe why you support the use of biotechnology?” 
Seven major categories were developed that describe the reasons. Open- 
ended questions like this are useful for gaining deeper insights into peoples’ 
perceptions.
The most common reason for support of biotechnology (represented 
by 22 percent of all responses) was that people be-
lieved it will enhance the quality of food prod-
ucts. Many of these respondents indicated that 
by using biotechnology the nutritional value, taste 
or other desirable qualities of food could be im-
proved. Some suggested that biotechnology could 
be used to reduce fat, cholesterol, pesticide resi-
dues or other undesirable aspects of food prod-
ucts. Others indicated that biotechnology would 
make food safer.
Of those who supported biotechnology, about one in five believed it 
would help increase the quantity of food produced. Many of those in this 
group expressed the opinion that food production needs to keep up with 
population growth. Some respondents viewed biotechnology as a means of 
reducing hunger. Biotechnology was considered by some to be an important 
method for producing more food at lower cost, with the use of less and/or other 
resources.
Approximately 14 percent of supporters felt biotechnology will benefit society 
by providing environmental or economic benefits.
Some respondents in this category indicated that 
biotechnology will be beneficial to American indus-
try and reduce the cost of production. Other in-
dividuals indicated that biotechnology may help 
reduce pollution, including agriculture’s depen-
dency on chemicals. Some respondents specifi-
cally suggested that farmers would benefit from 
the development of biotechnology.
Another group of respondents (14 percent) 
suggested that scientific and technological advances benefit society, in gen-
eral. Respondents viewed biotechnology as important for maintaining such 
leadership in the future. Respondents in this category basically felt that new 
developments in science and technology were necessary and desirable. Ap-
proximately 12 percent provided statements which suggested biotechnology 
will improve the overall quality of life. More specifically, some respondents 
in this category hoped it would improve health care, including finding cures 
for medical problems. Ten percent of the responses involved nonspecific
Respondents... 
basically felt new 
developments in 
science and 
technology were 
necessary and 
desirable.
The most common 
reason for support of 
biotechnology ...was 
that people believed it 
will enhance the quality 
of food products.
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statements of support for biotechnology. These responses simply implied a 
belief that biotechnology is good or beneficial without being able to provide 
specific reasons.
Nine percent of the respondents who supported biotechnology gave 
statements that reflected some apprehension. Some indicated there may be 
problems with biotechnology. Other respondents said they worried whether 
the experts would consider citizens’ best interests. Some responses indicated 
a willingness to support some applications (e.g., with plants) but not others 
(e.g., with animals). Overall, individuals in this final category indicated 
their support for biotechnology was conditional.
Reasons for Opposing Biotechnology
Just over one-third of all respondents who took a position on this question 
opposed the use of biotechnology. They were then asked: “Can you describe 
why you oppose the use of biotechnology?” Responses were again coded into 
several main categories. The most common reason for opposition to bio-
technology (given by over one-third of all respondents who opposed bio-
technology) involved concerns that it could threaten the balance of nature. 
Some respondents worried that biotechnology would lead to serious impacts 
on the natural environment. They felt such tampering with nature was 
wrong. Other respondents in this category opposed biotechnology because
it was “not natural.” Some mentioned concerns 
about loss of genetic diversity or the creation of 
harmful mutations.
Around thirty percent of those who op-
posed biotechnology said they were concerned 
about its unknown effects or long-term risks. 
Some respondents in this category mentioned 
lack of trust in scientists or government to ad-
equately control biotechnology. Others felt it 
could be used in an inappropriate manner. Some felt that not enough testing 
would be done regarding the possible side effects. Such reasons seemed to 
revolve around the general notion of perceived risk.
The third most common reason (about 13 percent) for opposition in-
volved concerns over the application of biotechnology with either humans 
or animals. Respondents also worried about possible impacts on human 
population growth. About eight percent of the respondents who opposed 
the use of biotechnology had concerns that it would promote the increased 
use of chemicals in farming or food processing. Some worried that food 
safety or quality would be negatively affected through the use of biotechnol-
ogy, resulting in possible harm to those who eat the food products.
The most common 
reason for opposition 
to biotechnology 
...involved concerns 
that it could threaten 
the balance of nature.
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Another eight percent of the comments from those opposing biotechnol-
ogy indicated that respondents opposed the use of biotechnology because they 
believed it was somehow against God’s will or con-
trary to their religious beliefs. This reason also in-          A significant commit- 
cluded a general sense of moral obj ection, as well as    ment to unbiased and
objection to trying to improve on “God’s creation.”             ongoing education is 
Four percent of those who opposed biotechnology needed
did so because of concern about impacts on the 
economy. Individuals mentioned potential social or
economic impacts that biotechnology could have for small businesses or fam-
ily farms. Two percent of the statements involved concerns over other impacts.
CONCLUSION AND IMPLICATIONS
This research project has a variety of implications for the development and imple-
mentation of educational efforts and public policies. In this final section, we 
describe some of the main implications in these areas. This section will con-
clude with a discussion of future social science research needs, including the 
limitations of such work.
Implications for  Education and Policy
Results of this work document the need for expanded education and informa-
tion efforts. Given relatively low levels of awareness and considerable interest 
in biotechnology, a significant commitment to education is needed. Outreach 
programs need to be developed and implemented to pro-
vide people with information they need to better un-
derstand the issues related to biotechnology. The goal 
should be to help consumers make their own informed 
decisions about this new technology. This should in-
volve a broad-based approach aimed at school children, 
organizations, opinion leaders and consumers. A wide 
range of groups and organizations can contribute to 
educational programs. Land-grant universities, such 
as those represented by NABC, are in a credible and in-
fluential position to play an important leadership role 
in such education.
This project indicates that consumer knowledge and attitudes about 
food produced through biotechnology will be influenced by general informa-
tion obtained from the media. Education efforts must recognize the limita-
tions and opportunities for media-based information. Education needs to be 
unbiased, ongoing and proactive. Adequate time, money and expertise must 
be devoted to education to ensure that opinion leaders and consumers are 
able to receive the information they want and deserve in a timely and credible
The goal should 
be to help 
consumers 
make their own 
informed 
decisions about 
this new 
technology.
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manner. The future of biotechnology in food production is by no means as-
sured without a much more proactive and open dialogue among all inter-
ested parties.
Our results indicate that one of the most important factors influencing 
public perception of biotechnology will be the perceived credibility of public 
policies and regulations. Consumers want government to play an active role 
in establishing policies that ensure environmental protection and food safety.
They also want government to expand the debate 
over the most appropriate uses of this powerful set 
of technologies. The federal government should 
pursue a proactive and credible approach to bio-
technology policy that empowers citizens to 
make informed decisions, while facilitating de-
velopment of appropriate products.
This project indicates that public confi-
dence in government agencies to effectively regu-
late biotechnology could be significantly improved. Few people understand 
the nature of government policies and regulations in this or other areas. Low 
confidence is, in part, a reflection of a more general erosion of public confi-
dence and trust in government. Attempts during the past decade to reduce 
regulation have been responsible, in part, for decreased public confidence in 
government. Most respondents felt that government should pay more atten-
tion to what citizens think about biotechnology. People want more say in de-
cisions that affect their lives. This is not unique to biotechnology, but in-
cludes other policy areas. Consumers expect public policies to be developed 
in an open manner with ample opportunities for involvement of all interested 
stakeholders.
...public confidence in 
government agencies to 
effectively regulate 
biotechnology could be 
significantly improved.
Future Research Needs
Biotechnology is a complex and dynamic public policy area. This project 
may have raised as many questions as it has answered about public percep-
tion of biotechnology. Because the telephone survey was done before the 
May, 1992 FDA announcement of regulations for food produced using bio-
technology, it represents a baseline for future surveys using the same ques-
tions. This final section will offer some general observations about the util-
ity and limitations of social science research.
Public attitude surveys, such as this one, are useful for identifying issues, 
interests, concerns, educational needs and public policy implications. Our 
work provides insights into these areas. For example, this work shows differ-
ent levels of consumer acceptance for different products. It also highlights 
important ethical and environmental issues. Our results also suggest appro-
priate education and information efforts.
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However, telephone surveys are not good for evaluating specific prod-
ucts or probing deeply into people’s basic beliefs. Other methodologies will 
be more appropriate and useful for testing consumer response to new food 
products. Focus groups and taste tests will provide guidance for marketing 
of specific products. Market-basket studies and computer simulation mod-
els will help evaluate and predict actual consumer behavior. Once people are 
actually able to taste a new food product, they will form much more definite 
opinions about its desirability.
Survey research is as much an art as a science. It is important to start 
with a clear set of objectives and a testable conceptual model. Research must 
be based on past research and theory as well as clear plans for analysis. Social 
science research is most useful when it goes beyond simple description into 
the realm of explanation and prediction. It is necessary to analyze why 
people feel the way they do. The population must be segmented into differ-
ent groups and compared on key questions. Our analysis along these lines is 
just beginning. Further results will be published in professional journals.
Realize that survey research is only one piece of the puzzle. Regulations 
must still be based on the best available science. Public policy will always in-
clude economic and political considerations. Surveys, however, do provide a 
cost-effective and systematic mechanism to incorporate public beliefs and 
values in decisions. If done right, surveys can reflect the views of a diverse 
cross section of citizens.
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I want to begin by discussing Henny Penny.
1 To the best of my knowledge, 
she has not been patented nor is she a registered trademark, but as is ap-
propriate for my presentation, she is eminently in the public domain. This 
story may be one of the first encounters most of us have had with the values 
relevant to risk assessment and since most public presentations about risk 
are in the form of stories, albeit television or newspaper, it may help to re-
mind ourselves how well this childhood pastoral legacy fits present day cir-
cumstances.
You know the story. Henny Penny is in the barnyard when suddenly she 
is hit on the head by an acorn. She immediately assumes the sky is falling 
and that she must hurry to tell those in authority. She recruits a number of 
her companions to join in the mission. On the way she and her friends are 
seduced by a wily fox to take a short cut from which she and her friends are 
never heard from again.
It presents a role model which derides conclusions based upon a foolish 
reaction to Nature because this response leads to even greater disaster. Na-
ture is very regular; she does not play tricks such as sending the sky to fall 
like rain and we can depend on that when we try to figure out what is going
1 Presently there are 10 listings for this story in Canada and 8 in the United States 
in current Books in Print.
What for the average 
North American 
resident symbolizes the 
state of contemporary 
agriculture as well as 
what to expect from 
biotechnology consists of 
a brew ofnaiveti and 
skepticism—Arcadia or 
the Monster.
on around us. True natural events which can be very destructive are not 
ruled out, but we can deal with these precisely because they are a part of 
common sense understanding of what the world is about. We must respect 
and can trust nature in its untampered state.
The presence of technology has altered this picture. Based on science, it 
tries to harness nature’s regularity and tame her power to produce predict-
able outcomes upon which a host of human ac-
tivities can be formed. On this view, animal 
domestication maybe one of the earliest ex-
amples of a technological change being im-
posed upon the natural world. Bronowsky 
(1973) has argued that the discovery of a culti- 
vatable form of wheat is one of the primal dis-
coveries of civilization. But there is a slight ca-
veat to which I would like to call your attention. 
Most people do not view the domestication of 
animals or the discovery of wheat as technology. 
They see it as an example of human ability to ex-
ploit natural abundance, fundamental to the 
Story of Creation which gives biblical authoriza-
tion to pastoral goodness. A contemporary example of how pervasive this at-
titude is, is found in Michael Fox’s introduction to his book, Superpigs and 
Wondercorn: The Brave New World of Biotechnology...and Where It All May 
Lead (1992). In it he describes the need to repair “this dispoiled planet” and 
the need to “dress and keep” the Garden of Eden.
The views just presented are not easily reconcilable. They offer conflict-
ing approaches to the course of human life. Most Americans know little of 
the history of science and technology. What for the average North American 
resident symbolizes the state of contemporary agriculture as well as what to 
expect from biotechnology consists of a brew of naivete and skepticism— 
Arcadia or the Monster. It is not hard to find vestiges of this style of moral 
understanding in current conflicts over the licensing of agricultural products 
having biotechnological modifications.
Here are three illustrations which I believe represent current versions of 
this state of Americana: First, there is the belief that if you grow something, it 
represents contact with a reality absolutely fundamental for human exist-
ence. Apartment dwellers with their three tomato plants 30 stories above the 
street can really get into this business of growing things. (Of course, it may 
also be a last desperate attempt to find a replacement for the wooden toma-
toes which adorn the average salad.) At this level, these plants can signify a 
desire to maintain one of the last vestiges of the pastoral dream from which 
most of life has been wrenched—roots, if you will.
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Second, there is the paradox inherent in the abundance which North 
American agriculture exemplifies. On the one hand, the industry remains 
one of the major unsolvable problems for modern governments, far outstrip-
ping the complications currently posed by the challenge to transform our de-
fense industry. On the other hand, this politicalization of agriculture has 
succeeded in disillusioning the very people who wallow in its largess. The 
difference in the effectiveness of the pork barrel in determining agricultural 
policy, while at the same time the failure of legislators to protect the consum-
ing public from the risks inherent in the raising and preparation of food for 
consumption, has not gone unnoticed, viz federal inspection of the meat 
packing industry.
Third, the effects of biotechnology as it applies to agriculture are a source 
of concern both rational and irrational. There is a real ignorance of science 
and how it works especially as related to probabil-
ity. There is a belief that the effects of biotechno-
logical manipulation pose a risk for a possible but 
unknown catastrophe. To the extent that the changes 
biotechnology proposes initiate an element of risk 
to those who use its products, they demand a form 
of control unknown to the simple morality of a pas-
toral ideal in conflict with an apocalyptic vision of 
a mechanical universe which would destroy the Gar-
den. To the extent that the present effectiveness of
the protective role of government has a high failure rate with no attribu-
tion of responsibility, there is real fear as to what Food and Drug Adminis-
tration (FDA) approval means in terms of protecting the consumer. This view 
of the failure to protect from risk can be dismissed as the continual failure 
of moral politics to understand and regulate the new face of agriculture. Finally, 
the extent to which contemporary patterns of food distribution make it diffi-
cult for the average person to chopse on the basis of accurate information— 
increases the paranoia of a public ignorant of science and fuels the notion that 
current regulatory procedures controlling agricultural biotechnology are 
untrustworthy.
That Americans were far from being prepared for a change of moral cli-
mate was suggested in 1964 by Leo Marx in his monograph, The Machine in 
the Garden. His review of American literature from the colonial period to the 
present day suggests that we are stunned by the magnitude of the protean con-
flict figured by the machine’s increasing domination of the visible world.
This recurring metaphor of contradiction makes vivid, as no other figure 
does, the bearing of public events upon private lives. It discloses that our in-
herited symbols of order and beauty have been divested of meaning. It com-
pels us to recognize that the aspirations once represented by the symbol of an
...the effects of 
biotechnology as it 
applies to agricul-
ture are a source of 
concern both 
rational and 
irrational.
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ideal landscape have not, and probably cannot be, embodied in our traditional 
institutions. It means that an inspiriting vision of a humane community has 
been reduced to a token of individual survival. To change the situation we re-
quire new symbols of possibility, and although the creation of these symbols is 
in some measure the responsibility of artists, it is in greater measure the re-
sponsibility of society. The machine’s sudden entrance into the garden pre-
sents a problem that ultimately belongs not to art, but to politics (Marx, 1964).
...the challenge presented 
by the new age is to 
transform our simplistic 
view of moral conflict 
with a nuanced theory of 
ethical accounting.
CLUES FROM BIOETHICS: INFORMED CONSENT
As I see it, the challenge presented by the new age is to transform our simplis-
tic view of moral conflict with a nuanced theory of ethical accounting. It re-
quires vocabulary which reflects awareness of 
the content of the public values just presented 
and a theoretical structure that incorporates the 
reason of science into our political reality. The 
paradigmatic instance of this change is played 
out in the history of bioethics over the last quar-
ter century. Now a mature enterprise, lessons 
from what has happened in medicine may pro-
vide some clues as to how traditional moral re-
sponses to biotechnology might be recast in a mold which will resolve current 
social deadlock.
The history of bioethics has been covered elsewhere (Clouser, 1970). For 
our purposes, I would emphasize its source in the awareness that individuals 
have the right to be protected from exploitation by those who are offering them 
medical care and treatment. Over the years, a series of cases have helped delin-
eate the circumstances under which this protection should apply (NIH, 1980). 
The result has been the creation of a working system whereby technology is 
supported at the same time protecting those who would be its beneficiaries or 
its victims (e.g., Halushka vs. University of Saskatchewan, 1965). In the center 
of this system has been FDA. There are three tiers to this system which are 
indispensable to its functionality: Tier One—the establishment of ethical prin-
ciples which must be realized in action; Tier Two—the demand that all activity 
must be backed by data which has been subject to the statistical demands de-
manded by contemporary science; and Tier Three—the development of a pro-
cess whereby the first two criteria may be acted upon. In addition, and indis-
pensable to the working of the system, is a definition of roles which separate 
the function of regulatory as opposed to developmental responsibilities. Let 
me describe in more detail the constituents of this practice:
Tier One
The establishment of ethical principles which provide a moral arena for action 
Here the dominant normative force has been autonomy. Functionally, this 
has led to the enshrinement of informed consent as its most important ex-
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pression. Subject to a caveat covering emergency treatment for children and 
the mentally incompetent, every act with its costs and benefits must first be 
understood before being accepted by an individual patient. The extension 
of risk to patients other than mentally competent adults is severely restricted 
to those interventions for which the benefit is clearly demonstrable. As it has 
developed, the practice of principled action has been most completely ex-
plored as it applies to individuals. Principles governing society, such as jus-
tice and fairness, have only recently been the subject of more sophisticated 
attention, particularly as it applies to the availability of health care. Here it is 
obvious that notions such as that of “the common good” are highly contro-
versial and the sharing of both costs and benefits has proved highly difficult 
to implement in a socially acceptable manner.
Tier Two
The requirement that all projected actions must be the subject of investigations 
which produce data conforming to current scientific practice as regards statisti-
cal probability is essential to developing a meaningful cost/benefit analysis. Of 
more than a little interest to those concerned about the effects of biotechnol-
ogy are the practices which cover the development and use of new drugs. The 
three-phase trial system which moves from animals to human subjects is used 
to determine general parameters of risk and efficacy (NIH, 1977). Only after 
passing all three phases can a drug be licensed for the task for which it was 
tested. This system is not perfect, but its shortcomings have not prevented it 
from working. Of some concern is the practice of using only adult males in 
the Phase 3 trials, the final step before licensing. The failure to include chil-
dren, women and the elderly in these protocols has led many to question the 
conclusions, particularly about dosage and side effects which are included in 
the approval documentation. The practice of asking physicians to report ad-
verse effects as they occur in the “field” has only been partially successful in 
developing a more complete dossier about each drug.
Tier Three
The development of a process through which principles may be combined with 
data to produce a distribution system which is safe within defined limits accept-
able to the consuming public is the final component in the practice Institu-
tional Review Boards (IRBs) must review all trials using human subjects for 
both scientific merit and ethical responsibility (Levine, 1961). The record 
has been neither incident nor scandal free.2 There was the famous thalido-
mide affair and perhaps more to our concern, the cancer risks to the daugh-
ters of mothers who had been prescribed diethylstilbestrol (DES) during
2 The most outspoken of recent critics has probably been Ivan Illich. c.f. Limits to Medi-
cine: Medical Nemesis: The Expropriation of Health. McClelland and Stewart, 
Toronto, Ont. 1976.
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pregnancy as an attempt to avoid early miscarriages (Potter, 1991). There 
have been detractors who insist that the present system is far too conserva-
tive in a time of crisis such as that produced by AIDS. Nonetheless, it is criti-
cal not to lose sight of the core process. It is the principle of informed con-
sent. This has allowed for the implementation of such widely differing prac-
tices as giving bioengineered growth hormone to children, gene therapy for 
cancer, and xenografts from hogs with transgenically altered immune sys-
tems. Each individual can in theory and in practice, supported by social con-
sensus, assume risk because each is free to choose whether or not to receive 
defined benefits. Consent is also understood as a process with several grada-
tions—with increased risk in relation to benefit requiring more awareness of 
what is being accepted.
The additional element in the practice just described is what, I believe, ac-
counts for its level of public acceptance. This is the attempt to separate regu-
latory responsibilities from developmental functions—the role of govern-
ment as distinct from that of industry. Jane Jacobs in her recent book, Sys-
tems of Survival-a Dialogue on the Moral Foundations of Commerce and Poli-
tics (1992), argues that these groups represent two distinct modes or syn-
dromes, the Guardian and the Commercial, which are essential to the func-
tioning of human society. The first, guardianship, arises from the behavior 
which we share with animals—foraging for food and protecting our territo-
ries. Guardians work in the armed forces and police, government ministries
and their bureaucracies, legislatures, courts 
and organized religions. The second, Com-
mercial, arises from trade and production of 
goods and is an endeavor unique to human 
beings. These two modes of survival have 
produced two discrete and contradictory 
ethical systems and are the source of conflict 
when the precepts appropriate to the guard-
ian system are imposed on the commercial 
and vice versa. In its everyday functionality, 
this means that drug companies are free to 
be as inventive as possible—expressed as profitability—so long as they oper-
ate within the structures and regulations designed to protect society. But, 
and this is a major qualifier, the individual (a patient in this case) is still free 
to determine whether he or she accepts the risks and benefits made available 
by this symbiotic structure. In the case of health care, the point where this 
assumption of risk and benefits occurs is not in terms of a market relation-
ship, but as informed consent. As we turn to the matter of agricultural bio-
technology, we encounter a significant difference in the risk/benefit struc-
There is great difficulty in 
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consent [in agricultural 
biotechnology] 
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to restrict action to all or 
nothing.
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ture. There is great difficulty in exercising informed consent because, as we 
have previously noted, the monolithic distribution system tends to restrict 
action to all or nothing. You either buy the product available or you do with-
out it. In practical terms, consumers are left with what appears to be an irra-
tional response—massive group threats of boycott—to what is more reason-
ably viewed as a need for rational discussion and understanding.3
CURRENT CONTROVERSIES: AN ETHICAL ANALYSIS 
In this final section I would like to review a number of current controversies 
involving bioengineered agricultural applications, subjecting them to the 
three-tiered structure I have proposed and which has been developed in the 
course of bioethics as well as the survival ethics proposed by Jane Jacobs (1992).
I will begin with the Tier Two of the structure. This is the requirement 
that all projected actions must be the subject of scientific investigation.
I think that what is most upsetting to the scientific community is the fact that 
on this criteria, agricultural biotechnology has performed quite well. Let me 
begin by comparing the cases of bovine and porcine somatatropin. The evi-
dence would suggest that, from the point of animal welfare, bST is accept-
able—the review of testing seeming to indicate that there is no increased risk 
of mastitis in animals given the hormone, as well as attesting that there is no 
contamination of the milk by bST. The effect upon hogs by bST has not been 
so benign and until the adverse effects on the animals can be controlled, on 
the basis of animal welfare alone, scientific evidence would tend to support 
withholding acceptance of this method of enhancing lean qualities of pork.
In both of these examples, there does not appear to be serious objection to in 
vivo investigations. When it comes to Bf-toxin in food crops to control in-
sects, the issue is more complex. Recent field tests of corn involving trans-
genic manipulation of an insecticidal protein derived from Bacillus thurin- 
giensis (Bt) has proved it to be highly resistant to heavy field infestation of the 
European corn borer (Koziel et al., 1993). Here, I believe, our experience 
from medical history may be helpful in delineating the issues. Are the long-
term effects of Bt-toxin similar to what has happened to the effectiveness of 
our recent treatments for tuberculosis or to the eradication of small pox?
Or to put the problem in another way, what is the evidence that the long-
term effects of Bf-toxin on pest control will be more successful than produced 
by the heavy use of insecticides? Then, there is the controversy of the Flavr 
Savr™ tomato. The likelihood that its use of the kanamycin-resistance gene
3 Compare the campaign waged by Jeremy Rifkin against the Flavr Savr™ tomato 
which involved threated boycott of McDonald’s and Campbell’s products as well 
as the enlistment of prominent chefs to refuse their use.
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as a marker in the reverse-RNA antisense process will produce human side 
effects by hooking up with the wrong bacteria during the digestive process is 
highly remote (Hoyle, 1992). The evidence appears to be at a level of cer-
tainty which would be perfectly acceptable had this 
been a drug being considered for licensing. It is not an 
overstatement to suggest that the level of scientific re-
search and testing involved in biotechnology is at least 
as good as that available in the health care field. If we 
want to understand what may be the problem, we must 
turn to the other tiers which round out the consumer 
protection package available to the user of health care.
This brings us to another look at Tier One—the 
establishment and implementation of ethical principles 
to provide a normative element that protects the user/ 
consumer from exploitation. I do not believe that different principles apply 
here from those which are used in our evaluation of health care. But our pre-
vious examination does suggest that informed consent by the individual to 
the risk/benefit involved in food product use has a more complex ethical ap-
plication. 4 Furthermore, the nature of risk is such that the specific instance 
in which it will appear cannot be determined, so that concepts of common 
good may unwittingly but unfairly single out victims. Theoretically it could 
be possible to establish a compensation system to help ease the morbidity/ 
mortality of victims, but the multisource of present risk for disease such 
as cancer would make the application of this worthy idea almost impos-
sible. So, I believe the resolution of our ethical case must take into ac-
count the general insistence of the American consumer that the decision to 
assume risk must be an individual one, even if there are notable instances 
when the actual rational weighing of outcome is honored more in the breach 
as, for example, in deciding to get a driver’s license.
Can the process powers of Tier Three produce a distribution system 
which is safe and accountable by reworking the ways in which we apply our 
ethical principles? We may get a better sense of what this orientation is up 
against by asking some leading questions. Is McDonald’s likely to give cus-
tomers a choice of Flavr Savr™ tomatoes or regular ones? What about 
Campbell’s? Labeling is one possible response, but it is ethically acceptable 
as reflecting the existence of choice only if alternatives are readily available. 
Merely spelling out contents is not enough because what is of paramount im-
How can govern-
ment regulate 
with one hand 
when its other 
hand is in the 
business of 
agriculture?
4 For a different approach see: MacLean, D. “Social Values and the Distribution of 
Risk.” In Values at Risk. D. MacLean, ed. Rowman & Allanheld, Totawa, NJ. 1986. 
p 75-93.
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portance is some indication of risk. Is there the equivalent available to us of 
a Phase 3 drug trial which could produce acceptable accounting of risk? (It would 
of course add considerably to the cost of food in the short run.) Who could run 
a large trial of 10,000 to 20,000 randomized participants? For what period 
of time? Most carcinogens are notoriously slow in producing symptoms of dis-
ease so we would probably have to accept animal evi-
dence here. Possibly a consensus conference, something 
like the Presidential Commission on Bioethics (1980) 
that produced the original ethical guidelines for health 
care could, in addition to offering insight as to the rela-
tionship of autonomy to common good, clarify the roles 
of government and industry. For example, only govern-
ment in the exercise of its guardianship role could ex-
tend the common good to include the ecosystem and 
produce the regulations to which development must con-
form. Certainly we need less of the kind of argument presented by Michael W. 
Fox (as cited by Johnson, 1993) that implies that eliminating profit motives is 
in the public interest, because it confuses even further the difference between 
protection and innovation, both of which are vital to our future welfare. This 
discussion has also shown that the social interaction we have called “process” 
is all too often subsumed under the term politics. Nowhere is this more true 
than in that paradoxical enterprise of our society called agriculture.
Jane Jacobs (1992) offers the vision that the human past and future is 
tied in quite absolute ways to the proper use of both guardian and commer-
cial enterprise. The application of biotechnology to agriculture seems des-
tined for more of the same unproductive confusion and mistrust by our citi-
zenry unless we can sort out the current confusion as to which is responsible 
for what. How can government regulate with one hand when its other hand 
is in the business of agriculture? Since the time frame of all living creatures 
is from the human perspective, is it nonetheless a fitting human response to 
expect that profitability take a somewhat longer perspective than the next two 
to five years? I would offer, as one possibility, that the combination of values 
which currently drives American skepticism about the future promised by 
biotechnology is demanding a standard of accounting closer to a view of time 
expressed by the evolution of natural life than the short term perspective that 
plagues both government and industry. Sub specie aeternitatis indeed!
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Communicating risk to the public looms as a confusing, perhaps even wildly unpredictable, process to many scientists and policymakers. 
People confronted with risky situations often seem to respond irrationally. 
Their reactions sometimes suggest that they are evaluating information in 
superficial and hasty ways. It is hard to see patterns in the judgments they 
make about whose information is credible and whose is not. Incredibly 
enough, they even seem to believe what they read in newspaper stories.
Others (see Hoban and Kendall, page 73) focused on how we, as indi-
viduals, perceive risks “out there.” This presentation will focus on some 
work by communication scholars that explores how we all use information 
to make judgments about risk. More specifically, I want to talk about how, 
given a risky situation, individuals choose information channels in order to 
learn about the risk, as well as to decide how worried to be about that risk.
Why care about information channels? Let me respond in two ways. 
One is that the old-fashioned view of the risk communication process—a 
simple stimulus-response scenario in which the expert spouts information
and the recipient ingests and then acts in ways consonant with that informa-
tion—rarely seems to work, and ignoring channel preferences may be one of 
the many reasons why. A second reason for caring 
about channels is that the findings of communication 
research suggests their role is counter-intuitive. Put 
another way, we all seem to routinely misjudge the ef-
fects of channel use on people’s risk judgments. If part 
of the goal of this report is to engage the agricultural 
biotechnology community in fruitful public discussion 
of risk, then reconfiguring our understanding of channel use is important.
FIRST, AN EXAMPLE....
Before discussing some of the things we have been learning about how folks 
use information channels to inform their risk judgments, let me begin with 
an example. A very personal one, I might add.
Some years ago, Steve, my partner, and I sat down to watch a NOVA pro-
gram about asbestos. Midway through, Steve wondered aloud if the stuff 
wrapped around the steam pipes in the basement of our old refurbished 
farmhouse might not be moldering asbestos. It was. We now had to decide 
what to do about it.
We began an intensive search for information. We called state agencies, 
the Environmental Protection Agency (EPA) and various information offices 
at our university. We rummaged through libraries. We ended up with a large 
pile of information about asbestos but, we felt, no information specific 
enough for our needs. So we next embarked on a search for individuals who 
could investigate our problem in person. Two engineers ultimately found 
their way into our basement. One resurfaced with the soothing message that 
we would be quite safe if we left the asbestos as is; the other hastened back up 
the basement stairs and warned us to stay out of the basement until the asbes-
tos had been removed.
In desperation, we finally asked ourselves: Would we ever return to 
the basement if we left the asbestos in place? The answer was no. A few 
weeks later we hired the best professional we could find to remove the stuff.
Although I did not realize it at the time, this saga nicely illustrates some 
of the more important channel factors that scholars have discovered in recent 
years. Three will be discussed here: 1. the notion of channel utility; 2. the ar-
gument that individuals use different channels to inform different dimen-
sions of risk judgment; and 3. the argument that individuals evaluate infor-
mation in some channels as more relevant to themselves than information in 
other channels. Be aware that I make a distinction between “channel” and 
“source.” A channel is a mode of transmission—The New York Times, 60 Min-
utes, an interpersonal interaction. Sources, on the other hand, are informa-
.. .reconfiguring 
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tion providers embedded in channels. A single channel can offer many 
sources, or just one.
CHANNEL UTILITY
Our world is awash in information channels. The mass media are obvious 
ones, and they often get fingered as the sole, or at least the primary, channels 
used by the public to learn about risks. But recall how you came to terms 
with a recent salient risk and you will realize that, in an information-rich so-
ciety such as this one, we have many channels at our disposal. In the asbestos 
example above, Steve and I utilized television, newspapers, various printed 
brochures and pamphlets, and human beings.
But we typically do not access these channels in equal dollops. Stanford 
researcher Steve Chaffee (1986) argues that our use of any particular channel 
depends on two things: the cost of getting to that channel and a judgment 
of the likely relevance of information that we may find there. The joint out-
come of those two factors determines something called “channel utility.”
Some channels are too costly to use, even when we judge the informa-
tion they contain to be of high quality. For example, many people will cite a 
physician as their preferred channel for information about health risks such 
as AIDS (Freimuth et al., 1987), but few individuals will actually discuss 
those risks with physicians. The physician ranks high in terms of likely in-
formation relevance, but she is also costly to access; most individuals in our 
culture either cannot afford to visit a doctor just to talk about health issues 
or are reluctant to ask time of such a high-status person.
Conversely, other channels may be easy to access but may be judged inap-
propriate for certain types of information. For example, some of the most ac-
cessible publications in the country are sitting in 
supermarket checkout lanes. Yet, many individuals 
would regard The National Enquirer as a poor 
source of information about biotechnology risks.
For most of us, juggling cost and relevance 
leads to channel tradeoffs. In fact, more often
than not, we may settle for a particular channel not because we prefer it, but 
because it is available. Many of our preferred channels may be too costly to 
access and we, thus, “make do” with a variety of channels—such as the mass 
media—whose information we may regard as reasonable but not necessarily 
on-point. For example, although we may prefer to learn about AIDS from 
our physicians, we do not. Instead, we rely heavily on the mass media for 
such health information. That reliance stems not from a judgment that 
newspapers are better sources of health information than physicians—to the 
contrary, when asked, individuals are quick to note otherwise (Reagan and
  For most of us, juggling 
   cost and relevance leads 
to channel tradeoffs.
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Collins, 1987)—but from the fact that newspapers are far easier to access and 
are regarded as being generally informative.
RISK JUDGMENT AND CHANNEL CHOICES
The days when scientists went looking for a tight fit between level of risk and 
behavioral response are long gone. Risk perception researchers have made it 
abundantly clear over the years that we all use multiple factors to evaluate a 
risk and that estimates of likelihood of coming to harm—while taken into ac-
count when available—are only part of the picture and must compete with 
other factors, such as our familiarity with the risk, our sense of control over it, 
and its catastrophic potential (Slovic, 1987).
If one acknowledges that decisions about risky situations are grounded in 
multiple dimensions rather than just one, then it is a short conceptual hop to 
the idea that individuals may prefer different channels to inform different di-
mensions of risk judgment.
And that is just what risk communication researchers are finding. Re-
cent work suggests that individuals differentiate between channels that are 
appropriate for learning about a risk and those best used to decide how wor-
ried to be about the risk. Specifically, individuals seem willing to rely on the 
mass media and other “impersonal” channels in order to gather information 
about a particular risk. But they seem unwilling to rely on those same chan-
nels to reach decisions about how worried to 
be. Instead, they prefer interpersonal chan-
nels to inform this “worry dimension.”
For example, in a study of young adults’ 
perceptions of the risk of contracting the 
HIV virus, Dunwoody and Neuwirth (1991) 
found that use of the mass media predicted 
to participants’ understanding of level of risk 
(a cognitive, knowledge variable) but not to 
their level of worry about contracting the vi-
rus (an affective variable). Rather, the best 
channel predictor of level of worry was interpersonal.
While this flies in the face of a pervasive cultural assumption that the 
mass media can scare us to death by “sensationalizing” information, it is 
quite consistent with a growing body of mass communication research that 
finds media messages far more closely linked to cognitions than to affect. 
That is, the media seem to operate principally as sources of information in 
our world, not as persuasive forces.
That distinction played itself out in the little asbestos saga above. Steve 
and I gathered lots of mass-produced information and learned a great deal 
about asbestos. But we were reluctant to use that information to construct a
...individuals differentiate 
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sense of how worried we should be about the stuff in our basement. Instead, 
we wanted to talk to human beings. We sought out interpersonal channels to 
help us with that dimension of risk judgment.
REFERENTIAL LEVEL AND CHANNEL CHOICES
Risk perception researchers have demonstrated that, when confronted with a 
hazard, we systematically differentiate between the level of risk it poses to 
others and to ourselves. Specifically, we underestimate our personal level of 
risk compared to that of others (Weinstein, 1989).
Again, it is a short conceptual hop to the idea that, if individuals distin-
guish between self and others when judging level of risk, they may utilize dif-
ferent information channels to inform those two different judgments.
And again, mass communication research bears this. Specifically, indi-
viduals seem to interpret mass media information as telling them about the 
risks to people “out there” but resist seeing those same messages as telling 
them anything about their personal level of risk. Instead, once again inter-
personal channels are the preferred source of personal risk information.
Two studies offer good illustrations of this phenomenon. Tyler and Cook 
(1984), in a series of experiments examining the ways in which information 
influenced individuals’ judgments of the risk of being victimized, found that: 
1. personal- and societal-level judgments were quite independent of one 
another; and 2. mass media crime stories influenced 
those societal-level judgments but not the personal 
ones. In other words, reading newspaper stories about 
crime leads you to think that folks around you (i.e., 
in your community, your state, your country) have a 
greater likelihood of being victimized, but the stories 
will not influence your assessment of your own per-
sonal level of risk. The world around you may look 
scarier, but you see your neighborhood as immune to 
that trend.
Similarly, Culbertson and Stempel (1985), in a survey of Ohio residents, 
found the self-other distinction: Seventy-five percent of the respondents 
criticized the availability of health care in the United States while only 5 per-
cent viewed their own health care environment negatively. Further, evalua-
tions of media coverage of health were correlated more with respondents’ as-
sessments of the quality of health care available to Americans than with their 
assessments of their personal care.
In sum, mass-mediated information influences our social-level percep-
tions but not our individual-level ones. This differential impact has come to 
be known as the “impersonal impact hypothesis,” as it suggests that, in the 
words of Tyler and Cook (1984), “the modality of indirect experience, which
...interpersonal 
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is most effectively controlled by society and which reaches the largest audi-
ences—the mass media—is the least effective in influencing personal con-
cerns” (p. 694).
This referential distinction emerged starkly during the asbestos saga. 
While Steve and I gathered reams of written information about asbestos, we 
resisted seeing the information as telling us something about our personal 
level of risk. We clung to the assumption that our situation was somehow 
unique. The more general written documents could not be sensitive, we felt, 
to the amount, age and condition of the asbestos in our basement. We finally 
resorted to bringing in human beings to stare at our asbestos and offer rec-
ommendations for dealing with it.
Again, the argument that mass media channels are ineffective at the per-
sonal level flies in the face of many individuals’ 
assumptions about our use of information 
channels. We all believe we have witnessed the 
impact of the media on personal perceptions, be 
it the specter of thousands of residents who fled 
their homes in 1979 in reaction to the news that 
the damaged Three Mile Island reactor might 
harbor a potentially catastrophic hydrogen 
bubble or the hundreds of phone calls to cancer 
or AIDS hotlines after the inevitable public disclosure of a well-known per-
sonality with the disease.
Indeed, a good bit of empirical evidence suggests that the mass media do 
serve an alerting function, that individuals use newspapers, radio and TV as 
social antennae to alert them to situations or issues “out there” that may need 
attention. But once the issue has become salient to an individual, that 
“agenda-setting” function is only the beginning of an elaborate process of in-
formation-gathering, one in which the mass media are only part of a panoply 
of channels, each being used for very specific but very different purposes.
By way of example, I turn again to the asbestos saga. It was television— 
specifically a NOVA program—that alerted Steve and I to the problem of as-
bestos. But when we began looking in earnest for detailed information about 
the risk, we gave little thought to seeking information in media channels. Me-
dia stories are time-based, intermittent, ephemeral. They lack detail. Their 
presence coincides with news “out there,” not with the personal situations of 
their readers. So for us, the mass media served its classic alerting function and 
then vanished as a relevant channel during the rest of our search.
...individuals use 
newspapers, radio and 
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THE LIMITS OF MASS MEDIA CHANNELS
This inability of media channels to inform individuals’ personal levels of risk 
is disconcerting to some policymakers for another reason: They engage in
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multimillion-dollar information campaigns to convince us to change a num-
ber of life-threatening habits, from smoking to having unprotected sex, and 
those campaigns traditionally rely heavily on the mass media to carry their 
messages. Our resistance to seeing mediated messages as relevant to our-
selves is costly to campaign designers—so costly that it has sparked a good 
deal of discussion about why the public makes this channel distinction and 
what can be done about it. Researchers have proffered a few educated 
guesses.
One argument is that our insistence on interpreting mediated channels 
as informing only our understanding of society is a learned response applied 
to all media messages. That is, we have all have grown up amidst the mass 
media and, over time, have learned that media stories are always about folks 
“out there,” never about us. We have learned, in other words, to interpret 
media messages as telling us about others, about society.
If this argument is correct, then one may be able to counteract that pattern 
either by recasting media messages in ways that signal to the reader that 
“this story is about you” or by training audience members to interpret existing 
messages differently. In the former camp, strategies might include begin-
ning stories with story narratives featuring individuals like the typical reader, 
or using the second-person “you” throughout the story. A focus on the latter 
strategy must begin with a better understand-
ing of how people interpret mediated messages 
and then would require a kind of resocialization 
process. Efforts to change audience perceptions 
through restructuring media accounts have not 
been fruitful to date (see Dunwoody etal., 1992).
Although scholars have not yet explored the no-
tion of “retraining” media message users, researchers have demonstrated the 
value of educational efforts in such areas as promoting better individual use 
of mathematical and statistical concepts (see Nisbett et al., 1983).
Another argument is that individuals do indeed use media channels to 
inform personal risk levels but that, since most of the risks reflected in me-
dia accounts are those whose likelihood of occurrence is low, no change in 
personal risk levels is necessary. Tyler and Cook (1984) maintain that, un-
der such conditions, “the rational and discerning response of most mem-
bers of the public probably should be to refrain from changing their estima-
tion of their own risk while acknowledging that the problem may be greater 
to society in general than they had thought” (p. 206). This hypothesis has not 
been tested, but the self-other distinction seems to hold across a range of 
risks and likelihood levels.
Finally, yet a third group argues that we are so resistant to seeing our-
selves as being at risk that nothing can dissuade us from interpreting our
...recastingmedia messages 
in ways that signal to the 
reader that “this story is 
about you”...
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level of risk as lower than that of the folks around us. If true, no amount of 
fiddling with media stories about hazards will convince audiences that those 
stories have something to say about their personal likelihood of coming to 
harm. Partial support for this position comes from Gunther and Mundy 
(1993), who found in one study that media stories recounting disadvanta-
geous consequences generated the self-other referential distinction while 
stories that posed potential benefits did not. Respondents immediately in-
terpreted the positive stories as relevant to themselves, in other words, but 
resisted seeing the negative stories in the same way. This suggests that at 
least part of the problem lies with our reactions to the message rather than to 
the channel.
DISCUSSION
Learning how people use information to inform their risk judgments is diffi-
cult. A literal blizzard of factors about the individuals themselves can in-
fluence those judgments, everything from a person’s available store of 
knowledge about the risk to personality factors that make some people 
more likely to take risks than others. Attributes of the messages them-
selves introduce another welter of factors, from 
the clarity of the words and phrases to the vivid-
ness of the text.
In this brief presentation I have tried to illu-
minate one element within that panoply of message 
factors: the influence of channel. The bottom line 
here is that channel makes a difference. Given chan-
nel choice, individuals will use different channels 
to help them make decisions about different dimensions of a risk. For ex-
ample, a magazine article about radon may contribute to their understand-
ing of the damage that radon can do to the human body. But when it comes 
to deciding whether or not to install a radon detector—that is, whether indi-
viduals should be worried enough about the risk to engage in some level of 
expense to determine the level of hazard to themselves—they will opt for a 
channel that they feel can take their personal situation into account. Almost 
without exception, that channel is interpersonal.
What does this mean for risk communicators? First, I think it requires 
us to be clear about our communications goals and to select channels that fit 
with those goals. You may employ very different channels to explain a risk— 
actual or potential-—than you will use to try to persuade audiences that the 
risk should or should not worry them.
Second, it forces us to ponder the inequitable nature of channel access.
In an ideal world, individuals could select among a myriad of channels to
But only a very few, 
socially advantaged 
souls have such 
extensive channel 
access.
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meet their informational and decision needs. They could locate both popu-
lar and technical documents in publications or in electronic databases; they 
could talk to experts.
But only a very few, socially advantaged souls have such extensive chan-
nel access. Many Americans live their lives in something of an informational 
straightjacket; economics and the social context within which they live have 
severely restricted their channel choices. They do not subscribe to a newspa-
per. They may buy only the occasional magazine off the newsstand. They 
have little experience with libraries, even less with searching for information 
by computer. They have no idea how to get to human experts. They have 
never made a phone call to a governmental agency in search of an answer to a 
question.
For these individuals, the cost of using even generally available channels 
to inform their risk judgments may be high indeed, so high that it serves as 
an effective barrier to informed decision-making.
Finally, research on channel use raises the specter of an active audience. 
Turn-of-the-century communication researchers viewed the audience as a 
passive mass that absorbed and reacted to messages in predictable ways. 
Studies since World War II have turned that image around, suggesting in-
stead that information users play an important role in selecting and process-
ing messages. That filtering process can make or break a communication at-
tempt, and it means that risk communication managers must be sensitive to 
the information recipient as a major player in the communication process.
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Communicating With the Public About Risk
Jerry E. Bishop 
Deputy News Editor 
(science) 
Wall Street Journal
s many biotechnologists, particularly those involved in agriculture, are
beginning to discover, it is not easy to communicate to the public the 
concepts of risk, at least not risk as understood by the scientific community. 
Many people find themselves baffled and chagrined by a weather forecast that 
says there is a 30 percent chance of rain when all they want to know is whether 
to take an umbrella to work.
Those who toil in the mass media are quite conscious of the difficulties 
of communicating risk concepts to the lay public. Hardly a week goes by 
when editors and reporters are not forced to decide whether to publicize 
some alleged threat to the public health. The threat may range from the risk 
of too little calcium or too much iron in the diet to the risk of using a cellular 
telephone or driving a pickup truck with the fuel tanks mounted outside the 
truck frame. Inevitably, one interest group will accuse the media of need-
lessly scaring the public while another interest group will charge that the me-
dia are failing to alert the public to a deadly danger.
The criticisms of the media from the scientific community, however, are 
of a different nature, are considerably more reasoned and, consequently, are 
more closely attended than those from special interest groups. One such
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critic is Daniel E. Koshland Jr., the esteemed editor of Science. In an editorial 
in late 1991, Koshland had this to say about the mass media:
There are many examples these days of improper conduct, of 
which the recent coverage of the chemical Alar, used to slow 
the ripening of apples, is a dramatic example. In that case, a 
clearly dubious report about possible carcinogenicity by a 
special interest group was hyped by a news organization without 
the most simple checks on its reliability or documentation.
This caused panic among consumers and losses of millions 
of dollars by apple growers. Confronted with the inadequacy 
of the data, a spokesman for the public interest group recently 
suggested that it was excusable because people are eating more 
apples than ever before. That is like an embezzler justifying 
embezzlement by saying the banking industry continues to 
survive. Worse, the public’s disdain for repeated scares indi-
cates that an individual publication’s (or broadcast group’s) 
willingness to cry‘wolf’ uncritically may be destroying the 
press’s own credibility and its ability to provide legitimacy 
to responsible environmentalists...the press has been too 
willing to publicize Jeremy Rifkin’s cries of alarm, which 
so far have been consistently wrong.
Koshland goes on to argue that the press should adopt a policy of revealing the 
sources of data that are claimed to be “scientific” and should distinguish be-
tween a report in a peer-reviewed scientific journal and the claims made at a 
“dataless press conference” or in “a public relations document.” He urges that 
“press conferences without peer-reviewed data should be greeted with heavy 
skepticism.”
Most scientists, particularly those in biotechnology who have been in 
the glare of Jeremy Rifkin’s pronouncements, probably agree with Koshland’s 
recommendations on how the press should perform. But Koshland begs the 
more basic question of why a reputable organization like CBS Television and 
a highly regarded program like 60 Minutes would deign in the first place to 
scare the wits out of the apple-eating American public by publicizing a re-
port that lacked peer-reviewed scientific data.
To understand why television, newspapers, news magazines and other 
media would publicize such an unsupported allegation of a health danger it 
might be useful to look at a few examples. None, in this case, deal directly 
with agricultural biotechnology but they offer an insight that might be use-
ful to those who might have to deal with the media and the public about is-
sues of safety and risk of genetically altered crops and irradiated foods.
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An interesting piece of history appeared a few years ago in the journal 
Preventive Medicine. Andrew McClary, a science historian at Michigan State 
University, had dug into newspapers and consumer magazines published in 
the early part of this century to see how they dealt with the problem of the 
housefly (McClary, 1982). The germ theory of disease was fairly new at the 
time and early research had discovered pathogens were harbored in the gut of 
the common housefly. It was well known, of course, that houseflies feed by re-
gurgitation and that they are commonly seen flitting from outhouses and gar-
bage cans to kitchens and dining rooms. These observations had led to the 
seemingly logical conclusion that the ordinary housefly could spread disease.
The evidence that the housefly was a vector of human disease was purely 
circumstantial. There had been no documented cases of human illness being 
directly transmitted via the housefly and infectious disease experts of the day 
said it seemed unlikely that the housefly was an important health hazard.
Nevertheless, the mass media fell in whole-heartedly with local campaigns 
to warn the public of the dangers of the housefly. In addition to many articles 
about proper sanitation, many newspapers 
championed “swat the fly” campaigns, McClary 
found. In Washington, D.C., 5,000 children 
brought in an estimated 7 million dead flies 
during a two-week campaign in which the 
Washington Evening Star offered prizes up to 
$25 for the most flies killed. The champion,
13-year-old Layton Burdette, brought in 
343,800 dead flies, having paid a company of 
25 boys to kill and collect flies for him.
It was the consumer magazines of the 
day, however, that went after the housefly 
with a vengeance, McClary found. In 1911, the Independent described the fly 
as “a monstrous being with more eyes than Argus, wings like a monoplane, 
six long, hairy legs and a mouth armed with horrid mandibles, sucking blood 
and dripping poison.”
McClure’s charged, in 1909, that the fly would “slaughter the little babies 
through the summer.” A year later, Ladies Home Journal asked its readers: 
“What will you do? Shall he continue in his death-dealing path or will you rise 
and‘swat’him?” In 1913, Good Housekeeping declared that “women are the 
mothers of babies and the makers of homes, and the fly is an enemy of both.”
These exaggerated assertions undoubtedly caused the public an immea-
surable amount of anxiety and led to the expenditure of an enormous amount 
of time and money to eliminate the housefly—an effort that continues to this 
day. But the media went unchallenged. Rarely, if ever, did infectious disease
Inevitably, one interest group 
will accuse the media of 
needlessly scaring the public 
while another interest group 
will charge that the media are 
failing to alert the public to a 
deadly danger.
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experts and public health officials step forward and accuse the media of scar-
ing the public on the basis of inadequate scientific evidence. Unlike the Alar 
controversy, the mass media’s “play” of the housefly menace did not damage 
any particular interest. The housefly had no defenders; there was no insect 
rights group trying to protect the innocent housefly. Fly control even 
spawned a not-so-small industry in window screens, fly paper, fly swatters 
and, years later, insecticides.
So it would seem that one aspect of communicating risk to the public 
is whether the communication is likely to affect some particular economic 
interest. Koshland’s editorial condemns “a clearly dubious report...by a spe-
cial interest group”—presumably the Natural Resources Defense Council— 
because it “caused panic among consumers and losses of millions of dollars 
by apple growers” but he fails to classify the apple growers as a special inter-
est group. One can only wonder whether the Alar story would have stirred 
such condemnation if it had not caused a precipitous—but temporary— 
decline in consumption of apples and apple juice.
Be that as it may, McClary raises a question regarding the housefly ar-
ticles that remains pertinent to this day:
Should one condemn these articles as failing to meet desired 
standards of popular science writing? Was it better to gain 
reader interest through mild sensationalism, or risk its loss 
through the use of unemotional, objective prose?
This is not a trivial question that applies only to the media in the early part of 
this century. It is particularly pertinent today when a potential news story 
deals with “risk.”
Every reporter and editor knows that if a story fails to interest the reader, 
the reader simply turns the page and looks for some other story that does in-
terest him or her. No reporter is going to waste his or her time and effort 
writing a story that no one will read. And any newspaper or magazine or 
television news program that consistently publishes articles that fail to inter-
est readers will quickly discover its readers going elsewhere for information.
At the same time, readers do not like to be misled; they resent it when 
they invest their time in reading a story that turns out to be far less interest-
ing and informative than promised by the headline and “lead” of the story. 
One can imagine the chagrin of readers who, a few years ago, spent a dollar on 
a supermarket tabloid with a headline “Man Shot Eight Times and Lives” only 
to discover the story is about a body found with nine bullet holes.
In news stories dealing with risk, the reporter and then the editor have to 
decide how to arouse a reader interest enough to make them pause and read 
the story and yet not mislead the reader. I was reminded recently how diffi-
110 Agricultural Biotechnology: A Public Conversation About Risk
cult it is to tread this line by an incident involving one of my own stories 
(Bishop, 1993), an incident which, I fervently hope, continues to be rare on 
The Wall Street Journal.
A medical journal had published an article describing a long-term fol-
low-up of women who had had chest irradiation after surgery for breast can-
cer. The analysis indicated that 10 years after irradiation there was a two-
fold increase in risk of lung cancer. Any story about breast cancer inherently 
stirs reader interest. Many readers have either had breast cancer or have fam-
ily members or friends who have had breast cancer.
And this story would carry particularly strong reader 
interest because in recent years many women diag-
nosed in the early stages of breast cancer have opted 
for a so-called “lumpectomy”—plus radiation— 
in hopes of preserving the breast.
But the report lacked certain information. It de-
scribed only relative risk. The absolute risk of a woman 
developing lung cancer after breast irradiation was 
not calculated. Moreover, the effect of cigarette smok-
ing on the relative risk of lung cancer was not taken into account. A call 
to the authors revealed that their main interest was not in the safety or long-
term effects of breast cancer therapy, but rather in gathering evidence on 
the induction of cancer by ionizing radiation. The lead author had had several 
calls from the press and was becoming a bit overwrought that news stories 
might unduly influence therapeutic decisions for women with breast cancer.
We assumed that many of our readers would hear of this study on the 
evening news or read it in their morning paper. We also felt that if the story 
were not presented in the proper context, women readers who have had or 
might have breast cancer would be unduly alarmed about the findings. There-
fore, it was decided that we would present the new findings to our readers in a 
context that was informative but not alarming. To this end the first sentence 
of the story, the “lead,” read:
A Columbia University scientist cautioned that his finding that 
radiation treatments for breast cancer increase the risk of lung 
cancer were mainly of scientific interest.
“I don’t think women who are being treated for breast cancer 
or who had radiation treatments for breast cancer in the past 
should be overly concerned” about the new finding, said Alfred 
I. Neugut, a cancer specialist at the College of Physicians and 
Surgeons, Columbia University’s medical school in New York.
Later in the evening, an editor on the copy desk decided that the lead sounded 
as though the finding of higher lung cancer risk was old news; it read as
...how to arouse a 
reader interest 
enough to make 
them pause and 
read the story, and 
yet not mislead the 
reader.
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though the reader already knew about the finding. He changed the lead as 
follows:
A new study says radiation treatments for breast cancer in-
crease the risk of lung cancer, but the Columbia University 
scientist who headed the research team said the finding was 
mainly of scientific interest and should not alarm women 
who receive the treatment.
This version subtly puts more emphasis on the increased risk of lung cancer. 
The change, however, is not too far from the original and still cautions the 
reader that the study should not affect decisions on breast cancer therapy. 
However, a headline has to be written that sums up the story in few succinct 
words. And the headline usually is a condensed version of the lead of the 
story. Thus, the next morning the story appeared with this headline:
STUDY LINKS BREAST CANCER TREATMENT TO HIGHER RISK 
OF THE DISEASE IN LUNGS
News of a risk 
attracts more 
interest than news 
of no risk.
The headline, which gives readers a certain “mindset” before they read the 
story, states exactly what we originally tried to avoid. But the episode shows 
how difficult it is sometimes to grab a reader’s interest without resorting to
the melodramatic exaggerations that the anti-house-
fly writers used three-quarters of a century ago.
The editor’s reaction to the original lead also 
underscores another aspect of reporting risk—ori-
ented stories. News of a risk attracts more interest 
than news of no risk. The original lead did not ap-
peal to the editor, in part, because it indicated that 
readers need not concern themselves about the finding. The change put 
more emphasis on the discovery of a previously unknown risk and the result-
ing headline stated it rather baldly.
This bias against “no risk” stories was described in late 1991 in a report 
appearing in the Journal of the American Medical Association, “Bias Against 
Negative Studies in Newspaper Reports of Medical Research” by Koren and 
Klein of the Hospital for Sick Children in Toronto (Koren and Klein, 1991). 
Earlier in the year a single issue had carried two articles on risk of cancer 
among populations exposed to radiation. One study, the “positive” finding, 
showed that atomic energy workers at the Oak Ridge National Laboratory 
had 63 percent higher than normal risk of developing leukemia. The other 
study, the “negative” study, failed to find any increased risk of cancer among 
people living near nuclear power plants.
Koren and Klein found 19 daily newspapers that had carried stories about 
the articles but only 10 of these reported the results of both studies and,
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Readers...want 
to know what 
such criticisms 
are and when 
they are 
expressed.
of those 10, most emphasized the “positive” finding of a leukemia risk among 
Oak Ridge employees and gave minor consideration to the “negative” finding 
of no risk. Nine of the newspapers reported only 
the “positive” finding.
Koren and Klein conclude: “Responsible journalists 
should acknowledge the importance of providing 
balanced information to the public when covering con-
troversial health issues and should give equal atten-
tion to positive and negative studies.”
Koren and Klein’s finding of bias against nega-
tive studies is not surprising. What Koren and Klein
actually uncovered was not so much a bias on the part of the newspapers as 
a bias on the part of newspaper readers. News of health risks must compete 
for reader attention each day against news of other happenings in the world— 
including wars, murders, economic declines, election campaigns, Congres-
sional votes on health care issues, stock market gyrations and the agonies and 
accomplishments of sports teams. It seems obvious that a scientific study that 
reveals a potential threat to one’s health will compete well for the reader’s at-
tention. On the other hand, a report that tells the readers they need not 
worry about getting cancer from living near a nuclear plant will be of little 
interest to people who do not live near a nuclear power plant, which prob-
ably includes most of the readership of the newspapers surveyed by Koren 
and Klein.
It is somewhat naive to assume that people will read whatever the press decides 
to print. The fact is that, unlike a teacher or even a preacher, the audience served 
by most publications is not a captive audience that 
is required to sit there and read every word impressed 
on the page. It is a capricious audience, a fickle au-
dience that picks and chooses what it wants to read.
This is the overriding criterion used by edi-
tors in deciding what news will be printed about 
risk or any other subject.
This criterion applies just as stringently to 
news about new technologies such as the geneti-
cally engineered economic animals and crops 
which the NABC audience deals with. First and 
foremost readers will want to know how the new
technology will affect their lives. Thus, they will have more interest in ge-
netically engineered tomatoes that will appear on their supermarket shelf 
than a strain of corn genetically engineered for drought resistance. Initially, 
they will be most interested—and the press will be most likely to report— 
how the new technology will benefit them, the readers.
First and foremost 
readers will want to 
know how the new 
technology will affect 
their lives... they will 
immediately want to 
know if it is in any 
way harmful or 
dangerous.
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But once the readers learn that they soon will encounter the products of 
a new technology and that its inventors are promising benefits, they will im-
mediately want to know if it is in any way harmful or dangerous.
The press is acutely aware of these desires of readers and will publish the 
information they want as it becomes available. The first stories will describe 
the new technology, its potential benefits and probably include the assurance 
of its developers that it is safe. But the reporters and editors will be on the 
alert for any indications that the new technology might carry known or un-
known risks. The risks, incidentally, could be financial as well as health-re-
lated since the readership includes those who might want to invest in the new 
technology.
This, for instance, is the reason the press gives publicity to pronounce-
ments and actions by critics like Jeremy Rifkin and Ralph Nader, and prints 
stories about chefs of famous restaurants agreeing not to serve genetically 
engineered foods. Readers, including many attending NABC 5, want to know 
what such criticisms are and when they are expressed. It is as important, or 
perhaps more important, for the scientists and venture capitalists involved in 
developing genetically engineered foods to know what Jeremy Rifkin and the 
chefs are doing as it is for the general public.
To use any other criteria for deciding what should be printed or not 
printed in a newspaper or any other medium of mass communications 
would be lethal for the newspaper. To paraphrase one of my editors of sev-
eral years ago, the newspaper editor who decides to print what he thinks 
people should read instead of what they want to read will soon find he has 
no newspaper to be editor of.
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PART IV
Roundtable
ll6 A PUBLIC CONVERSATION ABOUT RISK 
Marshall A. Martin, Moderator
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Martin (moderator): Good evening ladies and gentlemen. I am delighted 
to welcome you to NABC 5. The title of this conference is “Agricultural Bio-
technology: A Public Conversation About Risk.” Instead of having an after 
dinner speaker this evening, we will have a roundtable discussion regarding 
public concerns about biotechnology and its potential risks and benefits. I 
will follow a talk show format and interact with a panel that I will introduce 
to you in just a moment. By the time we conclude later this evening I hope 
you will be saying “I am glad that I came. I am glad to be a part of this con-
ference. I am looking forward to hearing the plenary session speakers. I am 
especially anxious to enter into a dialogue in each of the four workshops on 
Thursday and Friday.” This evening’s panel will offer an opportunity to set 
the stage, to excite you, and to increase your interest in the conference 
theme: “Agricultural Biotechnology: A Public Conversation About Risk.”
Let me briefly describe how we are going to proceed. I have a basic script 
that I intend to follow. I have shared with each of the panel members the 
general theme, but they don’t know the questions that I will ask, so the dis-
cussion will be extemporaneous.
Let me introduce our panel members. Lilly Russow comes from the De-
partment of Philosophy at Purdue. Seated next to her is Rosetta Newsome 
from Chicago, where she is with the Institute of Food Technologists and is 
Director of Scientific Affairs. Seated next to her, is Rebecca Goldburg from 
the Environmental Defense Fund in New York. Bill Greenlee is the Head of 
the Department of Pharmacology and Toxicology in the School of Pharmacy 
at Purdue. Ann Sorensen comes from the American Farmland Trust where 
she is the Director of the Center for Agriculture in the Environment. Ted 
McKinney is from Indianapolis. He works for DowElanco, a relatively new 
joint venture between the Elanco Division of Eli Lilly and the Dow Chemical 
Company. Karen Bolluyt is from Iowa State University, where she is the Di-
rector of the Agricultural Information Service. David Judson is a journalist 
with the Gannett News Service, based in the Washington, DC area.
As you can see, we have people with very interesting and diverse back-
grounds. You will have a chance to work closely with them on Thursday and 
Friday. They are going to serve as co-chairpersons for the four workshops. You 
also will hear from each of them in the wrap-up Session on Friday afternoon.
With this introduction, let us begin the evening program. Everyone 
travelled to this conference. Of course, some of you came from further away 
than others. Some only had to travel a short distance in West Lafayette, while 
others came from various places across the United States. No one chose 
Amtrak, although we do have service in Lafayette from Chicago to India-
napolis. How many came by commercial plane? About half the group. How 
many of you drove? Another half the group. Rebecca Goldburg, why did you 
decide to fly?
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Goldburg (Environmental Defense Fund): Mainly because it takes far less time 
than any other mode of transportation. Also, it’s relatively safe.
Martin: Good, she gave us two reasons: relatively safe and efficient in terms 
of time. Let me ask Ted McKinney the same question. Why did you decide to 
drive?
McKinney (DowElanco): The same reasons. It is far more efficient to drive 
the one hour from Indianapolis, and it’s fairly safe.
Martin: David Judson, you came from Washington, DC. Why did you choose 
to fly?
Judson (Gannett News Service): It’s a logical, efficient, quick way to get here.
Martin: Karen Bolluyt, did you drive over from Ames or fly?
Bolluyt (Agricultural Communications, Iowa State University): I flew.
Martin: You flew. There are some people here from Ames who drove. It took 
them about eight hours to drive. You chose to fly. Why?
Bolluyt: Because it was quick.
Martin: Rosetta Newsome, did you drive from Chicago?
Newsome (Institute of Food Technologists): Yes, I did, but had I realized there 
was Amtrak service, I might have considered that.
Martin: One of the choices that these individuals made in coming to this confer-
ence was how to get here. Some of you considered economics; some considered 
the time and convenience factors. And some considered risk. Let me give you 
some statistics about travel risk. In the United States, there were 515 fatalities in 
1989 for those folks who traveled by Amtrak. If you’d known that, Rosetta, do you 
think that you would have come by Amtrak from Chicago?
Newsome: No, I would have considered the ease of getting here.
Martin: Also in 1989 there were 278 fatalities on U.S. commercial airplanes. 
Someone commented that travel by air is relatively safe. Does anyone want to 
guess about how many automobile fatalities there were in 1989?
Goldburg: 50,000.
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Sorensen (American Farmland Trust): Much higher...
Martin: Like 100,000 maybe.
Russow (Philosophy Department, Purdue University): At least.
Martin: What do you think, Dave?
Judson: I’d say 75,000.
Martin: There were 46,000 passenger car fatalities in 1989. Ann, I understand 
that you drove down. I recall that in visiting with you on the telephone you 
said you prefer not to fly.
Sorensen: I am a nervous flyer; I am well aware that flying is safer than driv-
ing. It’s an irrational fear of flying, but I drive when I can.
Martin: So here we have a scientist that knows the facts about the risks of 
travel but tells us that sometimes emotion plays a factor. We’re going to talk 
about this during this conference. Let me move on now to another issue. 
Many Americans are concerned about food safety, particularly pesticide resi-
dues. Let us talk about food safety. I did some shopping. I bought a tomato. 
As far as I know, this one was produced with the application of pesticides.
Lilly, would you eat this tomato?
Russow: I wouldn’t buy it at a grocery store, but I would eat it at a restaurant.
Martin: Did it worry you that the salad you ate at the banquet tonight had to-
matoes in it that might have been grown with pesticides?
Russow: Not really, I don’t think it’s much of a risk. I think it’s much less of a 
risk than I took driving over here. But when I do have control over things, 1 
don’t buy things like that.
Martin: So, even though you know some of the scientific facts, you do make 
choices based on factors other than science.
Russow: I do.
Martin: If you had a chance to get a tomato from your garden or from a 
neighbor’s garden that you knew was grown with minimal or no pesticides, 
would you prefer that tomato over one from the store that might have some 
pesticide residue.
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Russow: Yes.
Martin: Let me turn to Rebecca Goldburg and ask the same question.
Goldburg: I think my response is quite similar to Lilly’s. When I can buy food 
without pesticides, I try to but I certainly often buy foods that were grown 
with pesticides.
Martin: So you weigh in your own mind the risks and try to make a reason-
able choice.
Goldburg: Yes, plus price and other factors.
Martin: Remember, David Judson is a writer for the Gannett News Service, 
and he often writes about science. David, let us assume that you have been as-
signed by your editor to write a news story about tomatoes and pesticide use. 
How would you tell the story? What do you think the issues should be, par-
ticularly about risks that maybe associated with this food?
Judson: I first would raise the question: Is the tomato good or bad for you? I 
think the context is probably the most important thing, i.e., the risk of eating 
a tomato against the risks of driving a car, of living in a house with lead- 
based paint, of living in a city like Washington, DC, or whatever. There are 
risks all over.
Martin: Ted McKinney is trained in agriculture and works for DowElanco, a 
company involved in agricultural chemicals. How does your company inform 
the public about the relative benefits and risks of the use of pesticides in to-
mato production, or in agriculture in general?
McKinney: It is particularly challenging because of the public perception. I 
think the perception is so strong about the perceived negative aspects of pes-
ticides relative to many other things that we all use in our daily lives that it is 
a huge task. We don’t believe in industry that we can afford to just turn on 
the airways like a media campaign and move the dial over because 51 percent 
doesn’t win. As a result, we try to build coalitions; we try to work with those 
who are informed such as the media. We believe that facts and science will 
win despite what seems to be an overwhelming task as it relates to public per-
ception.
Martin: Let me reach into my sack again. I found another tomato! This one 
could be called “Flavr Savr™,” one that enhances shelf life. The company that 
developed this type of tomato is Calgene. Many of you have been hearing
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about this, I am sure. Some of you may have worked on the research related to 
this type of technology. Now we are talking about biotechnology, or genetic 
engineering. This tomato is going to have a better flavor, more like that gar-
den variety you were talking about earlier. And it will have a longer shelf life. 
Let me ask the same questions. How does that sound to you, Lilly?
Russow: It depends on how it was grown. I want to know where it came from 
and about pesticides used on it.
Martin: So information is important to you.
Russow: Yes.
Martin: Rebecca, what would you say?
Goldburg: I must admit if Food and Drug Administration approves it, I am 
going to try it.
Martin: Rosetta, what about the food industry? How are they going to relate 
to this new tomato?
Newsome: I can’t speak for the food industry, but I think many consumers 
wish to have a tomato that tastes like the garden variety. They wish to have the 
tomato available year-round, they are anxious to have a good-tasting tomato 
available in the winter. Thus, the food industry would benefit by making a 
product available for purchase.
Martin: Karen, let us assume you are working on a story at Iowa State Univer-
sity. You want to tell a story to the consuming public through the Des Moines 
Register, a widely read newspaper in Iowa. What would you would want to say 
about this new tomato?
Bolluyt: My job at the College of Agriculture is to talk about what we know.
It is also important that I keep in mind that what we know is only part of the 
story. The story should show respect for people for whom that knowledge 
and that information is not enough. Their value system is different than the 
one which is motivated primarily by what we know about the tomato in sci-
entific terms.
Martin: I did some more shopping. I found another tomato. This one also is 
a genetically engineered tomato. Bacillus thuringiensis (Bt) protein gene has 
been introduced into this tomato. I don’t need to explain to this audience 
what Bt is, or how it works, but I do want to talk to the panel a little bit about
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this tomato. I am going to start with Lilly again. Would you be interested in 
eating this tomato?
Russow: I am going to sound like a broken record. I want to know how it was 
grown, what’s in it, and so on. I think that consumers are tired of the “here’s a 
tomato, it’s just like every other tomato; trust us...buy it.”
Martin: So you would like some labeling information, perhaps?
Russow: Definitely.
Martin: Maybe at the grocery store in the vegetable section there should be an 
information sheet that the customer could pick up and take home. Rebecca, 
let me ask you the same question I asked Lilly.
Goldburg: Information would be important to me. I am actually in a situa-
tion where I have published a paper on the toxicology of Bt.
Martin: It is interesting that you mention toxicology. I have a question for 
Bill Greenlee. As you recall, he is a toxicologist. Are there toxicological is-
sues that we should be concerned about? What are some of the issues we 
should look at to assure the public food is safe and to help them make more 
informed decisions.
Greenlee (Pharmacology and Toxicology Department, Purdue University):
I think one of the issues that was a recurring theme in both Ted and David’s 
comments was the potential adverse impacts on human health. The other is-
sue is how it is grown. Were pesticides used? Clearly, pesticide use and its 
chemistry has evolved. We are using far fewer amounts of pesticides per acre 
today. It really boils down to an issue of dose. What is the exposure dose? 
What is the likely dose from the consumption of the tomato? Do you con-
sume them all the time? Pesticides are likely to represent a very small residue 
on the tomato. We might ask how the fruit was handled in the store. There 
are a number of factors that need to be considered. This is a tremendous 
educational challenge, even among toxicologists. It is difficult to educate the 
scientists about what a dose response curve is. We have a tremendous chal-
lenge with the public because they see things as all or none.
Martin: This tomato grown with the Bt characteristic does not require insec-
ticides to control most insects. But, a new protein has been introduced into 
the tomato. Rosetta Newsome, from a food industry perspective what might 
be important in terms of information, education, allergen concerns, or other 
considerations that might be important to share with the public?
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Newsome: Well, we would want to share the development of the tomato. Of 
course, if the tomato looks like a tomato we want to be sure we are actually 
providing a tomato to consumers. If we are not, we need to let them know.
But I think along the lines that you were speaking there are further factors that 
need to come into play. If this tomato is indeed a tomato, and has similar nu-
tritional qualities to the traditional product, and does not have any known al-
lergens induced, then we want to consider the benefits of consuming the 
product. We know we need to eat increased amounts of fruits and vegetables 
to protect our health. And this would provide benefits along that line.
Martin: Let me turn back to Ted McKinney for a minute before we move on to 
something else. This tomato represents developments in other crops where 
we may see the Bt characteristic to prevent insect damage. It may be in soy-
beans, corn, cotton or others. Your company, DowElanco, has a long tradition 
of producing chemicals for insect control. Now, this comes along. How does 
that affect a company like yours in terms of strategies or planning? Do you 
feel threatened by it? Are you jumping into the biotechnology business? How 
are you going to respond?
McKinney: If you look at our traditional product lines, you could say that it 
represents a threat. But if you are a well-managed company, you are looking 
at biotechnology as perhaps the next generation of products that would re-
place traditional chemicals, e.g., fungicides, herbicides, insecticides, etc. And, 
in fact, that is what we are doing; we are looking at this kind of thing as well. 
But these are not panaceas. It takes years and years even with the traditional 
chemistry to develop and receive government approval of new products. It 
takes about 10 years to register a product, 100-plus tests, and the hurdle rates 
are enormous. I take comfort in the science that goes into new products. Bio-
technology represents new ground and, admittedly, a lot of questions must be 
answered from a safety and consumer standpoint.
Martin: So you suggest that regulations, although sometimes frustrating, play 
an important role. They provide assurance that a product is safe to the envi-
ronment, to consumers, to the producers, and others involved.
McKinney: Yes, I would state very clearly that I think reasonable regulations 
are an absolute necessity. In fact, Becky, you said that people need to look to 
FDA because not everyone is going to be as informed or able to get the infor-
mation at the local shopping store that guarantees how that product is pro-
duced. That is why we have regulatory agencies. So, absolutely, we support 
them.
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Martin: OK. Who would like to have my Bt tomato? Ted wanted the one pro-
duced with pesticides.
Judson: I would like to have it.
Martin: I now want to turn to a less controversial topic. I would like to talk 
about milk! Lilly, would you comment briefly, from your perspective in the 
area of philosophy, if you think there are different ethical or philosophical 
concerns with the application of biotechnology to crops versus animals?
Russow: I think that there are two. Specifically, nobody is worried about how 
the tomato feels about having various biotechnology products introduced 
into the plant, or the seed, or whatever, but certainly there are concerns about 
how the cows fare in terms of their welfare with the growth hormone, bST 
(bovine somatotropin). And, there is a concern about whether or not it has an 
impact on the quality of life for cows. Another issue has come up that really 
doesn’t have anything to do with the difference between plants and animals. 
That concern is with the impact on family dairy farms. I think that is very in-
teresting. It is not just a scientific issue anymore. It has to do with societal 
concerns in general; what kinds of lifestyles are important and what sorts of 
lifestyles society wants to protect or enhance.
Martin: If I understood you right, you mentioned at least two things. One is 
the impact that the technology may have on the animal, itself, and whether it 
enhances or not the well-being of the animal. Secondly, there may be a con-
cern about the economic, and perhaps social, impacts on farmers, of this tech-
nology. You mentioned animal agriculture in your example. What about the 
issue of manipulating genes, whether they are within different species of 
plants, within different animals, or maybe transgenic? Does this raise con-
cerns from an ethical point of view?
Russow: I think that that is a very difficult issue, and a very muddled one be-
cause we are not very clear on the whole issue of species and species bound-
aries. Many people have a very strong emotional reaction once you intro-
duce human beings. The introduction of animal genes into human beings, 
or human genes into animals, I think, worries the general public. There is 
less public concern about moving genes among plants. I think it is a concern 
among philosophers, because we don’t know what is going on. We don’t 
know whether species ought to be important or not. There are people who 
worry about playing God and messing up species, but that presupposes some-
thing about species being fixed. If you talk to biologists, they tell you the
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whole notion of the species is a very confused notion to begin with. It is not a 
very clear-cut issue at all.
Martin: Let me give you an example of something that happened to me sev-
eral years ago. A scientist was working with somatotropin to enhance produc-
tivity in fish. After a speech, someone in the audience asked this scientist 
“Where did you get the somatotropin?” He said, “Oh, I had some human 
growth hormone in the laboratory and I just used that.” What do you think 
about that? How do philosophers deal with that? Is that something that 
would concern them?
Russow: Personally, I think the question of where the somatotropins came 
from is not particularly important. On the other hand, some people are wor-
ried about the slippery slope; that is, as soon as you start harvesting human 
products of one sort or another, how far are you going to go? And, you get all 
sorts of Brave New World concerns with Frankenstein scenarios.
Martin: Like in Jurassic Park7.
Russow: Right.
Martin: I did a little more shopping. I found this milk at a local grocery store. 
I did some background research on this. This milk came from a dairy farm 
where there are Holstein cows, so we know the breed. And it is from a herd 
with a 20,000 pound rolling herd average. It is a well-managed, very produc-
tive dairy herd. The dairy farmer keeps good records on the cows. I also note 
that this is skim milk, and it is not high in butterfat. I am going to pour a glass 
of milk. So, we know that this milk is homogenized, pasteurized, comes from 
a well-managed herd, was purchased at a local store this afternoon, and has 
been refrigerated. Ann Sorensen, would you drink this for me?
Sorensen: No, I am allergic to milk!
Martin: I assume you had an allergic reaction and, after some medical tests, 
discovered that you had a problem drinking milk.
Sorensen: Yes, I have been allergic since birth.
Martin: So here we have a case where labeling information is important. Do 
you buy milk in a grocery store?
Sorensen: No, I don’t.
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Russow: It is probably like the milk that I regularly buy in the grocery store.
Martin: So you have confidence in it based on the information on the label 
and the fact that there is a regulatory system to control the quality of milk. 
Rosetta Newsome, would you drink this glass of milk?
Newsome: I definitely would not drink it.
Martin: Why not?
Newsome: Because it has been sitting there for at least a couple of hours.
Also, I don’t like warm milk.
Martin: So there are many issues that we take into account when considering 
potential risks. Some are from a health viewpoint. Others may be questions 
of personal taste and preference. Would anyone else on the panel want my 
glass of milk?
Judson: I can drink it without any problem.
Martin: I did a little more shopping. I bought some more milk. This milk is a 
little different. First, let me describe what is the same. This milk also comes 
from a well-managed dairy farm with a 20,000 pound rolling dairy herd aver-
age per cow. Again, it is skim milk. It is cool. It has not been sitting out very 
long. There is only one additional piece of information that I know about this 
milk that I didn’t about the first milk. It comes from a cow treated with bST.
I have another clean glass. I will not ask Ann Sorensen to drink this milk be-
cause we already know that she has an allergic reaction to milk in general. Ted 
McKinney, do you have a concern with drinking this milk?
McKinney: No, I would drink it.
Martin: Why?
McKinney: Well, partly because I have been involved in research and under-
stand the safety hurdles and tests that it takes to demonstrate bST safety. bST 
is found naturally in cows. I think it comes down to education. I understand 
the background about bST. I would feel very comfortable drinking that milk.
Martin: So there are times when consumer information is important. Lilly
Russow, would you drink this glass of milk?
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Martin: Karen Bolluyt, I wish to ask you a question similar to the one that I 
asked you before. Again, you are writing a story to be released by Iowa State 
University to appear in the Des Moines Register. How would you go about tell-
ing the story about the safety of milk, particularly milk that comes from a cow 
injected with bST?
Bolluyt: I hope my story would abide by two principles. One, that we are a 
trustworthy source of information. Two, that we respect people’s ability to 
make up their own minds once we give them accurate, factual information.
Martin: David Judson, let me ask you a similar question. You are writing this 
story for Gannett. The story will be carried across the nation. You want to tell 
the story about bST being used in milk. How would you approach the story? 
Where would you seek information?
Judson: I think the points that Karen raised are fundamental. You have to ask 
the question “Is it safe to drink?” You have to go to sources that are credible.
I think that the FDA, or similar sources, are probably regarded by most people 
as credible. The one thing that I think would be relevant to ask would be: 
What impact is it going to have on the general economics of the dairy indus-
try? What impact is it going to have on communities that rely upon dairy eco-
nomics? There may be risk issues, safety issues, and health issues in terms of 
the family farm.
Martin: OK, so economic issues as well as the science behind bST are impor-
tant. Now let me change my assumptions just slightly. I am going to come 
back to both of you with a question. The new information is that FDA ap-
proved milk from cows treated with bST as safe about six years ago, but has 
been analyzing its potential impacts on dairy cows and the environment. The 
new news story is that bST has just been approved by FDA for commercializa-
tion. You must write a story on this news event. Karen, and then David, how 
would you approach the story of FDA approval of bST for commercial use?
Bolluyt: That is difficult from a university perspective, since it is basically a 
private-sector story. What we might do is contact our scientists who have ex-
pertise in the area and put together a contact list for reporters.
Martin: So you would provide a source of information for reporters who are 
writing for various national or local newspapers as to where they might go for 
background information or answers to questions.
Bolluyt: Right.
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Judson: I don’t know. There is news value in the symbolic crossing of the 
regulatory threshold by one company. In other words, is this a harbinger of 
things to come? I think this would be the dimension of the story that would 
occur to me most immediately.
Martin: Ann Sorensen, let me turn to you for a moment. I want to bring the 
farmers into the discussion. FDA has now approved bST for at least one of the 
companies. You work with farmers. How do you think farmers might re-
spond to this news?
Sorensen: I wish I had the answer to that. I think farmers are split on the issue 
of bST. I know some dairy farmers who are very concerned about negative 
consumer reactions. There will probably be some dairy farmers who can in-
corporate the product immediately into their operations if they feel it is going 
to increase their efficiency or their productivity. I think there are other dairy 
farmers who won’t touch it. They either will not see a need for it or will be 
concerned about negative consumer reactions.
Martin: So there may be differences depending on a farmer’s operation, eco-
nomic situation, ability to manage the technology, and how he markets his 
milk.
Sorensen: Right. They are going to have to manage the new technology. They 
are going to have to keep track of individual cattle. They are going to have to 
know what their cows are eating. It is going to require, I think, a high level of 
management. Not all dairy farmers can do that.
Martin: Rosetta, you work with the food industry and food processors. How 
would this news event impact some of the people you work with?
Newsome: First, let me clarify that while many of the members of the Institute 
for Food Technologists are employed in the food industry, others are em-
ployed in regulatory agencies and academia. Perhaps, my primary role might 
be to provide the scientific information for inquiries we get, whether they be 
from journalists or consumers. If safety concerns remain, then we would 
strive to provide the background information on the science to satisfy these 
concerns.
Martin: Rebecca Goldburg, I would like to come back to you for a minute. I 
know you work closely with some of the environmental organizations. Would
Martin: David, how would you approach this bST story?
Roundtable 127
this news about FDA approval of bST raise questions or concerns from an en-
vironmental perspective?
Goldburg: I actually have not worked on any issues related to bGH (bovine 
growth hormone); so my concerns would probably be of a personal nature, 
and perhaps less about the safety of the milk and more about how we treat 
animals.
Martin: So you would be more concerned about animal welfare, animal man-
agement, or animal well-being.
Goldburg: Right, and also economic issues.
Martin: OK, but what about beneficial or adverse environmental impacts?
Goldburg: Well, there could be some adverse environmental impacts if we lose 
a lot of dairy farms in the northeast. This raises land management issues. I 
see it not so much as an environmental issue, but more of an agricultural 
policy and consumer safety issue.
Martin: Let me turn back to the audience. What we have done tonight, I 
hope, is give you a flavor of NABC 5. I hope we have set the tone for the con-
ference with two or three examples of some of the kinds of issues of concern to 
society, to the organizations that we represent including the private sector, to 
academia, to public interest groups, and to regulatory agencies. Some of the 
biotechnology examples we discussed this evening are already in place, some 
are on the near horizon, and others may be further away. Each of you has se-
lected one of four workshops. The four workshops are: public values, public 
assessment of biotechnology, technical assessment of risks and benefits asso-
ciated with biotechnology, and, finally, communication about risks. You will 
have six hours of workshop sessions, tomorrow and on Friday, where you can 
speak, share your views, raise your questions, express your concerns, or make 
your recommendations. I hope you do that. I hope you participate. Inclos-
ing, let us take a moment to express our appreciation to our panel members. 
Thank you very much. I hope this was an enjoyable evening for all of you. 
Good night. (Applause).
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